',6&/2685(
5('$&7('[ZIP_CODE]&2/$0(1'0(17
&&&//
$3KDVH0XOWL&HQWHU5DQGRPL]HG'RXEOH%OLQG3DUDOOHO*UR XS6WXG\2I
7KH6DIHW\$QG(IILFDF\2I'LIIHUHQW/HQDOLGRPLGH5HYOLPLGÂŠ'RVH5HJLPHQV,Q
6XEMHFWV:LWK5HODSVHG2U5HIUDFWRU\%&HOO&KURQLF/\PSKRF\WLF /HXNHPLD
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 
&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1([ZIP_CODE],(7$5<,1)250$7,21V,Q,Q
HPLDPLD
QRWEHVKDUHGRWEHVKDUHG
FKHUVDQGSDKHUVDQ
HJXOJXODWLRQVUHDWLRQVU
DORUFRUFRQWUDFRQWUDF
WRFHUWDLQSFHUWDLQS
DLQLQIRUPDWLQLQIRUPDW
W&HOJHQHÂ¶V&HOJHQHÂ¶V
SULQFLSOHVSULQFLSOHV
H\\VSDFHPDVSDFHPD
ILILFDWLRQRILFDWLRQRIL
QFRQILGHQQFRQILG WLWL
DLQLGHQWLILDLQLGHQWLI
OVRPD\FRQOVRPD\FR
LVJHQHUDWLQLVJHQHUDWL
DWWDFKPHQWVWWDFKPHQ
\RIWKHUHSRRIWKHUH
XW&HOJHQHY&HOJHQHY
KDWLQIRUPDKDWLQIRUPD
DERXWRXUYDERXWRXU
RQDERXW&HDERXW&
QGDWKWWSZQGDWKWWSZ
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 1 CC-5013-CLL-009 Amendment 6 Final 15Apr2015TITLE PAGE 
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, 
PARALLEL-GROUP STUDY OF THE SAFETY AND EFFICACY OF 
DIFFERENT LENALIDOMIDE (REVLIMIDÂ®) DOSE REGIMENS IN 
SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC 
LYMPHOCYTIC LE[LOCATION_006]EMIA
STUDY DRUG: Lenalidomide
PROTOCOL NUMBER: CC-5013-CLL-[ADDRESS_281469] NUMBER 2009-009836-54
DATE FINAL: 09 March 2009
AMENDMENT #1 10 June 2009
AMENDMENT #2 11 February 2010
AMENDMENT #3 9 December 2010
AMENDMENT #4 12 May 2011
AMENDMENT #5
AMENDMENT #69  November 2011
15 April 2015
___________ {See appended electronic signature [CONTACT_3264]} ___________
Signature [CONTACT_233327]
__________   _____________________
Printed Name [CONTACT_233328] __________________
                   dd mmm yyyy 
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
[CONTACT_10825], your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by [CONTACT_27614].  Persons to whom the information is disclosed must be informed that the information is confidential and may not 
be further disclosed by [CONTACT_476].&(/*This protocThis protoc
you, youyou, you
docudoc&(/*(1([ZIP_CODE],(7$5<,1)250$7,2111
vevembmber 201er 20
55April 201April 201
appended eappended 
ature of Ceature of C
______
(3Printed NPrinted
*/*
&&&(3
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 2 CC-5013-CLL-009 Amendment 6 Final 15Apr2015COORDINATING PRINCIPAL INVESTIGATOR [INVESTIGATOR_96874]
[include if applicable]
Signature [CONTACT_137838] [INVESTIGATOR_233202]________
By [CONTACT_27616], I agree to supervise and oversee the conduct of this study and to ensure its conduct is in compliance with the protocol, informed consent, IRB/EC procedures, instructions from Celgene representatives, the Declaration of Helsinki, ICH 
Good Clinical Practice guidelines, and the applicable parts of the [LOCATION_002] Code of 
Federal Regulations and local regulations governing the conduct of clinical studies.
&(/*(1([ZIP_CODE],(7$7$7$5<,1)250$7,210$0$0$0$
of this studof this stu
med consenmed consen
he Declarathe Declara
parts of theparts of th
ng the condng the cond
7$
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281470] is in compliance with the protocol, informed consent, 
IRB/EC procedures, instructions from Celgene representatives, the Declaration of 
Helsinki, ICH Good Clinical Practice guidelines, and the applicable parts of the [LOCATION_002] Code of Federal Regulations a nd local regulations governing the conduct of 
clinical studies.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210$0$0$0$
udydyatatyymy my sts
ormed consrmed c
he Declarate Declarat
icable partscable par
overning thverning th
$5$5
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281471] INFORMATION
Table 1: Celgene Emergency Contact [CONTACT_233261] SÃ rl
Celgene R&D
Route de Perreux 1
2017 Boudry, Switzerland
Telephone:  Email:  
 Celgene International SÃ rl
Celgene R&D
Route de Perreux [ZIP_CODE] Boudry, Switzerland
Telephone:  
Mobile:  Email:  
Drug Safety Contact
**Contact 
[CONTACT_233262] a separate document.Global Drug Safety
International Celgene Corporation
Telephone:  
Fax:  E-mail: [EMAIL_1271]
Celgene Global Drug Safety
Celgene International SÃ rlRoute de Perreux [ZIP_CODE] Boudry, SwitzerlandTelephone:  
Fax:  
Email:  
&(/*(1([ZIP_CODE],(7$5< 
ill:  : 
onal onal Celgene CoCelgene C$5
/*1((7<, ,1)250$7,21$7
l
Switzerlandwitzerland255
<, 15<$5<
(7$(7(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 5 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 1: Celgene Emergency Contact [CONTACT_7171] (Continued)
Role in Study Name [CONTACT_233329] SÃ rl
Celgene R&D
Route de Perreux 1
2017 Boudry, Switzerland
Telephone:  Mobile:  Email:  
 
Telephone:  
Mobile:  Email: 
Note: The back-up [ADDRESS_281472] call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls  
Back-up [ADDRESS_281473] Call Center: +[PHONE_4875]
&(/*(1([ZIP_CODE],(7$5<,<center shocenter sh
) or Medicor Medic
all Centerall Center7$(7,1)250$7,21$7
50
)21)2,1)<, 1
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 6 CC-5013-CLL-009 Amendment 6 Final 15Apr20152. SYNOPSIS
Name [CONTACT_790]/Company:   Celgene Corporation
Name [CONTACT_791]:   lenalidomide
Protocol Number: CC-5013-CLL-009
Protocol Title: A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Study Of 
The Safety And Efficacy Of Different Lenalidomide (RevlimidÂ®) Dose Regimens In Subjects 
With Relapsed Or Refractory B-Cell Chronic Lymphocytic Leukemia
Indication : For the treatment of patients  with B-cell chronic lymphocytic leukemia who have 
failed at least 1 prior therapy
Study Duration:
Subjects may receive study drug until disease 
progression or unacceptable toxicity develops, whichever 
occurs first.
Study will be closed once 80% of the subjects
randomized to the study have progressed or died or up to 
five years after the last subject was randomized, whichever occurs later.  All subjects ongoing on study 
drug at the time the study is closed will be transferred to 
lenalidomide on a free basis in agreement with the site principal investigator [INVESTIGATOR_233203].Phase of development:
Phase 2
Objectives
Primary
!To evaluate the safety of different len alidomide dose regimens in subjects with 
relapsed or refractory B-cell CLL.  
Secondary
!To evaluate the efficacy of different lena lidomide dose regimens in subjects with 
relapsed or refractory B-cell CLL.  
Study Endpoints
Primary
!Safety [type, frequency, and severity of adverse events (AEs) and relationship of 
AEs to lenalidomide]
Secondary&(/*(1([ZIP_CODE],(7$or up to or up to 
d, ,
g on studyg on study
e transferretransferre
ment with thent with t
g to l to localocal rel7$5<,1)250$7,217$7$7StudyudyOfOfyy
n Subjects n Subjects$7$7$7$7$7$7$7
ukemia whukemia w2525
of devf dev elopelop
ase 2ase 21)
7$
e the safete the safet
d or refractor refract
yy
To evaluaTo evalua
relreapseaps52
tudy Endpudy Endp
PrimPrim(/*&
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 7 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Response rate; International Workshop on Chronic Lymphocytic Leukemia 
(iwCLL) Guidelines for the diagnosis and tr eatment of CLL (Hallek, 2008)
!Duration of response 
!Time to response (TTR)
!Time to progression (TTP)
!Event-free survival (EFS)
!Progression-free survival (PFS)
!Overall survival (OS)
Exploratory
!Evaluation of response rate in predefined biologic risk group
!
!Investigate the relationship between pharmacokinetics (PK) and response 
(biomarkers or clinical outcomes as appropriate)
!Quality of Life
Study Design
CC-5013-CLL-[ADDRESS_281474] active disease per the iwCLL Guidelines for the diagnosis and treatment of CLL (Hallek, 2008) .
At the time of randomization, study subjects will be stratified by [CONTACT_4868]:
!Relapsed vs. refractory to their last purine-analog or bendamustine based treatment 
regimen [relapsed/refractory as defined per the iwCLL guidelines for diagnosis and 
treatment of CLL (Hallek, 2008) ].  If subject has received both, the status post most 
recent purine-analog or bendamustine regimen will be used for stratification.
!Age < 65 years of age vs. â‰¥ [ADDRESS_281475] the following assessmen ts / samples collected: &(/*(1([ZIP_CODE],(7$5<,1)K) and resp) and resp
mized, doubmized, dou
yyand efficaand effica
se a stepwise a stepw
mg dailymg daily
 days to redays to re
y 105105subjesubj
after or is rfter or is
or treatmenor treatme
t regimen. regimen
sis and treats and tre
mization, stumization, st
sed vs. refraed vs. refr
imenimen [rel[relapap
reatmreatm ent oent o
recent recent pupu
!!AgeAge
ScreeningScreening
SubjectSubje
cre5<)250$7,21$7$7
&1)2
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 8 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Vital signs, including height and weight
!Pregnancy testing as specified in Appendix 21.9
!Pregnancy and risk counseling as specified in Appendix 21.9
!Assessment of ECOG performance score
!Assessments of constitutional symptoms
!Physical examination to assess the lymph nodes, spleen and liver
!Clinical staging using Rai and /or Binet as defined per the iwCLL guidelines for 
diagnosis and treatment of CLL (Hallek, 2008) inAppendix 21.4
!12-lead ECG
!Peripheral blood smear, bone marrow aspir ate and bone marrow biopsy (reference 
samples) for central pathology reviewer (l ocal pathology results will also be 
captured on the eCRFs).
!Peripheral blood for disease c onfirmation by [CONTACT_137766][INVESTIGATOR_233204] , 2008 .
!Peripheral blood sample f or complete blood counts (CBCs), serum chemistries and 
thyroid function tests
!Urine sample for urinalysis
!Calculated (method of Cockroft-Gault) creatinine clearance (creatinine clearance 
may also be obtained by [CONTACT_941] 24-hour collection method at the investigatorâ€™s 
discretion)
!Peripheral blood sample for a direct antiglobulin test (DAT)
!CT scans of the neck, chest, abdomen and pelvis to assess lymphadenopathies
Local/Central Laboratories and Reviewers
Data generated by [CONTACT_221751] a nd evaluations performed by [CONTACT_233263]â€™s efficacy results.
Laboratory tests that may result in dose inte rruption and/or modification as specified in Table [ADDRESS_281476] visits.
At a minimum the following hematology/chemistry assessments must be performed locally:  
hemoglobin, absolute lymphocyte count, ab solute neutrophil count and pl atelet count, 
potassium, calcium, phosphorus, creatinine, to tal bilirubin, AST/SGOT, ALT/SGPT, and uric 
acid.  
At screening, subjects must meet eligibility criteria based on central lab results.  At Study Day 
1, subjects must meet eligibility criteria based on lo cal or central lab results prior to initiating 
study therapy, however, a re-calculation of creat inine clearance is not required at Study Day 1.
Exploratory Assessments
The following exploratory assessments will be performed in all subjects:&(/*(1([ZIP_CODE],(7$5<,1)250$7for 
iopsyopsy (ref(refyy ef
will also bwill also 
enotynotypi[INVESTIGATOR_233205]
(CBCs), ser(CBCs), se
creatinine creatinine
ollectolle ioion n
diirect antirect antiii gg
st, abdoment, abdome
d ReviewerReviewer
oratoriratori es aes
locally genocally ge
at mmay resuay resu
erformerform ed led l
um the fom the fo llollo
bin, n,absoabsolulu
iiumuii, calciucalciu
d.  d.  
AtAt screeni screen
1, subje1, sub
ud&$7,21$7$7
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 9 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Blood samples for ZAP-70, V Hmutational status /TP53 mutation analysis, FISH 
studies for cytogenetic assessment,  
will be collected at baseline.  
 
 
 
 
 
 
Subjects will complete quality of life questionnaire (FACT-Leu and EQ-5D questionnaires) at 
time points detailed in Table [ADDRESS_281477] centers.  Intensive sampling and sparse sampling will be discontinued as of this 
amendment, protocol amendment #6.
Treatment
Subjects must meet all eligibility criteria to be randomized for the study.
Initial randomization
Initially subjects will be randomized (1:1:1) in a double-blind fashion to the 5 mg, 10 mg, and 
15 mg starting dose arms (treatment arm 1, treatment arm 2, and treatment arm 3 respectively).  The randomization procedure will be accomplished by a validated interactive voice response 
system (IVRS).  Subjects will be stratified at randomization by (i) relapsed vs refractory to 
their last purine-analog or bendamustine based treatment reg imen (if subject has received both, 
the status post most recent purine-analog or bendamustine regimen will be used for 
stratification) and (ii) age < 65 years of age vs âˆ€65 years of age.  The subjects will receive 
lenalidomide once daily in a 28 day cycle and will be escalated every 28 days as tolerated in a 
stepwise manner up to a maximum of 25 mg daily.
Stoppi[INVESTIGATOR_233206](s)
After 18 subjects complete one 28 day cycle, an interim analysis will be conducted to review 
the safety of each starting dose arm(s).  Subsequent interim analyses to review the safety and progression rate of each starting dose arm(s) will o ccur at 13-week intervals.  After review of 
each interim analysis, a treatment arm may be dropped.  At any time accrual to a starting dose 
arm will also be stopped if unacceptable toxicities are observed in that arm.  If a treatment arm is dropped then all new subjects will be randomized equally into the remaining arm(s).
Dose Regimens:&(/*(1([ZIP_CODE],(7$5<,1)255D questionD question
bjects whobjects
l be discontl be discon
be randombe random
d (1:1:1) ind (1:1:1) 
ment arm 1, ment arm 1
will be accwill be acc
will be stratwill be str
or bendamuor bend
recent ecent purinurin
(ii) age < 6(ii) age < 6
nce daily innce daily i
anner up to anner up to 
g of Treatmof Trea
er 18 subjeer 18 subje
hhe safete safe y y o
progressiprogress
each ieach i&50$7,21$7$7$0$
250
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281478] tolerability, as 
follows:
!Treatment Arm 1: 5 mg â†’10 mg â†’15 mg â†’20 mg â†’25 mg/daily
!Treatment Arm 2: 10 mg â†’15 mg â†’20 mg â†’25 mg/daily
!Treatment Arm 3: 15 mg â†’20 mg â†’25 mg/daily
For toxicities requiring dose interrupt ion and/or modification see Section 10.2.3 . Note that a 
more gradual stepwise dose escalation of lenalidomide (more than one 28 day cycle for each 
dose level) might be needed at the discretion of the treating physician due to adverse events that do not require dose reduction or interruption.
Subjects unable to escalate to the [ADDRESS_281479] dose achieved in the previous cycle or as indicated in the dose modification section (see Section 10.2.3 ).
Study visits and serial measurements of safety and efficacy will be performed as outlined in 
Table 2 .  The severity of adverse events (AEs) will be graded according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 with 
the exceptions of hematological toxicities and TLS.  Hematological toxicities will be graded as 
specified in the iwCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia ( Hallek, 2008 ) (Appendix 21.4) .  TLS will be graded as specified by [CONTACT_137785]-
Bishop grading system ( Appendix 21.3 ).
The use of hematopoietic growth factors is permitted.  Treatment with myeloid growth factors 
is strongly encouraged following ASCO guidelines recommendation ( Smith, 2006 ) for dosing 
and administration when the absolute neutrophil count (ANC) is less than 1,000/ Î¼L [NOTE: 
per the inclusion criteria, subjects must have an ANC â‰¥ 1000/Î¼L to be eligible for study entry].  
Subjects will continue in the study and receiv e study drug until discontinuation from the study 
for any of the following reasons: disease progression; AEs that, in the judgment of the
Investigator, may cause severe or permanent harm  or which rule out continuation of study drug, 
subject withdraws consent, subject is lost to  follow-up, death, protocol violation that may rule
out continuation of study drug and other reasons  that in the judgment of the Investigator may 
rule out continuation of study drug.
For those subjects who discontinue study drug for reasons other than disease progression or 
withdrawal of consent, study visits should c ontinue every [ADDRESS_281480].  During these visits only the following assessments will be required: 
hematology, ECOG performance status, evaluation of constitutional symptoms, physical exam 
for liver, spleen and lymph nodes, adverse events, assessment for second primary malignancies,concomitant medications/therapi[INVESTIGATOR_014], and assessment of response.
For subjects who develop PD characterized by [CONTACT_233264] a more aggressive histology 
[i.e. Richterâ€™s syndrome (lymphomas) or prolymphocytic leukemia], this diagnosis should be established by [CONTACT_233265].
Subjects who are discontinued from the study drug for any reason, except for withdrawal of &(/*(1([ZIP_CODE],(7$5<,1)250$7ach ach 
vents vents 
ntinue witinue wi ththiii
fication sectfication sec
rformed asrformed a
rding to therding to th
CI CTCAECTCAE
logiogicalcal toxtoll
eatment of atment o
e graded as e graded a
mitted.  Treaitted.  Tre
delines recodelines reco
trophil counrophil cou
have an Ahave an 
and receivand recei
: disease disease prp
re or permare or perm
t, subject issubject i
dydy drug anddrug ayy
n of study dn of study
cts who discts who disc
f consent, sconsent,f
atition ofon of  disdisff
ver comes comes
atolatologyogy, EC, E
r liver, splliver, spl
concomitconcomit
For sFor s&$7,21$7$7
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 11 CC-5013-CLL-009 Amendment 6 Final 15Apr2015consent, will be followed every 12 weeks fo r survival, secondary primary malignancies and 
subsequent CLL therapi[INVESTIGATOR_233207] (see Figure 1 Overall Study Schema).
Study will be closed once 80% of the subjects randomized to the study have progressed or died
or up to five years after the last subject was randomized, whichever occurs later.  All subjects 
ongoing on study drug at the time the study is closed will be transferred to lenalidomide on a 
free basis in agreement with the site principal investigator [INVESTIGATOR_233208].
Response Assessment
Tumor response will be assessed according to the iwCLL guidelines for the diagnosis and 
treatment of CLL ( Hallek, 2008 ), including CR, CRi, nPR, PR, SD and PD.  Evaluation of 
response will be performed after [ADDRESS_281481], abdomen and pelvis 
to assess lymphadenopathies will be performed at the PR and CR/CRi confirmation visits ( â‰¥ 8 
weeks to â‰¤ 12 weeks)after all clinical and laboratory response criteria have been met for PR or 
CR/CRi).  Those subjects whose response was down-graded based on the CT scan 
interpretation at the PR or CR/CRi confirmation visit will have the CT scan repeated 4 months 
later at the location where remaining disease has been documented, as long as clinical and laboratory response remains present to try to document further improvement.
For those subjects who reach CR or CRi, a bone marrow aspi[INVESTIGATOR_233209]/CRi confirmation visit ( â‰¥ 8 weeks to â‰¤ [ADDRESS_281482] been m et).  If the bone marrow is hypocellular, a repeat 
specimen should be obtained after [ADDRESS_281483] recovered. If 
the bone marrow biopsy shows disease involvement (30% or greater lymphocytes, or nodules positive for B-CLL cells by [CONTACT_9064]), an additional bone marrow biopsy and 
aspi[INVESTIGATOR_233210] [ADDRESS_281484] analysis by [CONTACT_233266]/CRi confirmation visit.
!If peripheral blood and bone marrow are both MRD-positive, peripheral bl ood 
samples will be repeated and assessed up to [ADDRESS_281485] negativity in subjects who reach confirmed CR or CRi (see Follow-up MRD assessments).
!If peripheral blood is MRD-negative and bone marrow is MRD-positive, both 
peripheral blood and bone marrow should be retested for MRD negativity after â‰¥ [ADDRESS_281486] will be performed.
!If both the peripheral blood and bone marrow are MRD-negative, peripheral blood 
will be tested every [ADDRESS_281487] assessments:
!If any of the repeat peripheral blood assessments indicate MRD-negativity, a bone &(/*(1([ZIP_CODE],(7$5<,1)250$7of of 
men and pelen and pe
matatioion visin vis tsi
been met fbeen met
e CT scan e CT scan 
T scanT scan reperep
d, as long as, as long as
mprovemeprovem
pi[INVESTIGATOR_233211]â‰¤ 1â‰¤ 122
ne marrowne marrow
ed that the ed that th
ment (30% ment (30%
mistry), anmistry), an
ng as clinicg as clini
nt fnt further iurthefff
hose subjecose subj
ill be collecill be colle
blood and bblood and b
ill be repeaill be repea
ocument Mcument M
w-w-up MRDup MRD
If peripheraIf periphera
periperipherpheriii
weekweek
wiwi
!!&$7,21$7$7
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281488] negativity. 
#If the bone marrow is MRD-positive, both peripheral blood and bone marrow 
should be retested for MRD negativity after â‰¥ [ADDRESS_281489] will be performed.
#If at any time, the bone marrow is MRD-negative, peripheral blood will be 
tested every [ADDRESS_281490] discontinues study drug.
Prophylaxis for Tumor Lysis Syndrome (TLS), infection and thromboembolism and treatment of 
tumor flare reaction (TFR):
TLS and TFR 
TLS prophylaxis, comprising of oral hydration a nd allopurinol 300 mg/day will be initiated at 
least [ADDRESS_281491] be instructed to drink 8 to 10 eight ounce (240 mL) glasses of water each 
day for the first [ADDRESS_281492]â€™s cardiovascular status indicates the possibility of volume overload.
Grade 1 TFR may be treated with NSAIDs and TFR â‰¥ Grade 2 may be treated with 
corticosteroids.  Narcotic analgesics may be added as needed for pain control in subjects 
experiencing â‰¥ Grade 2 TFR.
Subjects will be monitored for TLS and TFR as follows:
!On Day 2 and 4 and then weekly (Days 8, 15, 22) for cycle [ADDRESS_281493] cycle of 
each dose escalation
!On Day 1, 8 and 15 of cycle 2 (if not dose escalated)
!At least every 28 days thereafter and as clinically indicated.
Thromboembolic Events Prophylaxis
Lenalidomide may increase the risk of thromboembolic events in subjects who are at high risk 
(high risk is defined for example as a history of a thromboembolic event and/or taking a concomitant medication associated with an increased risk for a thromboembolic event and/or a 
known hypercoagulable state regardless of thromboembo lic history). All subjects s hould 
receive anti-thrombotic prophylaxis during study treatment.  For subjects who enter the study with a platelet count close to the eligibility criteria of â‰¥ 50,000/ Î¼L, the medical monitor should 
be contact[CONTACT_233267]-thrombotic prophyl axis.  The recommended prophylaxis is low-
dose aspi[INVESTIGATOR_248] [ASA] (70-100mg) daily; however, another prophylactic anti-thrombotic therapy 
may be used per investigatorâ€™s discretion during study treatment. Choice of the most 
appropriate anti-thrombotic therapy for each s ubject should be based upon a careful evaluation 
of the different risk factors associated with each therapy, and a corresponding assessment of the individual subjectâ€™s underlying medical condition.  Selection should be based on the overall 
benefit-to-risk ratio. Use of low molecular we ight heparin or warfarin (or equivalent Vitamin K &(/*(1([ZIP_CODE],(7$5<,1)250$7ment of ent of 
ll be inil be ini titiiat
atment cyatment cy c
those whothose who
tacted.  Tacted.  T o
0 mL) glas0 mL) glas
n perin per od.  HH
owered if thowered if
verload.erload.
â‰¥ Grade 2 mâ‰¥ Grade 2 m
as needed as needed
R as foR as fo llolloww
eeklyeekly  (Days (Dayy
of cycle 2of cycle 2 (
8 days there8 days there
nts Prophynts Prop
increase thncrease th
ned for exaned for exa
medicatmedicat ioion
percoagulabpercoagulab
anti-i-thhromromhhh
a a plplatelaet cet c
contact[CONTACT_233268][INVESTIGATOR_233212] b
pr&$7,21$7$7
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281494]) to keep the International Normalization Ratio (INR) in the range of 2-3 or other 
anti-thrombotic therapy according to hospi[INVESTIGATOR_233213].
If platelets drop below 50,000/ Î¼L, the investigator should consider interrupting or adjusting the 
dose of anti-thrombotic therapy. In the event that platelets drop below 20,000/ Î¼L and the anti-
thrombotic therapy has not already been in terrupted, the investigator should again strongly 
consider interrupting the anti-thrombotic therapy.  In addition, for platelets < 20,000/Î¼L, 
lenalidomide should be interrupted and CBC s hould be followed every 7 days.  Appropriate 
interventions (i.e., platelet infusion) should be considered where applicable. 
Infection
Prophylactic antibiotics should be considered in subjects with neutropenia.  In addition, 
subjects who were on prophylactic treatment for infection while on alemtuzumab therapy 
should continue prophylactic treatment for at least 6 months following the discontinuation of 
alemtuzumab therapy and can be enrolled into the study while continuing prophylactic therapy.
Data Monitoring Committee
An independent external Data Monitoring Committee (DMC) will review safety and efficacy 
data collected during the conduct of the study.  DMC Meetings will occur approximately every 3 months during enrollment (with the first meeting occurring when ~[ADDRESS_281495] cycle of treatm ent) and twice per year thereafte r.  In addition, safety data 
will be reviewed in an ongoing manner to assess benefit-to-risk considerations; accrual will be stopped to a treatment arm if unacceptable toxicities are observed in that treatment arm.
Response Adjudication Committee
An independent Response Adjudication Committee (RAC) will perform a blinded, independent 
assessment of response (including the development of PD) prior to database lock.  The RAC 
adjudicated response data will be used in the efficacy analysis for the study.
Number of planned subjects
Approximately 105 subjects 
Study Population
Key Inclusion Criteria
!Must understand and voluntarily sign an informed consent form
!Age â‰¥ 18 years at the time of signing the informed consent form
!Must be able to adhere to the study visit schedule and other protocol requirements
Must have a documented diagnosis of B- cell CLL [iwCLL guidelines for diagnosis and 
treatment of CLL ( Hallek, 2008 )] meeting at least one of the following criteria:
#Evidence of progressive marrow failure as manifested by [CONTACT_66867], or 
worsening of, anemia and/or thrombocytopenia
#Massive (i.e., > 6 cm below the left costal margin) or progressive or 
symptomatic splenomegaly&(/*(1(35CriteriaCriteria
t understanunderstan
Age Age â‰¥ 18 yâ‰¥ 18 y
!Must bMust 
ust have a dust have a d
treatmtreatm ent oent o35235,(7$5<,1)250$7,21n, n, 
therapyherapy
ntntinuatinuat ioionn
ophylactic ophylactic 
eview safetview safet
will occur api[INVESTIGATOR_233214] a
when ~18 swhen ~
thereafter. thereafter.
toto-ririsk consk con
re reobserveobserve
mittee (RAmittee (RA
elopment olopment o
in the efficain the eff$7$7
23
35
&
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 14 CC-5013-CLL-009 Amendment 6 Final 15Apr2015#Massive nodes (i.e., > [ADDRESS_281496] diameter) or progressive or symptomatic 
lymphadenopathy
#  
#A minimum of any one of the following disease-related symptoms must be 
present:
#Unintentional weight loss â‰¥ 10% within the previous 6 months
#Significant fatigue (i.e., ECOG PS 2; cannot work or unable to perform 
usual activities)
#Fevers of greater than 100.5Â° F or 38.0Â° C for 2 or more weeks without other 
evidence of infection
#Night sweats for more than 1 month without evidence of infection
#Must be relapsed or refractory to at least 1 prior regimen for treatment of CLL 
[relapsed / refractory as defined per the iwCLL guidelines for diagnosis and 
treatment of CLL (Hallek, 2008) ].  At least one of the prior treatments must 
have included a purine-analog or be ndamustine based treatment regimen
#Relapsed is defined as a subject who has previously achieved the criteria of a 
complete remission (CR) or partial remission (PR), but after a period of â‰¥6 
months, demonstrates evidence of disease progression
#Refractory is defined as treatment failure [e.g. Stable disease (SD), non
response, or progressive disease] or disease progression within [ADDRESS_281497] antileukemic therapy
!Must have an Eastern Cooperative Oncology Group (ECOG) performance status 
score of â‰¤2.  
!Females of childbearing potential (FCBP) must:
#Have a negative medically supervised pregnancy test prior to starting study 
drug.  She must agree to ongoing pregnancy testing during study therapy and 
after discontinuation of study drug as specified in Appendix 21.[ADDRESS_281498] practices complete and continued sexual abstinence.
#Either commit to continued abstinence from heterosexual intercourse (which 
must be reviewed on a monthly basis) or agree to use, and be able to comply with, effective contraception without interruption, prior to starting study drug, 
during study drug therapy, and after discontinuation of study drug as specified 
in Appendix 21.9 .
!Male subjects must:
#Agree to use a condom during sexual contact [CONTACT_4490] a FCBP, even if they have 
had a vasectomy, during study drug therapy and after discontinuation of study drug as specified in Appendix 21.9 . &(/*(1([ZIP_CODE],(7$5<,1)250$7m 
witwithout othhout ot
ffinfectinfect ioonn
n for treatmn for trea
elines for dlines for d
f the prior tthe prior 
based based tre
reviously aviously 
ssissionon (PR) (PRnn
sease progrsease pro
nt failure [ent failure [e
ase] or disease] or dise
operative Ooperative O
earing potenaring poten
gattive ive medimed
he mhe ust agst am
discontinudiscontin
ven if the suven if the su
EiEither cother cii
must must 
wiw
&$7,21$7$7
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 15 CC-5013-CLL-009 Amendment 6 Final 15Apr2015#Agree to not donate semen or sperm during study drug therapy and after 
discontinuation of st udy drug as sp ecified in Appendix 21.9 .
!All subjects must:
#Have an understanding that the study drug could have a potential teratogenic 
risk
#Agree to abstain from donating blood during study drug therapy and after 
discontinuation of study drug as specified in Appendix 21.9 .
#Agree not to share study drug with another person
#Be counseled about pregnancy precautions and risks of fetal exposure as 
specified in Appendix 21.9 .
Key Exclusion Criteria
!Any serious medical condition, laboratory a bnormality, or psychiatric illness that 
would prevent the subject from signing the informed consent form
!Active infections requiring systemic antibiotics
!Systemic treatment for B-cell CLL within 28 days of initiation of len alidomide 
treatment
!Alemtuzumab therapy within 60 days of initiating lenalidomide treatment
!Prior therapy with lenalidomide
!History of grade 4 rash due to prior thalidomide treatment
!Planned autologous or allogeneic bone marrow transplantation
!Pregnant or lactating females
!Central nervous system (CNS) involvement as documented by [CONTACT_15209][INVESTIGATOR_233215].  Subjects who have signs or symptoms suggestive of leukemic meningitis or a history of leukemic meni ngitis must have a lumbar puncture 
procedure performed within two weeks prior to initiating study drug
!Prior history of malignancies, other than CLL, unless the subject has been free of 
the disease for â‰¥5 years.  Exceptions include the following:
#Basal cell carcinoma of the skin
#Squamous cell carcinoma of the skin
#Carcinoma in situ of the cervix
#Carcinoma in situ of the breast
#Carcinoma in situ of the bladder
#Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
!History of renal failure requiring dialysis&(/*(1([ZIP_CODE],(7$5<,1)250$7as as 
chiatrichiatri c illnc illn
nt formnt form
of initof init iatio
tiatating lenaing len
r thalidomithalidom
eic bone mic bone m
aless
m (CNS) inm (CNS) in
cts who havts who hav
historyhistory ofoyylf
rformerforme d wid
toryoryofofyymmfal
easeease fofor râ‰¥â‰¥
Basal celBasal ce
##SquaSqua
#
&$7,21$7$7
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 16 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and/or 
Hepatitis C Virus (HCV) infection
!Evidence of TLS per the Cairo-Bishop defi nition of laboratory TLS (subjects may 
be enrolled upon correction of electrolyte abnormalities)
!Any of the following laboratory abnormalities:
#Calculated (method of Cockroft-Gault) creatinine clearance of <60 mL/min 
(creatinine clearance may also be obtained by [CONTACT_941] 24-hour collection method at the investigatorâ€™s discretion)
#Absolute neutrophil count (ANC) < 1,000/ Î¼L (1.0 X 10
9/L)
#Platelet c ount < 50,000/ Î¼L (50 X 109/L)
#Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic 
transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 3.0 x upper limit of normal (ULN)
#Serum total bilirubin > 1.[ADDRESS_281499]
!Uncontrolled hyperthyroidism or hypothyroidism
!Venous thromboembolism within 12 months
!â‰¥ Grade-2 neuropathy
!Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
!Disease transformation [i.e. Richterâ€™s Syndrome (lymphomas) or prolymphocytic 
leukemia]
!Participation in any clinical study or having taken any investigational therapy within 
28 days prior to initiating lenalidomide therapy
!Known presence of alcohol and/or drug abuse
Investigational product, dosage and mode of administration:
Celgene Corporation will supply lenalidomide 2.5 mg, 5 mg, 10 m g, 15 mg, 20 mg and 25 mg 
capsules for oral administration.  Subjects will receive 28 days of lenalidomide per cycle.
Study drug will be packaged in bottles containing study capsules for 28 days.   
Assessments
Efficacy
!Physical Exam (lymph nodes, spleen and liver measurement)
!Complete blood count (CBC) and differential
!Immunophenotypi[INVESTIGATOR_233216]
!Histopathology (bone marrow aspi[INVESTIGATOR_337]/biopsy)
!Assessment for MRD by [CONTACT_233269] (peripheral blood and bone marrow &(/*(1ntsnts
fficacyfficacy(1([ZIP_CODE],(7$5<,1)250$7acetacetic ic 
m glutamatem glutamat
N))
nemia or thnemia or t
râ€™s Syndromâ€™s Syndro
studystudy  or hor y
g g lenalidolenalid m
alcohoalcoho l l andan$7,21$7$7
dosage andosage an
will supplywill supply
dministratioministrati
l be packagl be packag35
!!PP(1
&
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 17 CC-5013-CLL-009 Amendment 6 Final 15Apr2015aspi[INVESTIGATOR_337])
!Computed tomography (CT) scans
!ECOG Performance Status
!Assessment of constitutional symptoms (weight loss, fever, night sweats, fatigue)
Safety
!Vital signs
!Clinical laboratory evaluations
!Pregnancy testing
!Electrocardiogram (ECG)
!Concomitant medications
!AEs by [CONTACT_137773] 3.0, with m odifications recommended by [CONTACT_233270] ( Hallek, 2008 ), and by [CONTACT_137785]-
Bishop grading system for TLS
!Second primary malignancies will be monitored as events of interest and should be 
included as part of the assessment of adverse events throughout the course of the 
study. Investigators are to report any second primary malignancies as serious 
adverse events regardless of causal relationship to study drug, occurring at any time for the duration of the study, from the time of signing the informed consent up to 
and including the survival follow up phase . Subjects will be followed until 80% of 
the subjects have progressed or died or up to five years after the last subject was randomized, whichever occurs later.
Exploratory
!FISH analyses, V
Hmutational status assessment, TP53 mutation,  
, ZAP-70  expression by [CONTACT_4133]
!!Beta-2 Microglobulin ( Î²2M)
!Plasma PK (in up to [ADDRESS_281500] centers)
!!Quality of Life as measured by [CONTACT_53926]-Leu questionnaire and EQ-5D
Statistical Analysis
OverviewThis study will be conducted using a randomized Bayesian schedule-administration design that 
jointly models toxicity/disease progression outcomes using an extension method.  The object of interest is to determine if a particular treatment administration schedule is superior to other 
competing schedules.&(/*atistical Antistical An/*(QualitQualit y y
/*(1(3croglobulincroglobulin
aaPKPK (in up (in upKK35235,(7$5<,1)250$7,21mended by [CONTACT_233271] 
, 20082008 ), an), an
events of ievent
ents througents throug
primaryprimary my
nship to stunship to stu
ime of signime of sig
phase. Subphase. Sub
iededor up toor up to
laterlater..
tatitionalal st stll$7$7
OverviewOverview
This This/*
&[ZIP_CODE]
*(1
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 18 CC-5013-CLL-009 Amendment 6 Final 15Apr2015The approximate sample size will be 105 subjects, 35 per arm, barring early stoppi[INVESTIGATOR_007].
Operationally the study will proceed as follows:  Subjects will be randomized to one of the 
three treatment arms.  The first interim analysis (toxicity only) will be performed once [ADDRESS_281501] incidence rates of all AEs (including serious, Grade 3, Grade 4, treatment-related [with and without 
discontinuation] and events requiring the discontinuation of investigational product), will be 
tabulated by [CONTACT_137775], preferred term, and severity using MedDRA terms and by [CONTACT_137773] 3.0, with modifications recommended by [CONTACT_233272] ( Hallek, 2008 ), and by [CONTACT_137785]-Bishop grading system for 
TLS.  Time to first dose reduction will be summarized for each regimen.
Death and clinically important AEs (including TFR, TLS, second primary malignancies and 
thrombosis) will also be summarized.
All other measurements will be summarized using means, standard deviations, medians, 
minimum, and maximum.  Graphical displays will be provided where useful in the 
interpretation of results.
Efficacy Analysis
Efficacy analyses will be performed on the intent-to-treat (ITT) population that includes all 
subjects randomized.
Response, duration of response, TTR, TTP, EFS, PFS, and OS will be summarized.  The 
Kaplan-Meier procedure will be used to characterize the time-to-event curves in these analyses 
when there is censoring.
Exploratory Analysis
 
  
Pharmacokinetics Analysis
If the data are sufficient, noncompartmental PK parameters, such as T
max, Cmax, AUC, CL/F, 
and t 1/2, will be estimated.  Descriptive statistics w ill be provided for plas ma concentrations and 
PK parameters.  Lenalidomide concentration data obtained from all visits may be used to develop the population PK model.  The relati onship between pharmacokinetics and response 
(biomarkers or clinical outcome s as appropriate) will be explored.
Analysis and Reporting&(/*macokinetmacokinet
f the data af the data a
and tand t 1/21/2,ww
PK paPK pa&(1([ZIP_CODE],(7$5<,1)250$7yy analyses.  analyses.yy
mmedicatedicat ioio
ubject inciubject inci dd
wiiththii and wiand wihh ii
onal produnal pro
RA terms aRA terms 
wCLL guideCLL guid
iroro--BiBishop
each regimeeach regim
LS, second LS, secon
ng means, ng means, 
s will be prs will be pr
ed on the ind on the i
onse, TTRonse, TT
e will be use will be
ing.ing.
nalysisnalysis$7,21$7$7
*(1/*(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 19 CC-5013-CLL-009 Amendment 6 Final 15Apr2015In addition to the interim analyses focusing on toxicities and disease progression, efficacy 
analyses will be performed when 80% of the subjects have progressed or died, or five years 
after the last subject was randomized, whichever occurs later.  
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 20 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Figure 1: Overall Study Schema
&(/*(1(352priprietet52352
7$5<,1)250$7,21e Corporae Corpora
21
1)2501)250
5<,1)5<,1)
0$70$7
7$7$
35,(7$7$

('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 21 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 2: Schedule of Assessments
ProcedureaScreen-
ing â‰¤[ADDRESS_281502] cycle 
at 
Dose Level
+1,+2,+3,+4
+/- [ADDRESS_281503] 
cycle at 
Dose Level
+1, +2,+3, +4
Days 8 and 
15 of Cycle 2
+/- 2 daysEvery 28 
days
(4 wks)b, c
(1stday 
of each 
cycle)At time of 
clinical 
manifestation 
of TFRAt time of 
clinical 
resolution 
of TFRCR/CRi/ 
PR 
confirma-
tion visitTreat-
ment 
discon-
tinuationcEvery 12 
weeks
(+/- 7 
days) 
until 
study 
closure
ICF/Inclusion/Exclusion X -- -- -- -- -- -- -- -- --
Clinical staging for CLL (Rai or 
Binet classification)X - - - - - -- -- -- - - - - - - -
Medical history 
 X - - - - - -- -- -- - - - - - - -
Pregnancy testdXdXd-- -- Xd-- -- -- Xd--
Pregnancy and risk counseling XeXe-- -- Xe-- -- -- Xe--
ECOG Performance Status X X -- -- X -- -- -- X --
Evaluation of constitutional 
symptomsX X -- -- X -- -- -- X --
Physical examination to assess 
lymph nodes, spleen and liverf X X -- -- X -- -- -- X --
Vital signs including weight, height 
(at screening only)g XX X X X - - - - - - X - -
CT scanshX - - - - - -- -- -- - XhXh--
ECG (12 lead)i
X- - - - - -X 
(starting at 
C3D1 then 
every 84 
days 
thereafter)-- -- -- X --
TLS monitoring and prophylaxis 
and TFR monitoringj XX X X X - - - - - - - - - -
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietete of e of 
nical nic
esolution esoluti
of TFRof TFRCR/CCR/C7,2
125$7
---111)1 ---,1111
--<
$5XXd$5$5$5$
Xee7$(XX(((75,(---5,(5,(5,(5,(
---35
52XX52525252---35( ----(((3
(1(
X*(((
(/*(/*(/*(/*(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 22 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 2: Schedule of Assessments (Continued)
ProcedureaScreen-
ing â‰¤[ADDRESS_281504] cycle 
at 
Dose Level 
+1,+2,+3,+4
+/- [ADDRESS_281505] 
cycle at 
Dose Level 
+1, +2,+3, +4
Days 8 and 
15 of Cycle 2
+/- 2 daysEvery 28 
days
(4 wks)b, c
(1stday 
of each 
cycle)At time of 
clinical 
manifestation 
of TFRAt time of 
clinical 
resolution 
of TFRCR/CRi/ 
PR 
confirma-
tion visitTreat-
ment 
discon-
tinuationcEvery 12 
weeks
(+/- 7 
days) 
until 
study 
closure
HematologykXX X X X - - - - - - X - -
ChemistrylXX X X X - - - - - - X - -
UrinalysismXX X X X - - - - - - X - -
Calculated (method of Cockroft-
Gault) creatinine clearance (24-hour 
collection method may also be used 
at the investigatorâ€™s discretion)lX - - - - - -- -- -- - - - - - - -
Direct antiglobulin (DAT) testnX - - - - - -- -- -- - - - - - - -
Thyroid function testo
X- - - - - -X 
(starting at 
C3D1 then 
every 84 
thereafter)-- -- -- X --
Bone marrow aspi[INVESTIGATOR_337], biopsy, 
peripheral blood slidespXpXp-- -- -- -- --Xp
(CR/CRi 
only)-- --
Disease diagnosis confirmation 
)q -- X -- -- -- -- -- -- -- --
MRD evaluationr
-- -- -- -- -- -- --Xr
(CR/CRi 
only)-- --
&(/*(1(priprietet(1([ZIP_CODE],(7$5-$5<,1)250$7,21e Corporae Corpora
21
me of me of 
clinical linic
resolution resolution 
of TFRof TCRC777,
125$7
111)1 ---,1111
----<5<$5
--(7,(
---(,(,(,(
25,(
222352
--35( ----(((
(1(1(1(1(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 23 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 2: Schedule of Assessments (Continued)
ProcedureaScreen-
ing â‰¤[ADDRESS_281506] cycle 
at 
Dose Level 
+1,+2,+3,+4
+/- [ADDRESS_281507] 
cycle at 
Dose Level 
+1, +2,+3, +4
Days 8 and 
15 of Cycle 2
+/- 2 daysEvery 28 
days
(4 wks)b, c
(1stday 
of each 
cycle)At time of 
clinical 
manifestation 
of TFRAt time of 
clinical 
resolution 
of TFRCR/CRi/ 
PR 
confirma-
tion visitTreat-
ment 
discon-
tinuationcEvery 12 
weeks
(+/- 7 
days) 
until 
study 
closure
FACT-Leu and EQ-5D questionnaire
-- X -- --X 
(starting at 
C3D1 then 
every 56 
days 
thereafter)-- -- -- X --
Study drug administrations-- X -- -- X -- -- -- X --
Adverse eventstXX X X X - - - - - - X - -
Assessment of Second Primary 
Malignancyu XX X X X - - - - - - X X
Concomitant medication/therapi[INVESTIGATOR_233217] X X X - - - - - - X X
Assessment of responsev-- -- -- -- Xu-- -- -- X --
Survivalw-- -- -- -- -- -- -- -- -- X
Beta-2 Microglobulin ( Î²2M)x- - X - - - -- -- -- - - - - - - -
ZAP-70 expressiony- - X - - - -- -- -- - - - - - - -
VHmutational status/ TP53 
mutationy - - X - - - -- -- -- - - - - - - -
Cytogenetic analysis (FISH)y- - X - - - -- -- -- - - - - - - -
a. All study procedures should be performed within Â± [ADDRESS_281508] be performed every 28 days (Â±3days).  If a Day [ADDRESS_281509] every 28 days (Â±3days) during the study.
&(/priprietet/*(1(35---
(XX(((3(XX1(((
(1(1(1(1(
performed wierformed wi
erformed evermed ev
re performedre performed5235,(7$5<,1)250$7,21e Corporae Corpora
21
me of me of 
clinical linic
resolution resolution 
of TFRof TCRC777,
125$7
----111)
$51
X$5$5$5$5XX7$$$$
XX(75,(XX5,(5,(5,(5,(----35---23222252352
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281510].  During these visits 
for these subjects only the following assessments are required: hematology, ECOG performance status, evaluation of constitution al symptoms, physical exam 
for liver, spleen and lymph nodes, adverse events, assessment for second primary malignancies, concomitant medications/therapi[INVESTIGATOR_233218].  
d. Females of childbearing potential (FCBP) must have a medically supervised pregnancy test (serum or urine with sensitivity of at least 25 mIU/mL) per the 
frequency specified in Appendix 21.[ADDRESS_281511] palpable nodes in each of the following sites:  cervical, 
axillary, supraclavicular, inguinal and femoral.  The size of th e liver and spleen will be assessed by [CONTACT_233273].
g. Vital signs include:  temperature, pulse, blood pressure, weight and height (height to be measured during screening only).h. CT scans of the neck, chest, abdomen and pelvis to assess lymphadenopathies will be performed during screening and at the PR and CR/CRi confirmation 
visits (â‰¥8 weeks - â‰¤ [ADDRESS_281512] been met for PR or CR/CRi) and for all subjects, except those  who 
discontinue due to PDs, at the treatment discontinuation visit.  At screening, if medically justified, the possibility of not r epeating the CT Scan when 
previously performed within [ADDRESS_281513] scan interpretation at the PR or CR/CRi confirmation visit will have the CT scan repea ted 4 months later at the 
location where remaining disease has been documented as long as clinical and laboratory response remains present to try to docu ment further improvement..
i. ECG will be performed and interpreted locally.  After the screening ECG, the next ECG will be done at Cycle 3 Day 1, and then every 12 weeks while on 
study drug, and at treatment discontinuation.
j. TLS prophylaxis, comprising of oral hydration and allopurinol 300 mg/day will be initiated at least [ADDRESS_281514]â€™s cardiovascular status indicates the possibility of volume overload.
k. Hematology: Local lab assessments include HGB, ANC, ALC and platelet count.  At screening, subject must meet eligibility crit eria based on central lab 
results.  At Study Day 1, subject must meet eligibility criteria based on local or central lab results prior to initiating stud y therapy
l. Chemistry: Local lab assessments include potassium, calcium, phosphorus, creatinine, total bilirubin, AST/SGOT, ALT/SGPT, and  uric acid.  At screening, 
subject must meet eligibility criteria based on central lab results.  At Study Day 1, subject must meet eligibility criteria ba sed on local or central lab results 
prior to initiating study therapy, however, a re-calculation of creatinine clearance is not required at Study Day 1.
m. Urinalysis:  Local laboratory assessments will in clude ketones, sediments and specific gravity.  
n. DAT (direct antiglobulin test) will be performed at screening and analyzed at the central laboratory.  The DAT test should be repeated if the investigator 
suspects hemolytic anemia during the course of the study. Analysis of DAT will be completed by [CONTACT_233274] a mendment, protocol 
amendment #6.
o. TSH (thyroid-stimulating hormone), free T3, and free T4 levels will be assessed at screening, Cycle 3 Day 1 and every 12 week s while on study drug and at 
treatment discontinuation.  All samples will be analyzed centrally.  Collection of TSH samples is discontinued as of this amend ment, protocol amendment #6.
p. A peripheral blood, bone marrow aspi[INVESTIGATOR_233219] 1 day 1and at the CR/CRi confirmation visit.  At screening, if medically justified, the possibilit y of not repeating the bone 
marrow aspi[INVESTIGATOR_337]/biopsy when previously performed within 56 days of randomization will be evaluated by [CONTACT_233275] a case by [CONTACT_23353] 
&(/priprietet(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21ontinue everyntinue eve
st.  During tht.  During th
 symptoms, pymptoms, 
pi[INVESTIGATOR_233220]
y of of at least at least 2
nAppendix 2Appendix 2
erery y28 days t28 days
e nodes in eae nodes in ea
tion and recon and re
ng screeningng screening
rring screeninscreen
r PR or CR/CR or CR/C
fied, the posfied, the p
edical Monitedical Monit
nfirmation vinfirmation vi
tory responstory respons
t ECG will bECG will
will be initiatwill be initi
ol prior to stuol prior to stu
fluid intake, suid intake, 
on period.  Hon period.
ility of volumility of volum
C and plateleand platel
ria based on ria based on
alcium, phospcium, phosp
lab results.  Alab result
culation of cration of cr
nclude ketonnclude keto
med at screenmed at scre
rse of the sturse of the stu
, free T3, andfree T3, an
mples will bmples will b
ow aspi[INVESTIGATOR_233221] a
e 1 day 11 day 1 and and
when previouwhen previo
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 25 CC-5013-CLL-009 Amendment 6 Final 15Apr2015basis if sufficient and appropriate samples are available for submission to the central pathology reviewer.  For those subjects  who reach CR or CRi, a 
peripheral blood, bone marrow aspi[INVESTIGATOR_233222]/CRi 
confirmation visit ( â‰¥ 8 weeks - â‰¤ [ADDRESS_281515]  been met).  If the bone marrow is hypocellular, a repeat 
specimen should be obtained after [ADDRESS_281516] recovered.  If the bone marrow biopsy shows dise ase involvement (30% or 
greater lymphocytes, or nodules positive for B-CLL cells by [CONTACT_52265]), an additional bone marrow biopsy and aspi[INVESTIGATOR_20325] e will be taken 4 months 
later as long as clinical and laboratory response remain to document further improvement.  All bone marrow and aspi[INVESTIGATOR_233223].
q. Peripheral blood for disease diagnosis confirmation (by [CONTACT_137766][INVESTIGATOR_233224], 2008 )  will be drawn at Study Day 
[ADDRESS_281517] assessment: MRD status will be evaluated for those subjects who reach CR or CRi. A peripheral blood and bone marrow aspi[INVESTIGATOR_233225]/CRi confirmation visit ( â‰¥8 weeks - â‰¤ [ADDRESS_281518] been met for CR/CRi).  If peripheral blood and bone marrow are both MRD-positive, peripheral blood samples will be repeate d and assessed up to [ADDRESS_281519] negativity in subjects who reach confirmed CR or CRi (see Follow-up  MRD assessments). If 
peripheral blood is MRD-negative and bone marrow is MRD-positive, both peripheral blood and bone marrow should be retested for MRD negativity after â‰¥ 
[ADDRESS_281520] assessments :  If any of the repeat peripheral blood assessments i ndicate MRD-negativity, a bone marrow aspi[INVESTIGATOR_233226].  If the bone marrow is MRD-positive, both peripheral bl ood and bone marrow 
should be retested for MRD negativity after â‰¥ [ADDRESS_281521] is in.  This includes any second primary malignancy, regardless of causal relationship to study drug, occurring at any time for the duration of the 
study, from the time of signing the informed consent up to and including the survival follow up period.  Subjects will be follo wed until 80% of the subjects 
have progressed or died or up to five years after the last subject was randomized, whichever occurs later.  Events of second pri mary malignancy are to be 
reported using the SAE report form and must be considered an â€œImportant Medical Eventâ€ even if no other serious criteria apply;  these events must also be 
documented in the appropriate page(s) of the CRF and subjectâ€™s source documents.  Documentation on the diagnosis of the second primary malignancy must 
be provided at the time of reporting as a serious adverse event (e .g., any confirmatory histology or cytology results, X-rays, CT scans, etc.).
v. Investigators to provide assessment of CR, CRi, nPR, PR, SD, and PD based on laboratory, physical exam, assessment of constit utional symptoms and if 
appropriate CT scan findings (CT scans are to be performed at baseline and to confirm PR or CR/CRi).  For confirmed PR, nPR or CR/CRi, response must be 
maintained for â‰¥ 8 weeks as per the iwCLL guidelines for the diagnosis and treatment of CLL ( Hallek, 2008 ) Tumor response will be assessed according to 
&(/*priprietet/*(1([ZIP_CODE],(7$5<,1)2eral eral blood anblood an
ksafter all clafter al
blood sampleblood sample
rmed CR or rmed CR o
d bone marroone marro
erformed.  If rformed. 
il subjel subje ct disct dis
nts indicate Mts indicate M
marrow is Mmarrow is M
w is MRDw is MRD -p
ery [ADDRESS_281522] scans areT scans are
s per the iwCper the iwC2550$7,21e Corporae Corpora
21CR or CRi, a R or CRi, 
at the CR/CRat the CR/CR
hypocellularypocellular
sease involvase involv
aspi[INVESTIGATOR_233227]
250
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 26 CC-5013-CLL-009 Amendment 6 Final 15Apr2015the iwCLL guidelines ( Hallek, 2008 ) for the diagnosis and treatment of CLL ( Hallek, 2008 ), including CR, CRi, nPR, PR, SD, and PD.  Evaluation of 
response will be performed after 3 cycles of therapy and every 4 weeks thereafter.
w. Subjects who develop PD or disease transformation [Richterâ€™s syndrome (lymphomas) or prolymphocytic leukaemia], at any time, or who choose to 
discontinue study participation for any reason, or who begin a new CLL therapeutic regimen will be discontinued from the study and will be followed for 
survival, assessment for second primary malignancies and subsequent CLL therapi[INVESTIGATOR_233228] 80% of the subjects have progressed or di ed or up to five years 
after the last subject was randomized, whichever occurs later.
x. Blood samples for Î²2M will be collected at baseline.   
All Samples will be analyzed centrally.   
y. Blood samples for ZAP-70, V Hmutational status / TP53 mutation analysis and FISH studies for cytogenetic assessment (CCND1/IgH fusion, 11q, 17 p, 13 q, 
and Trisomy 12) will be collected at Study Day 1 pre-dose.   
All samples will be analyzed centrally.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietetEvaluation oEvaluation 
or who choor who choo
yand will be nd will be
ed or diedor died or 
sessment (CCsessment (C50250
1)2
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281523] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ...........................34
5. INTRODUCTI ON..................................................................................................38
5.1. Chronic Lymphocytic Leukemia .............................................................................38
5.2. Lenalidomide ..........................................................................................................40
5.3. Background and rationale for lenalidomide in chronic lymphocytic leukemia .........40
5.3.1. Background ............................................................................................................40
5.3.2. Clinical studies .......................................................................................................41
[IP_ADDRESS]. Relapsed/refract ory CLL ........................................................................................41
[IP_ADDRESS]. Previously untreated symptomatic CLL ..................................................................43
[IP_ADDRESS]. Study CC-5013- CLL-[ADDRESS_281524] IVES ...........................................................................................46
6.1. Primary Objective ...................................................................................................46
6.2. Secondary Ob jectives .............................................................................................46
7. STUDY ENDPOI NTS............................................................................................47
7.1. Primary ...................................................................................................................47
7.2. Secondary ...............................................................................................................47
7.3. Explorat ory.............................................................................................................47
8. OVERALL STUDY DESIGN ................................................................................48
8.1. Design Rationale ....................................................................................................48
8.1.1. Study Desi gn ..........................................................................................................48
8.1.2. Adaptive Study Design ...........................................................................................48
8.1.3. Randomization ........................................................................................................48
8.1.4. Duration of Treatmen t ............................................................................................49
8.1.5. Study Population ....................................................................................................49
8.1.6. Dose and dose interval ............................................................................................49
8.1.7. Safety ................................................................................................................... ..49&(/*(1([ZIP_CODE],(7$5<,1)250$7,2177
.......343
................383
..........................
.........................
yytitiyyc leukemc leukem
...........................
....................
...................
.......................
..................
.........................
.......................
.........................
..................
S.........................
.....................
.................
oryry....................
RALL STURALL STU
Design RatioDesign Rati
StudyStudy DDyy
AdaAd
.1.3..1.3.
8.1.4..1.4.
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281525] ug ......................................................................................57
10.2. Treatment Assign ments ..........................................................................................57
10.2.1. Randomization ........................................................................................................57
10.2.2. Treatment ...............................................................................................................58
10.2.3. Dose Modification or Interruption ...........................................................................58
10.3. Emergency Unb linding ...........................................................................................65
10.4. Prior/Concomi tant Medications ..............................................................................65
10.4.1. Prophylaxis and/or Treatment for TLS, TFR, Neutropenia, and 
Thromboembolic Events .........................................................................................66
[IP_ADDRESS]. Tumor Lysis Syndrome (TLS) Prophylaxis .............................................................66
[IP_ADDRESS]. Tumor Flare Reaction (TF R) Treatme nt..................................................................66
[IP_ADDRESS]. Neutropenia Supportive Treatment .........................................................................66
[IP_ADDRESS]. Infection Prophylaxis ..............................................................................................66
[IP_ADDRESS]. Thromboembolic Ev ents Prophylaxis ......................................................................67
[IP_ADDRESS]. Other ................................................................................................................. .....67
[IP_ADDRESS]. Prohibited Concomitant Therapy ............................................................................67
10.5. Discontinuation f rom Treatment .............................................................................67
11. STUDY DRUG MATERIALS AND MANAGEMENT .........................................69
11.1. Supplier(s) ..............................................................................................................[ADDRESS_281526] of Admin istration .......................................................................................70&(/*(1([ZIP_CODE],(7$5<,1)250$7,2133
.......535
..............545
.........................
..........................
..........................
..........................
..........................
..................
.........................
.............................
, TFR, Neu, TFR, Neu
...........................
ProphylaxiProphylaxi
R) Treatm) Treatm e
e TreatmenTreatmen
xisis................
lic Events Pc Events
......................
ted Concoted Conco
scontinuaticontinua
STUDY DSTUDY 
SuppSupp
.2. DD
11.3.1
4
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281527] ug .............................................................................................................82
15.7. Concomitant Th erapy .............................................................................................83
15.8. Safety Evalu ation....................................................................................................83
15.9. Interim Analy ses.....................................................................................................83
15.10. Sample Size and Powe r Considerati ons...................................................................84
15.11. Other Topi [INVESTIGATOR_1102]...........................................................................................................84
15.11.1. Pharmacokinetics  Analysis: ....................................................................................84
15.11.2. Explor atory Analy sis ..............................................................................................84
16. QUALITY CONTROL AND QUALITY ASSURANCE ........................................85
16.1. Monitori ng .............................................................................................................85&(/*(1([ZIP_CODE],(7$5<,1)250$7,2144
.......747
..............757
.........................
..........................
..........................
..........................
................ ..........
..................
.........................
..........................
.........................
........................
..................... ..
.................
.......................
sesses.............
and Demognd Demog
ugug....................
omitant Thomitant Th
afetetffy y EvaluEvalu
Interim Interim 
.. SamSa
[IP_ADDRESS].
[IP_ADDRESS].1
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 30 CC-5013-CLL-009 Amendment 6 Final 15Apr201516.2. Audits and Ins pections............................................................................................85
16.3. Inve stigator(s) Responsibilities ...............................................................................[ADDRESS_281528]/Independent Ethics Committee Review and 
Approval ................................................................................................................[ADDRESS_281529] Confide ntiality ...........................................................................................88
18. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] .....................................................89
18.1. Data/Documen ts .....................................................................................................89
18.2. Data Management ...................................................................................................89
18.3. Retention of Records ..............................................................................................89
19. PREMATURE DISCONTINUATION OF THE STUDY .......................................91
19.1. Single S ite ..............................................................................................................9 1
19.2. Study as a Whole ....................................................................................................91
20. REFERENCES.......................................................................................................92
21. APPENDICES ........................................................................................................96
21.1. Adverse Ev ent ........................................................................................................96
21.2. Declaration of Helsinki .........................................................................................101
21.3. Cairo-Bishop Definition and Grading of Tumor Lysis Syndrome (Cairo, 
2004) ................................................................ .................................................... 102
21.4. Grading of Hematological Toxicity (Hallek, 2008) ...............................................103
21.5. ECOG Performance Status Scale ..........................................................................104
21.6. Clinical Staging of CLL Patien ts...........................................................................105
21.6.1. Rai staging system (m odified) (R ai, 1987) ............................................................ 105
21.6.2. Binet staging sys tem (Binet, 1981) ....................................................................... [ADDRESS_281530]-Leu Questi onnaire .....................................................................................106
21.8. EQ-5D Health Qu estionnaire ................................................................................109
21.9. Pregnancy Prevention Risk Minimization Plans ....................................................111
21.9.1. Lenalidomide Pregnancy Prevention Risk Management Plan ................................111
[IP_ADDRESS]. Lenalidomide Pregnancy Risk Minimisation Plan for Celgene Clinical Trials .......111
[IP_ADDRESS]. Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and 
Acceptable Birth Control Methods ........................................................................112&(/*(1([ZIP_CODE],(7$5<,1)250$7,21..[ADDRESS_281531] --LeuLeu
EQEQ--5D5D
9.. PrPr
[IP_ADDRESS].9.1.
.9.191
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 31 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.9.1.3. Lenalidomide Education and Counseling Guidance Document .............................116
[IP_ADDRESS]. Lenalidomide Informatio n Sheet ...........................................................................[ADDRESS_281532] udy................................................................ .................................... 122
21.10.4. Decis ion Rules ......................................................................................................123
21.10.5. Operating Characteristics of Simulation Study ......................................................124
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2122
...[ZIP_CODE]
............[ZIP_CODE]
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281533] OF TABLES
Table 1: Celgene Emergenc y Contact [CONTACT_233276]..................................................................4
Table 2: Schedule of Assessments ........................................................................................21
Table 3: Abbreviations and Specialist Terms ........................................................................34
Table 4: Dose Regimen by [CONTACT_233277] m...........................................................................58
Table 5: Dose Reduction and Modification Guidelines for Lenalidomide .............................59
Table 6: Dose Reduction Steps for Lenalidomide .................................................................65
&(/*(1([ZIP_CODE],(7$5<,1)250$7,215858
......5959
..................... .65.6
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281534] OF FIGURES
Figure 1: Overall Study Schema ............................................................................................20
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281535] OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Table 3: Abbreviations and Specialist Terms
Abbreviation or Specialist Term Explanation
AE Adverse event
ALC Absolute lymphocyte count
ALT (SGPT)Alanine transaminase (serum glutamate 
pyruvic transaminase)
ANC Absolute neutrophil count
ASCO American Society of Clinical Oncology
ANOVA/ANCOVA Analysis of Variance/Covariance
AST (SGOT)Asparate transaminase (serum glutamic 
oxaloacetic transaminase)
ATC Anatomic Therapeutic Chemical 
Î²2M Beta-2 Microglobulin
âˆƒ-HCG Beta-human chorionic gonadotropin hormone
BUN Blood urea nitrogen
CBC Complete blood count
CFR Code of Federal Regulations
CI Confidence Interval
CrCl Creatinine Clearance
CLL Chronic lymphocytic leukemia
CMV Cytomegalovirus
CNS Central nervous system
CR Complete response
CRiComplete response with incomplete bone 
marrow recovery
eCRF Electronic case report form
CR MRD+Complete response â€“ Minimal residual disease 
positive
CR MRD-Complete response â€“ Minimal residual disease 
negative
CT Computed tomography
CTCAECommon Terminology Criteria for Adverse 
Events&(/*R MRD+R MRD+/*(1([ZIP_CODE],(7$5<,1)250$7,21$$$0$0$0$0$cologycology50anceance25serum glutamrum gl
nase)ase))2
peutic Chemutic Chem,1
oglobulinoglobulin<
maman chorionn chorion5<
od urea nitrood urea nitr$5
Complete bComplete 7$
Code Code ,,,(5,CoCo5,5,5,5,[ZIP_CODE]
235235(31(
*(/*
CR MR M&(&&&
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 35 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 3: Abbreviations and Specialist Terms (Continued)
Abbreviation or Specialist Term Explanation
DAT Direct Antiglobulin Test
DCF Data Clarification Form
DLT Dose-limiting toxicity
DMC Data Monitoring Committee
DVT Deep vein thrombosis
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
EE Efficacy Evaluable Population
EFS Event-free survival
EMA European Medicines Agency
EQ-5D EuroQol 
F Fludarabine
FACT-LeuFunctional Assessment of Cancer Therapy-
Leukemia
FCBP Female of childbearing potential
FDA Food and Drug Administration
FISH Fluorescence in Situ Hybridization
FNA Fine Needle Aspi[INVESTIGATOR_233229]-stimulating factor
HGB Hemoglobin
HCT Hematocrit
HIV Human immunodeficiency virus
HRQL Human Related Quality of Life
ICH International Conference on Harmonization
IEC Independent Ethics Committee
VH Immunoglobulin Heavy-chain Variable-region
IL-6 Interleukin 6&(VV&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$$$0$0$0$0$500
GroupGroup5
ionon2
1)2es Agencyes Agency,1<, nee5< ional Assesonal Asses
ukemiaukem$5
FemaFema le ofe of(7,Food Food 5,5,5,(5,F5555
235253(1((1*
ECEC(/*HH&(&ILIL&&&
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 36 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 3: Abbreviations and Specialist Terms (Continued)
Abbreviation or Specialist Term Explanation
IMiD Immunomodulatory drug
IMP Investigational Medicinal Product
IND Investigational New Drug
INR International Normalized Ratio
IRB Institutional Review Board
ITT Intent to Treat
IV Intravenous
IVRS Interactive Voice Response System
iwCLL International Workshop on CLL
LDH Lactate dehydrogenase
 
LN Lymph node
MDS Myelodysplastic syndrome
MedDRA Medical Dictionary for Regulatory Activities
MRD Minimal residual disease
MTD Maximum-tolerated dose
MTDEL Maximum tolerated dose escalation level 
NCI CTCAE National Cancer Institute Common 
Terminology Criteria for Adverse Events 
NCI-WGNational Cancer Institute Working Group 
criteria for chronic lymphocytic leukemia
NK cells Natural killer cells
NOS Not otherwise specified
NSAID Non-steroidal anti-inflammatory drug
ORR Overall Response Rate
OS Overall Survival
PD Progressive disease
PFS Progression free survival
PK Pharmacokinetic&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$$$0$0$0$0$000
temem5
CLLCLL2)21
<, plastic syndlastic syn5< cal Dictionacal Dictiona$5 MinimaMinima l resil resi7$MaximuMaximu(75,MaxMa5,5,5,(5,[ZIP_CODE]
5235(31((1*( DD/*PFSPFS(/&PKK&&(&&<, 1
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 37 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 3: Abbreviations and Specialist Terms (Continued)
Abbreviation or Specialist Term Explanation
PR Partial Response
PS Performan ce Status
RAC Response Adjudication Committee
RBC Red blood cell
RIC Reduced intensity conditioning
SAE Serious adverse event
SC Subcutaneous
SCID severe combined immunodeficiency 
SCT Stem cell transplantation
SD Stable disease
SGOT Serum-Glutamic-Oxaloacetic Transaminase
SLL Small Lymphocytic Lymphoma
SOP Standard Operating Procedure
TFR Tumor Flare Reaction
TLS Tumor Lysis Syndrome
TNF-% Tumor necrosis factor alpha
TNM Tumor-node s-metastasis 
TP53 Tumor protein 53
TSH Thyroid stimulating hormone
TTE Time to event
TTF Time to treatment failure
TTP Time to progression
TTR Time to response
VEGF Vascular Endothelial Growth Factor
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$$$0$0$0$0$000
ency ncy 52)2
xaloacetic Toacetic1
ocytic Lympcytic L<, Operating Prperating 5< r Flare Reacr Flare Rea$5 umumor Lysisor Lysis7$TumTumor nor n(75,TumTum5,5,5,(5,[ZIP_CODE]
235235(31((1*(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281536] of newly diagnosed patients are under the age of 65 years ( Leukemia and Lymphoma 
Society, 2008 ).  It is an incurable lymphoproliferative malignancy manifested by [CONTACT_233278], 
bone marrow, and lymphoid tissues.  The clinical course of CLL ranges from indolent disease 
(Rai 0, Binet A) with long-term survival over 12 years to aggressive disease (Rai III/IV, Binet C) 
with median survival of 2 years ( Montserrat, 1995 ).
Multiple, randomized, Phase [ADDRESS_281537] attempted to identify treatments that improve overall 
survival (OS).  Chlorambucil, approved by [CONTACT_69391] 1957, is a well-tolerated oral agent that can induce partial remissions (PR) in advanced stage CLL patients and has been in use for 
many decades.  In early stage CLL patients, the French Co-operative group on CLL ( Dighiero, 
1998 ) reported that early therapy with alkylato r-based therapy did not improve survival 
compared to observation alone. Due to the av ailability of newer treatment options demonstrating 
improved efficacy, chlorambucil is not cons idered the optimal first-line treatment cho ice by 
[CONTACT_233279].  However, the drug is still considered a valid treatment option for elderly patients and those with comorbidities that preclude treatment with more aggressive 
treatment regimens.
Fludarabine is approved by [CONTACT_1622] (April 1991) as  a second-line agent.  Clinical studies of 
fludarabine have shown superior overall response rates, complete response rates, and progression 
free survival, but no improvement in overall survival was noted ( Rai, 2000 ) (Catovsky, 2007 )  In 
recent years, data from several phase 2/3 clinical studies in which fludarabine was combined with cyclophosphamide and/or rituximab demonstr ated high response rates and long progression-
free survivals, with increased toxicity compared to chlorambucil, but as yet have not shown a 
survival benefit ( Oâ€™Brien, 2001 ) (By[CONTACT_26752], 2003 ) (Wierda, 2005 ) (Eichhorst, 2006 ) (Tam, 2007 ).
In September 2007, alemtuzumab was also approved as first line therapy of B-cell CLL.  In an 
open-label, randomized (1:1) study of 297 p atients, the patients receiving alemtuzumab 
experienced longer PFS compared to those randomized to receive chlorambucil (median PFS 14.6 months vs. 11.7 months respectively).  The overall response rates (ORR) were 83% and 
55% (p < 0.0001) and the CR rates were 24% and 2% (p < 0.0001) ( Hillmen, 2007 ).
In March 2008, bendamustine was approved fo r the treatment of pati ents with chronic 
lymphocytic leukemia.  The labeling states â€œEfficacy relative to first line therapi[INVESTIGATOR_233230]â€.  The study comparing bendamustine, 100 mg/m
2 IV on 
days 1 and 2 every 28 days, to chlorambucil , 0.8 mg/kg/day orally on days 1 and 15 every 28 
days, was conducted in 301 patients (153 on bendamustine and 148 on chlorambucil) with Binet 
stage B or C (Rai stages I-IV) requiring treatment.  The ORR was 59% for bendamustine vs 26% 
for chlorambucil (p < 0.0001) with 8% vs <1% CRs for bendamustine and chlorambucil arms, respectively.  The median PFS was 18 months for bendamustine vs 6 months for chlorambucil (p 
< 0.0001) ( TREANDA package insert, 2008 ).  Since receiving FDA approval in 2008, market blood, blood, 
isease ase
IV, Binet CIV, Binet C
hat improvehat improv
ellell--toltolerateerate
and has beed has b
group on Cgroup on 
not improvnot impro
r treatmtreat ent
mal firstal first -linein
l considerel considere
lude treatmlude treatm
91) as a sec1) as a se
ponse ratesponse rates
rall survivarall surviva
2/3 clinical /3 clinical 
imab demomab dem
iciticity coy compmp
11) () (By[CONTACT_26752], 2By[CONTACT_26752], 
tuzumab wauzumab
d (1:1) studd (1:1) stud
PFS compaFS compa
11.7 month11.7 month
001) and the01) and th
2008, bend008, bend
ocyocytiyc lleukeeuk
rambucil hrambucil h
days 1 and 2ays 1 and 
days, wadays, wa
age B
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281538] line and in the 
relapsed/refractory setting either as a si ngle-agent or in combination with rituximab.
Based on these data and the indolent clinical course of many CLL patients, the current medical 
practice for most early stage CLL patients is that of â€œwatchful waiting.â€ For those CLL patients with advanced stage disease who require treatmen t, initial treatment selection is largely based on 
age, performance status and co-morbid conditions and is either chlorambucil monotherapy,
fludarabine-based or bendamustine-based combination regimens.
Many CLL patients relapse after initial therapy.  Second-line treatment and subsequent 
treatments often consist of purine-analog-bas ed treatment regimens.  Eighty-five percent of 
patients previously responsive to fludarabine respond to re-treatment with the same agent but the response rate falls to 12% in patients who were refractory to previous fludarabine therapy when 
re-treated with fludarabine single agent ( Thomas, 1998 ), and between 39% to 58% in patients re-
treated with fludarabine combined therapy (fludarabine with cyclophosphamide, or cyclophosphamide and rituximab) ( Oâ€™Brien, 2001 ) (Wierda, 2005 ).  Patients who become 
refractory or resistant to purine analogues containing regimens have a poor prognosis and limited 
therapeutic options.
On 07 May 2007, alemtuzumab was initially a pproved for patients previously treated with 
alkylating agents and refractory to fludarabine.  In a study of 93 heavily pretreated fludarabine 
refractory patients a response rate of 33% (2% CR) was achieved, with the median time to progression for responders of 9.5 months and a median overall survival of 16 months for all 
patients and 32 months for responders ( Keating, 2002 ).  Subjects in this study with at least one 
lymph node > 5 cm (bulky lymphadenopathy) achieved a 12% PR and 0% CR.  Toxicity with alemtuzumab therapy was not negligible a nd included infusion-re lated toxicity (81%), 
immunosuppression, and infections (55%) with reactivation of cytomegalovirus seen in 7 
patients.
On 19 September 2007, alemtuzumabâ€™s accelerated approval was converted to a full approval 
with a revised indication, â€œas a single agent for the treatment of B-cell chronic lymphocytic 
leukemia (B-CLL)â€.  In an open-label, randomized (1:1) study of 297 patients, the patients who 
received alemtuzumab experienced longer PFS comp ared to those randomized to receive 
chlorambucil (median PFS 14.6 months vs. 11.7 months, respectively).  The ORRs were 83% 
and 55% (p < 0.0001), and the CR rates were 24% and 2% (p < 0.0001).  Despi[INVESTIGATOR_233231], use of alemtuzumab as a treatment for previously untreated patients remains very limited.
Although alemtuzumab has demonstrated efficacy in  the fludarabine-refractory CLL population, 
several studies have shown that patients that have CLL bulky disease (i.e lymphadenopathy greater than 5 cm) are poor responders to alemtuzumab therapy ( Keating, 2002 ) (Fiegl, 2006 ) 
(Osterborg, 1997 ). A recent historical review by [CONTACT_233280] ( Tam, 2007 ) underlines that 
fludarabine refractory CLL patients who have bulky lymphadenopathy constitute a high unmet medical need despi[INVESTIGATOR_233232].
On 26 October 2009 the U.S. Food and Drug Administration granted accelerated approval to 
ofatumumab (Arzerraâ„¢) for the treatment of patients with chronic lymphocytic leukemia (CLL) 
refractory to fludarabine and alemtuzumab. The approval was based on a clinically meaningful 
and durable overall response rate (ORR) observed in a single-arm, multicenter trial in 154 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21f 
nt but the nt but the
erapyerapy whenwhenyy
% in patientin patien
e, or , or 
who becowho bec
or prognosir prog
s previprevi ouslyousl
3 heavily prheavi
ieved, witheved, with
verall surverall sur vii
).  Subj.  Subj ects ects
eved a 12%eved a 12%
luded infusluded infus
th reactivatth reactivat
s accelerataccelerat
le agent fore agent fo
lalabel, randbel, rand
enced longeenced long
14.[ADDRESS_281539] sho
n 5 cm) are5 cm) are
org, 1997org, 1997 ).)
rabine refrarabine ref
edical neededical need
purine anapurine ana
2626
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281540] dose of fludarabine or alemtuzumab. The primary 
efficacy outcome was durable ORR as determin ed by [CONTACT_941] 1996 National Cancer Institute 
Working Group (NCIWG) Guidelines for CLL.
5.2. Lenalidomide
Lenalidomide (REVLIMIDÂ®; Celgene Corp., NJ, [LOCATION_003]) is a member of a class of pharmaceut ical 
compounds known as immunomodulatory drugs (IMiDs PÂ®
P).  It offers potential benefit over the 
first commercially available IMiD, thalidomide, in terms of both safety and efficacy in human 
subjects ( Galustian, 2004 ) (Tohnya, 2004 ).  The key to its therapeutic potential lies in the fact 
that it has multiple mechanisms of action, which act to produce both anti-inflammatory and anti-
tumor effects.  These effects are thought to be contextual in that they depend on both the cell 
type and the triggering stimulus.  To date, lenalidomide has been associated with TNF- Î± 
inhibitory, T cell costimulatory, and antiangiogenic activities ( Galustian, 2004 ).
REVLIMIDÂ®has been approved by [CONTACT_233281] (including the FDA, but 
excluding the EU) for the treatment of patients with transfusion dependent anemia due to Low-or Intermediate-1-risk myelodysplastic syndrome associated with a deletion 5q cytogenetics 
abnormality with or without other cytogenetic abnorm alities.
REVLIMID
Â®has also been approved by [CONTACT_233281] (notably including 
the US and EU) in combination with dexamethasone, for patients with previously treated 
multiple myeloma. 
Lenalidomide is being investigated as treatment for various oncologic indications, including 
multiple myeloma, non-Hodgkinâ€™s lymphomas, and solid tumors.  It is also being explored as a 
treatment for inflammatory conditions.  While man y of the studies are ongoing, results from 
controlled and uncontrolled studies in subjects with MDS and MM are available.
5.3. Background and rationale for lenalidomide in chronic lymphocytic 
leukemia
5.3.1. Background
The cellular interplay between the microenvironment and the malignant CLL clone and the 
decreased sensitivity of B-CLL cells to apoptotic signal is thought to play an important role in 
the pathophysiology and development of CLL disease ( Ghia, 2005 ).  CLL cells can secrete 
various prosurvival cytokines (TNF- Î±, IL-6 and VEGF) and modulate their receptor expression 
in a paracrine/autocrine growth loop manner ( Hoffbrand, 1993 ).
Lenalidomide has been reported to inhibit TNF- Î±production, modulate cytokine production and 
also to have immunomodulatory properties that ar e thought to be critical for the activity of this 
drug in chronic lymphocytic leukemia ( Corral, 1996 ) (Corral, 1999 ).  Lenalidomide co-
stimulates T-cells and enhances antitumor immuni ty, which is mediated by T-helper-1 type 
cytokines, such as interferon- Î³ and interleukin-2 (IL-2); it also enhances other innate immune uttical ica
er the r the 
n human human 
in the fact in the fact
matorymatory andandy
on both theon both the
d with TNFd with TNF
n, 2004n, 2004 ).).
ties (includties (incl
dependent dependent 
with a deletwith a del
es.
alal HealHealll ththlllAAhh
e, for patiee, for pati
ment for varment for var
hoomamas,s,andand
.  While ma While m
in subjectsn subject
nd rationand ration
undnd
rplay betwerplay betwe
sittivitivity of By [CONTACT_233282]/auaracrine/a
enalidoenalido midmi
also to halso to ha
ug igi
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 41 CC-5013-CLL-009 Amendment 6 Final 15Apr2015cells such as natural killer cells, which can increase tumor cell death ( Bartlett, 2004 ) (Hayashi, 
2005 ).
Additional experiments performed in vitro confirmed the ability of lenalidomide to increase NK-
cell mediated killing of primary B-CLL tumor cells in both a PBMC co-culture model and NK mediated antibody-dependent cellular cytotoxicity (ADCC) model ( Wu, 2008 )(Lapalombella, 
2008 ).  Co-treatment of B-CLL cells and NK cells with lenalidomide was shown to enhance
rituximab-mediated ADCC in vitro, however a greater enhancement was observed when B-CLL cells were not pre-treated with lenalidomide sugge sting that alternative sequencing strategies 
might be also beneficial when combining the two drugs in a clinical setting (Lapalombella, 
2008) .  Interestingly, lenalidomide also synergized with rituximab to promote animal survival in 
a severe combined immunodeficiency (SCID) mouse-disseminated lymphoma xenograph model.  
Lenalidomide treatment enhanced rituximabâ€™s NK cell antitumor activity, and resulted in the in 
vivo expansion of murine NK cells, suggesting a role for the co-stimulatory properties of this agent in this model ( Hernandez- Ilizaliturri, 2005 ).
The potential ability of lenalidomide to enhance immune cell recognition in CLL was also 
reported in a recent work by [CONTACT_233283]. ( Ramsay, 2008 ) demonstrating that lenalidomide can 
modulate the actin cytoskeleton and improve the defect in B-CLL cells and T-cells immune 
synapse formation and function. 
Additional work is underway to better elucidate lenalidomideâ€™s mechanism of action in CLL and 
its ability to modul ate the cellular interplay between the microenvironment and the malignant 
CLL clone.
5.3.2. Clinical studies 
[IP_ADDRESS]. Relapsed/refractory CLL
Initial clinical studies were conducted with thalidomide, a less potent immune modulator than 
lenalidomide also capable of inhibiting TNF- Î±, that has known anti-angiogenic properties.  
Thalidomide was studied in combination with fludarabine in previously untreated CLL ( Chanan-
Khan, 2005 ).  Although this study investigated the efficacy and safety of the combination 
regimen of fludarabine and thalidomide, the design of the study called for the administration of 
thalidomide alone for the first 7 days of therapy, after which fludarabine was added.  Antitumor 
effects, manifested as reduction on the peripheral blood lymphocyte count, occurred within 7 days of starting thalidomide, prior to institution of fludarabine, suggesting that thalidomide alone 
has anti-CLL activity.
Based on the observations made with thalidomide, single-agent lenalidomide was studied in 
relapsed/refractory CLL ( Chanan-Khan, 2006a ) (Ferrajoli, 2008 ).  Chanan-Khan treated patients 
with relapsed/refractory CLL with lenalidomid e (25mg x 21 d q 28 days).  Patients with stable 
disease (SD) or better response were continued on therapy for a maximum of 12 months while those with progressive disease (PD) were to receive monthly rituximab (375mg/m2) added to 
lenalidomide.  Forty-five patients were e nrolled.  Median age was 64 years (range: 47 to 75 
years), and advanced Rai stage (III or IV) disease was noted in 64%.  The median number of prior therapi[INVESTIGATOR_233233] (range:  1 to 10 therapi[INVESTIGATOR_014]), with 51% of the patients refractory to 
fludarabine.  Using an intent-to-treat analysis, major responses were seen in 26 patients (57.7%; 
95% CI, 32% to 62%) with six patients (13.3%) achieving a CR, including 5 (11%) molecular 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21vival in ival in 
aph model.ph model
ted in the ited in the 
perties of thperties of th
in CLL wain CLL
ting that lting that l ene
ells and Ts and T
eâ€™s mechaneâ€™s mecha
microenviromicroenviro
with thalidoith thalid
ng TNFng TNF -Î±
ination witination w
udydyinvestinvest ii
thalidohalido midm
e first [ADDRESS_281541] 7 d
reduction oreduction o
lidomide, plidomide, p
ivitivity.y.
e observate observat ii
reffractoryractoryfff CCy
elelapsed/refapsed/ref
ease (Sase (S D) oD) o
hhose wiose wi ththiiphh
lenalidoenalid
ars
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 42 CC-5013-CLL-009 Amendment 6 Final 15Apr2015CRs, and 20 (44.4%) achieving a PR.  Antitumor activity of lenalidomide was evident as early as 
day 8 of treatment with 24 (70.5%) of 34 patients (34 patients who had day 1 ALC of >5000 
cells/uL and day 8 ALC available) demonstrating a decrease in their peripheral blood absolute 
lymphocyte count (ALC).  Clinical responses (CR or PR) were observed in 40% of the patients with del (11)(q23) adverse cytogenetics and in 40% of patients with bulky disease.  The median 
PFS of all patients enrolled was 19.4 months (range 1.2-31.8) ( Chanan-Khan, 2007 ).  Fatigue 
(83%) and flare reaction (tender swelling of lymph nodes and/or rash) (58%) were the mostcommon non-hematologic AEs reported.  Other important AEs reported were tumor lysis 
syndrome (5%); Grade 3 and 4 thrombocytopenia (45%), and Grade 3 and 4 neutropenia (70%).  
Pulmonary embolism was reported in two patients (5%).
Ferrajoli treated patients with relapsed/refractory  CLL with lenalidomide administered daily for 
[ADDRESS_281542] by 5 mg increments every 28 days to a 
maximum dose of 25 mg daily.  Forty-four (44) patients have been enrolled and were evaluated 
for response.  The median daily dose of lenalidomid e tolerated by [CONTACT_233284] 10 mg.  The 
median age was 64 years (range:  49 to 86 years), the median number of prior treatments was 5 (range:  1 to 15), and the median Î²2M at entry was 4.3 mg/dL (1.6 to 10.1).  Fifty nine percent of 
the patients carried unfavorable genomic abnormalities (17p or 11q23 deletions) and 66% had 
unmutated V
H.  Twelve patients (27%) were refractory to fludarabine.  Responses according to 
NCI-WG criteria assessed after 3 months of treatment based on an intent-to-treat analysis 
showed that 14 patients (32%) had achieved a response [3 CR (7%), 1 nodular PR (2%), 10 PR 
(23%)].  Time to best response was 6 months in 11 patients and 9 months in 3 patients.  The median response duration has not been reached.  Eleven patients (25%) had stable disease (SD) 
or clinical improvement and were able to continue on treatment past the third month, and 17 
patients (39%) progressed and two patients died of early infectious complication.  Thirty two patients (73%) are alive with a median follow up of [ADDRESS_281543] 
common toxicity with in the courses, 41% âˆ€Grade 3 neutropenia and 16% Grade 3 
thrombocytopenia.  TFR was observed in 12% of the courses (Grade &2 in 10% and Grade âˆ€3 
in 2%), with a greater incidence (53%) in patients  with lymph nodes larger than 5 cm.  Grade âˆ€3 
fatigue and diarrhea were reported in 1% and 2% of the courses, respectively.
TFR was a frequent adverse event reported in both studies and was well managed with non 
steroidal anti-inflammatory agents (NSAIDs) and/ or corticosteroids or in some case narcotic 
analgesics.  In Chanan-Khanâ€™s study (Chanan-Khan, 2006b ), out of the [ADDRESS_281544] 29 patients (Group A).  Subsequently, 
16 patients received prophylaxis with prednisone 20 mg po qd x 5 days followed by 10 mg po qd x 5 days starting on Day 1 of treatment (Group B).  The prophylaxis did not decrease the 
incidence of TFR (83% [Group A] vs. 81% [Group B]).  TFR â‰¥ Grade 2 was seen in 31% of 
Group A and 6% of Group B.  It thus appears that steroid prophylaxis decreases the severity of the reaction, but not the overall incidence.  In the group of patients who developed tumor flare, 4 
CRs were achieved, all in patients who had experienced â‰¥ Grade 2 tumor flare reaction in 
comparison to 19 patients with â‰¤ PR who had experienced a median tumor flare severity Grade 1 
(Chanan-Khan, 2006a ).  These preliminary data seem to indicate that patients who develop a 
more severe flare reaction may also achieve a better  remission.  However, in Ferrajoli et al. study 
the occurrence of a tumor flare reaction did not predict for a higher response rate with an overall response of 38% and 34% in patients with and without a TFR ( Ferrajoli, 2008 ).&(/*(1([ZIP_CODE],(7$5<,1)250$7,21%).  %). 
d daily for daily for 
domide at domide at 
days to a days to a 
nd were evnd were ev
nts was 10nts was 10
f prior treatf prior tre
o 10.1).  Fif10.1).  Fi
q23 deletq23 delet ioi
arabine.  Rearabine.
on an inteon an inte
3 CR (7%)CR (7%
tients and 9tients and 
leven pateven pa ieie
ue on treatmue on treatm
ied of earlyied of early
low up of 1ow up of 1
1% % âˆ€âˆ€GradGra
ved in 12% ed in 12%
(53%) in pa53%) in p
orted inrted in 1%1%
se event repevent re
atory atory agentsagent
ann--Khanâ€™s Khanâ€™s
TFR prophTFR proph
eived propeived pro
arting on Drting on D
e of TFR (8f TFR 
p A and 6%p A and 6%
reactireacti on, bon, b
CRs were CRs were 
omomparparmm
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 43 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Additional single-center clinical studies investigating other dose regimens in relapsed/refractory 
CLL are in progress.
[IP_ADDRESS]. Previously untreated symptomatic CLL
In addition, two studies were conducted in  previously untreated symptomatic CLL subjects
(Chen, 2008 ), (Ferrajoli, 2008 ).
Chen treated previously untreated symptomatic CLL subjects with single agent lenalidomide.  
The starting dose for lenalidomide was initially [ADDRESS_281545] 2 subjects 
(TLS requiring dialysis; neutropenic sepsis) led to a study halt with DSMB review, and 
subsequent protocol amendments to reduce both the starting and target doses (2.5 mg and 10 mg, respectively, days 1-21), slow the dose escalation rate (2.5 mg cycle 1, 5 mg cycle 2, 10 mg 
cycle 3 and thereon), extend allopurinol TLS prophylaxis to a minimum of 3 cycles, and increase 
frequency of TLS lab monitoring.  Deep vein  thrombosis (DVT) prophylaxis with low dose 
aspi[INVESTIGATOR_233234].  Steroids were allowed for management of TFR symptoms as needed.  
Twenty-five (25) subjects have been enrolled on the amended protocol.  The median age is 60 
(range 33-78), 10 subjects (40%) were Rai stage III-IV, bulky nodes were present in 9 subjects (36%), organomegaly in 23 pts (92%).  Twenty-three (23) subjects have received at least 1 cycle 
and are evaluable for toxicity.  Ten (10) subjects  (43%) developed grade 3-[ADDRESS_281546] 1 cycle (at doses 2.5-10 mg) which was the most common cause for dose reductions/interruptions.  Six (6) subjects have required intermittent GCSF support (none 
requiring routine use).  Three (3) subjects (13%) developed grade 3-4 thrombocytopenia (without 
bleeding).  The most common non-hematologic toxicities were:  Fatigue (74%), non-desquamating rash (48%), all were reported as gra de 1-2.  Infections (43%) were mostly minor 
non-neutropenic respi[INVESTIGATOR_696]/sinus/skin infections.  TFR occurred in 18 subjects (78%).  Although 
most subjects experienced TFR in the first week on study, many also continued to experience flare symptoms with subsequent cycles (30.6% of all 186 cycles).  Most tumor flare symptoms 
resolved spontaneously but eight subjects require d steroids on at least one occasion with prompt 
resolution.  Four (4) subjects were hospi[INVESTIGATOR_233235]/or pneumonia.  No further TLS has been noted.  Seventeen (17) subjects have completed at least 3 cycles and are 
evaluable for response.  Eleven (11) subjects (65%) have achieved a PR, 6 SD (35%), and none 
have progressed.  Responses were reached at a median of 4 cycles (range 2-15).  Although 
dramatic lymphocyte reductions were seen as early as week 1 (lenalidomide dose 2.5 mg/d), 
rebound during cycle days 22-[ADDRESS_281547] withdrawn from 
the study due to lack of response after 10 cycles (SD) and prolonged Grade 3-4 neutropenia and thrombocytopenia, respectively.  The median daily tolerated dose is 10 mg with 26% of subjects 
requiring dose reductions to 5 mg (most due to cytopenias).
Ferrajoli used lenalidomide as initial treatment of eld erly subjects with CLL.  Subjects were 
eligible for this study if age [ADDRESS_281548] 56 days.  The 
lenalidomide dose could then be titrated up by 5 mg increments every 28 days to reach a maximum dose of 25 mg daily.  Allopurinol 300 mg daily was given from day 1-14 as TLS 
prophylaxis.  Sixty patients were enrolled into the study.  All 60 patients were evaluable for 
response and toxicity. Median age was 71 years (range, 66-85).  The overall response (OR) rate was 60%. 5 patient (8%) achieved a complete response (CR), 5 (8%) a nodular partial response 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_281549] week on 
s (30.6% of(30.6% o
bjects rjects r equeq
re hospi[INVESTIGATOR_233236] (Seventeen 
even (11) sven (11) 
onses were nses wer
reductireduct onson
ycle days 22cle days 22
o lack of reo lack of re
openia, respopenia, resp
dose reducose reduc
jojoli used leli used 
gible for thgible for th
NCINCI-WG gWG 
enalidoenalid
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 44 CC-5013-CLL-009 Amendment 6 Final 15Apr2015(nPR) and 26 (43%) a PR. Median time to treatment failure was not yet reached with a median 
follow-up of 19 months.  Grade 3-4 neutropenia, thrombocytopenia, and anemia were noted in 
35%, 4%, and <1% of cycles; Grade 3-4 infections were reported in 7% of patients. There were 
no cases of Grade 3 or Grade 4 tumor lysis or tumor flare reactions, 30 (50%) patients experienced Grade 1 or Grade 2 tumor flare. ( Badoux 2010 ).
[IP_ADDRESS]. Study CC-5013-CLL-001
Based on these initial data in patients with relaps ed/refractory CLL, a large multicenter phase 2 
study (CC-5013-CLL-001) was initiated to investigate two lenalidomide dose regimens, 10 mg 
daily and 25 mg x 21 days q 28 days, and confirm the efficacy and safety of lenalidomide in the 
treatment of relapsed/refractory CLL.  The study  did not include a dose escalation peri od.  After 
[ADDRESS_281550] cycle of treatment.  Metabolic 
abnormalities and/or renal dysfunction resolved with supportive therapy in [ADDRESS_281551] been observed with other active and immune modulating 
agents in CLL ( Yang,1999 ) (By[CONTACT_26752], 2007 ) mostly occurring in early phases of treatment.  The use 
of low dose-intensity regimens at the initiation of therapy, aggressive TLS prophylaxis, and 
increased patient monitoring decreased the incidence of TLS during treatment with these therapi[INVESTIGATOR_014].  TFR during lenalidomide therapy has been observed in both CLL and small 
lymphocytic lymphoma (SLL) patients.  TFR and TLS were also observed in two phase 2 studies 
that recently reported the effects of lenalidomide in patients with relapsed or refractory CLL (Chanan-Khan, 2006a ) (Ferrajoli, 2007 ).  In the Chanan-Khan et al. study TFR occurred in 58% 
of patients (Grade &2 in 50% and Grade âˆ€3 in 8%) and TLS occurred in 5% of the patients (all 
Grade 3).  The second study by [CONTACT_233285]. reported 37 % TFR (Grade &2 in 30% and Grade 
âˆ€3 in 7% of patients) and no TLS.  Notably, the Chanan-Khan et al. study used a starting dose of 
[ADDRESS_281552] by 5 mg increments every 28 days to a 
maximum dose of 25 mg daily.
TFR in lenalidomide-treated CLL patients in clinical studies has usually been Grade 1-2 and has 
been well managed with non-steroidal anti-inflammatory agents or steroids.
The CC-5013-CLL-001 protocol was amended into a phase 1/[ADDRESS_281553] failed fludarabine were started on 2.5 mg of lenalidomide daily, 
followed by [CONTACT_233286]-patient dose escalation to 5 mg after 28 days as tolerated ( Wendtner, 
2010 ).  Doses were then escalated as tolerated by 5 mg every 28 days by [CONTACT_233287] 6 
patients, until the maximum tolerated dose escalation level (MTDEL) was defined or a maximum 
dose of [ADDRESS_281554] 3 cycles.  The redesigned phase I study enrolled 52 patients with a median 
age of 65 (range, 37â€“80) and bulky disease (>5 cm) in 70%. Patients were heavily pretreated 
with a median of 4 prior therapi[INVESTIGATOR_014] (range,1â€“14); 54% were fludarabine refractory (no-&(/*(1([ZIP_CODE],(7$5<,1)250$7,21mg mg 
in the in the 
od.  Afod.  Af ter terfff
d TLS of d TLS of 
and bone pand bone p
MetabolicMetabolic
2 patien2 patien ts,ts,nn
e and immand imm
rly phases ophases 
gressive TLgressive T
LS during trS during 
bserved in berved in
S were alsoS were als
n patients wn patients w
e ChananChanan --K
 in 8%) an in 8%) an
et alet al. repor. repor
otably, the otably, the 
y once dailonce dail y
ttioion schemn schem
by [CONTACT_233288].ily.
reated CLLreated CLL
with nonwith non --
CLLCLL -001-001 pr
e doses wase doses wa
g agent andgent and
ed by [CONTACT_233289]
00).  Doses ).  Doses 
&patiatients, unents, un
dose of dose of 2
LS pS
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 45 CC-5013-CLL-009 Amendment 6 Final 15Apr2015response/relapse â‰¤ 6 mo), 42% had prior FCR or PCR and 21% had prior alemtuzumab. The TLS 
prevention strategy resulted in only 2 (3.8%) cases of TLS, both observed at 2.5 mg/daily (1 
patient with Grade 2 and another with lab TLS).  Grade 3/4 tumor flare occurred in 5 (9.6%) 
patients and was managed with NSAIDs or lo w-dose steroids. The most common Grade 3/4 
adverse events (AEs) included neutropenia (65%) and thrombocytopenia (33%). Febr ile 
neutropenia occurred in 4 (8%) patients. Grade 3/4 infections were observed in 21 (40%) 
patients; 10 (19%) patients developed pneumonia and 3 developed sepsis; 2 cases of sepsis-related death at day 37 and 94 of therapy were also noted but deemed unrelated to study drug by 
[CONTACT_473]. Reasons for study discontinuation included disease progression (37%), AEâ€™s 
(29%), consent withdrawal (15%), death (4%), other reasons (10%).  For 16 (31%) patients, 2.5 mg/daily was the maximum dose reached a nd 22 (42%) patients were  unable to escalate be yond
5 mg/daily.  Grade 4 neutropenia was the primary reason for delay in dose escalation. By [CONTACT_104992]-
to-treat (ITT) analysis, 6 patients (12%) had a partial response (NCI-WG 1996), 30 patients (58%) had stable disease and 13 patients (25%) progressed; 3 patients were non-evaluable. 
Median duration of treatment was 3.1 months (range , 0.07-18.4) and the median  time to response 
was 4.3 months (range, 2.8-7.4). Responses we re observed at 10 mg/daily (n=3), at 15 mg/daily
(n=1), and at 20 mg/daily (n=2); Median PFS (ITT) was 5.5 months and median PFS for 
responders was 12 months. Three patients still remain on therapy and were transferred to 
commercial lenalidomide. (Data on file at Celgene)
5.3.3. Rationale for study CC-5013-CLL-009
Patients with purine-analog or bendamustine relapsed/refractory CLL have limited therapeutic 
options and the addition of novel agents with alternative mechanisms of action are needed.  Several studies have been conducted with lenalidomide in relapsed/refractory CLL and have 
demonstrated a good activity; however an optimal starting dose remains to be determined.  Three 
different starting dose regimens of 5 mg daily, 10 mg daily and 15 mg daily respectively will be 
evaluated in CC-5013-CLL-009.  These starting doses are based on a review by [CONTACT_233290] (DMC) and an expert steering committee review of the 
safety and efficacy results of CC-5013-CLL-[ADDRESS_281555] demonstrated a consistent, manageable, comparable toxicity profile for subjects 
beginning therapy at either the 2.5 mg, 5 mg or 10 mg starting doses when adequate prophylaxis 
measures for TLS are implemented (increased duration of allopurinol prophylaxis with increased hydration, and increased monitoring of electrolytes  with correction of electrolyte abnormalities 
prior to the initiation of study drug) ( Ferrajoli, 2008 ) (Chen, 2008 ).  Data also indicate that 
starting therapy at lenalidomide doses higher than 2.5 mg daily may provide superior efficacy.  In light of these data, Celgene consulted expert clinicians; these experts supported a reduction in 
the number of dose escalation steps and thought a minimum efficacious dose to be in the range 
of 10 to 15 mg in relapsed CLL.  As a result,  CC-5013-CLL-009 was developed to study starting 
dose of 5 mg, 10 mg and 15 mg followed by a step-wise dose escalation to a maximum dose of 
25 mg daily as tolerated to allow for fewer escalations to reach a higher dose.
This study will be conducted in accordan ce with â€œgood clinical practiceâ€ (GCP) and all 
applicable regulatory requirements, including, where applicable, the 2008 version of the 
Declaration of Helsinki (see Appendix 21.2 ).
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21y
s 
ts, 2.5 s, 2.5 
beyondbeyond
. By. By [CONTACT_233291]
30 patients patients 
n--evaluableevaluab
dian tdian t ime time 
y(n(n=3), at =3)
nd median d median
nd were trand were t
refractoryrefractory C
atative ivemechmech
domide in romide in r
imal startinimal startin
ailyly, 10 mg , 10 mg
starting dostarting d
(DMC) andDMC) a
013-3CLLLL
nsistent, mnsistent, m
he 2.[ADDRESS_281556]
plicli
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 46 CC-5013-CLL-009 Amendment 6 Final 15Apr20156. STUDY OBJECTIVES
6.1. Primary Objective
!To evaluate the safety of different le nalidomide dose regimens in subjects with 
relapsed or refractory B-cell CLL.
6.2. Secondary Objectives
!To evaluate the efficacy of different lena lidomide dose regimens in subjects with 
relapsed or refractory B-cell CLL.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21with th 
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 47 CC-5013-CLL-009 Amendment 6 Final 15Apr20157. STUDY ENDPOINTS
7.1. Primary
!Safety [type, frequency, and severity of adverse events (AEs) and relationship of AEs 
to lenalidomide]
7.2. Secondary
!Response rate; International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 
Guidelines for the diagnosis and treatment of CLL ( Hallek, 2008 )
!Duration of response 
!Time to response (TTR)
!Time to progression (TTP)
!Event-free survival (EFS)
!Progression-free survival (PFS)
!Overall survival (OS)
7.3. Exploratory
!Evaluation of response rate in predefined biol ogic risk group
!!Investigate the relationship between pharmac okinetics (PK) and response (biomarkers 
or clinical outcomes as appropriate)
!Quality of Life
&(/*(1([ZIP_CODE],tween phartween phar
ropriate)priate(7$5<,1)250$7,21wCLL) wCLL) 
ed bioed bi lologicgic
5,(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281557] udy will compare different treatment regimens (starting dose 
of 5 mg, 10 mg and 15 mg daily, followed by [CONTACT_182903]-patient escalation up to a maximum of 25 
mg daily) using a Bayesian approach to evaluate both efficacy and toxicity.  This adaptive design will consider joint efficacy (progression rate) and toxicity outcomes to stop randomization of less 
promising arms ( Bekele, 2008b ).  At any time accrual to a star ting dose arm will be stopped if 
unacceptable toxicities are observed in that arm.
8.1.3. Randomization
Based on consideration of the Bayesian approach the following randomization schema will be 
followed:
!Initially subjects will be randomized (1:1:1) in  a double-blind fashion to the 5 mg, 10 
mg, and 15 mg starting dose arms (treatment arm 1, treatment arm 2, and treatment arm 3 respectively).  
!After 18 subjects complete one 28 day cycle, an interim analysis will be conducted to 
review the safety of each starting dose arm(s).  Subsequent interim analyses to review 
the safety and progression rate of each starting dose arm(s) will occur at 13-week 
intervals.  After review of each interim analysis, a treatment arm may be dropped.  At any time accrual to a starting dose arm will also be stopped if unacceptable toxicities 
are observed in that arm.  If a treatment arm is dropped then all new subjects will be 
randomized equally into the remaining arm(s).
Stratification
To minimize potential imbalances within treatment groups due to select patient characteristics 
that may impact outcomes, study subjects will be stratified by [CONTACT_233292]:
!Relapsed versus refractory to their last purine-analog or bendamustine based 
treatment regimen [relapsed/refractory as defined per the iwCLL guidelines for diagnosis and treatment of CLL ( Hallek, 2008 )].  If a subject has had prior purine-&(/*(1([ZIP_CODE],(7$5<,1)250$7,21nd then then 
daily baseddaily bas
nt regimensnt regimen
atation up to n up t
nd toxicitnd toxicit y
comcomes to sto
starting dostarting d
ach the foach the fo ll
ndondomized (mized (
dose arms (ose arms
comcomplete opletm
etyofofyeacheff
nd progresnd progres
.  After revAfter rev
me accrualme accrual
observed observed
randorando mizemize
icationcation
o minimize minimize 
thhat mayat may imimyy
andoando mm
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281558]â€™s status post most recent regimen.
!Age < 65 years of age versus â‰¥ [ADDRESS_281559] received lenalidomide therapy for more than one year continue to improve their response to treatment ( Chanan-Khan, 
2006a ) (Chanan Khan, 2007 ) (Ferrajoli, 2008 ).  In the Chanan-Khan study the median time to 
best response was 5.9 months (range 1.6 to 18.3 months).  In the Ferrajoli study time to best response was [ADDRESS_281560] tolerability, as follows:
!Treatment Arm 1:  5 mg â†’10 mg â†’15 mg â†’20 mg â†’25 mg/daily
!Treatment Arm 2:  10 mg â†’15 mg â†’20 mg â†’25 mg/daily
!Treatment Arm 3:  15 mg â†’20 mg â†’25 mg/daily
Toxicities requiring dose interruption and/or modification are described in Section 10.2.[ADDRESS_281561]â€™s treatment regimen, 
the study was a double-blinded trial.  The blind was removed once all patients had completed 3 
cycles of treatment.
8.1.7. Safety
Subjects will be evaluated for AEs at each visit with the NCI CTCAE (Version 3.0) used as a 
guide for the grading of severity with the ex ceptions of hematological toxicities and TLS.  
Hematological toxicities will be graded as spec ified in the iwCLL guidelines for the diagnosis 
and treatment of chronic lymphocytic leukemia ( Hallek, 2008 ) (Appendix 21.4 ).  TLS will be 
graded as specified by [CONTACT_137785]-Bishop grading system ( Appendix 21.3 ).
Second primary malignancies will be monitored as events of interest and should be included as 
part of the assessment of adverse events throughout  the course of the study. Investigators are to &(/*(1([ZIP_CODE],(7$5<,1)250$7,21han, n, 
me to e to
to best to best 
ctorytory to at ltoyy
ve included e included
in ain adoubldoubl
sed on indivsed on indiv
â†’15 m15 m g â†’2g â†’mm
mmg â†’20 mg â†’20 m mm
â†’20 m20 m g â†’gâ†’m
ion and/or mion and/or 
or this studyr this stud
or both safboth saf
doubldoubl e-eblinblin
tmment.ent.
SafetySafety
bjects will bjects will b
guiuide fde for thor thfff
HemHe atolato
dt rd
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 50 CC-5013-CLL-009 Amendment 6 Final 15Apr2015report any second primary malignancies as serious adverse events regardless of causal 
relationship to study drug, occurring at any time for the duration of the study, from the time of 
signing the informed consent up to and including the survival follow up period.  Subjects will be 
followed until 80% of the subjects  have progressed or died or up to five years after the last 
subject was randomized, whichever occurs later.
8.1.8. Efficacy 
Tumor response will be assessed according to the iwCLL guidelines for the diagnosis and 
treatment of CLL ( Hallek, 2008 ), including CR, CRi, nPR, PR, SD, and PD.  Evaluation of 
response will be performed after [ADDRESS_281562], abdomen and pelvis 
to assess lymphadenopathies will be performed at the PR and CR/CRi confirmation visits ( â‰¥8 
weeks to â‰¤ [ADDRESS_281563] been met for PR or 
CR/CRi).  Those subjects whose response was down-graded based on the CT scan interpretation at the PR or CR/CRi confirmation visit will have the CT scan repeated 4 months later at the 
location where remaining disease has been documented, as long as clinical and laboratory 
response remains present to try to document further improvement.
For those subjects who reach CR or CRi, a bone marrow aspi[INVESTIGATOR_233237]/CRi confirmation visit ( â‰¥ 8 weeks to â‰¤ [ADDRESS_281564] been m et).  If the bone marrow is hypocellular, a repeat 
specimen should be obtained after [ADDRESS_281565] recovered. If 
the bone marrow biopsy shows disease involvement (30% or greater lymphocytes, or nodules 
positive for B-CLL cells by [CONTACT_9064]), an additional bone marrow biopsy and aspi[INVESTIGATOR_233210] [ADDRESS_281566] analysis by [CONTACT_233266]/CRi confirmation visit.
!If peripheral blood and bone marrow are both MRD-positive, peripheral bl ood 
samples will be repeated and assessed up to [ADDRESS_281567] negativity in subjects who reach confirmed CR or CRi (see 
Follow-up MRD assessments).
!If peripheral blood is MRD-negative and bone marrow is MRD-positive, both 
peripheral blood and bone marrow should be retested for MRD negativity after â‰¥ [ADDRESS_281568] will 
be performed.
!If both the peripheral blood and bone marrow are MRD-negative, peripheral blood 
will be tested every [ADDRESS_281569] discontinues study 
drug.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21and pelvis and pelvis
n visitsn visits ((â‰¥8â‰¥
met for PRmet for
T scan interT scan int
mmonths lonths l atet
nical and laical and l
te and bonee and bone
â‰¤ 12 weekâ‰¤ 12 wee
marrow is hmarrow is h
hat the bloohat the bloo
t (30% or g(30% or 
try), an addry), an add
s clinics clinic al anal an
 subjects wsubjects w
e collected collecte
d and boned and bone
e repeated aepeated 
ment MRD ment MRD
up MRD asMRD as
ripheral bloripheral blo
erieripheralpheralii blblll
weeks.weeks. IfIf
be perfep e r f
!!IfIf
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281570] assessments:
!If any of the repeat peripheral blood assessments indicate MRD-negativity, a bone 
marrow aspi[INVESTIGATOR_233238] a nd retested as soon as possible to 
confirm MRD negativity. 
#If the bone marrow is MRD-positive, both peripheral blood and bone marrow 
should be retested for MRD negativity after â‰¥ [ADDRESS_281571] will be performed.
#If at any time, the bone marrow is MRD-negative, peripheral blood will be tested 
every [ADDRESS_281572] discontinues study drug.
Response Adjudication Committee
An independent Response Adjudication Committee (RAC) will perform a blinded, assessment of 
response (including assessment of SD and of PD) prior to database lock.  The RAC adjudicated response data will be used in the efficacy analysis for the study.
8.1.9. Independent Data Monitoring Committee
An independent external Data Monitoring Committee (DMC) will review safety and efficacy 
data collected during the conduct of the study. DMC Meetings will occur approximately every 3
months during enrollment and no less than twice per year thereafter.  In addition, safety data will 
be reviewed in an ongoing manner to assess benefit-to-risk considerations; accrual will be stopped if unacceptable toxicities are observed in a treatment arm.
8.1.10. Pharmacokinetics
Pharmacokinetic (PK) studies will be performed in up to 40 subjects.  Following the enrollment 
of 90 subjects, participation in the PK sub-study will be mandatory for all additional subjects 
enrolled.  Intensive sampling and sparse sampling will be discontinued as of this amendment, 
protocol amendment #6.  Lenalidomide concentration data obtained from all visits may be used 
to develop the population PK model.  The relationship between pharmacokinetics and response 
(biomarkers or clinical outcomes as appropriate) will be explored.
8.1.11. Exploratory Biomarkers
Rationale
Biomarkers are objectively measured indicators of biological or pathogenic processes, or 
pharmacologic responses to a therapeutic intervention.  In CLL, there is particular interest in the 
molecular changes that may identify disease subtypes, stage of disease, or predict high-risk 
disease or disease progression.
 
 
 
 
 (/*(1([ZIP_CODE],(7$5<,1)250$7,21ested sted 
rug.ug.
d, assessmd, assessm
RAC adjudRAC adju
ll review sareview sa
will occurwill oc
hereafter.  Iereafter.  I
sk considerk consid
atment aatment a rm
med in med in up up 
bb--studystudy wilily
se samse sam plingplingmmm
mideideconcenconce
odel.  The rdel.  The r
mmes as appres as app
y BiomarkeBiomar
objobjectivelyectively
gigc responsec response
changes thhanges th
or diorseasesease
&(/&(&&
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281573] 
shortened time to treatment or increased risk of disease progression. These markers are: V H
mutational status, ZAP-70 expressi on, , Beta-2 Microglobulin ( Î²2M), and 
genomic var iations identifiable by [CONTACT_4656] (del 13q, del 11q, del 17p, trisomy 12).  These classic 
prognostic markers will be evaluated in this study.  
8.1.12. Other Outcomes
Quality of life d ata will be collected as detailed in Table [ADDRESS_281574]-Leu and EQ-5D 
questionnaires.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21u and EQand EQ 5$0$
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281575] meet all of the following inclusion criteria to be eligible for enrollment into 
the study:
1. Must understand and voluntarily sign an informed consent form2. Age â‰¥ [ADDRESS_281576] a documented diagnosis of B- cell CLL [iwCLL guidelines for diagnosis and 
treatment of CLL ( Hallek, 2008 )] meeting at least one of the following criteria:
!Evidence of progressive marrow failure as manifested by [CONTACT_66867], or 
worsening of, anemia and/or thrombocytopenia
!Massive (i.e. > 6 cm below the left costal margin) or progressive or symptomatic 
splenomegaly
!Massive nodes (i.e., > [ADDRESS_281577] diameter) or progressive or symptomatic 
lymphadenopathy
!
!A minimum of any one of the following disease-related symptoms must be present:
#Unintentional weight loss â‰¥ 10% within the previous 6 months
#Significant fatigue (i.e., ECOG PS 2; cannot work or unable to perform usual 
activities)
#Fevers of greater than 100.5Â° F or 38.0Â° C for 2 or more weeks without other 
evidence of infection
#Night sweats for more than [ADDRESS_281578] 1 prior regimen for treatment of CLL [relapsed / 
refractory as defined per the iwCLL guidelines for diagnosis and treatment of CLL 
(Hallek, 2008 )].  At least one of the prior treatments must have included a purine-analog
or bendamustine based regimen
!Relapsed is defined as a subject who has previously achieved the criteria of a 
complete remission (CR) or partial remission (PR), but after a period of â‰¥6 months, 
demonstrates evidence of disease progression
!Refractory is defined as treatment failure [e.g. Stable disease (SD), nonresponse, or 
progressive disease] or disease progression within [ADDRESS_281579] antileukemic 
therapy&(/*(1([ZIP_CODE],(7wing diseasing disea
10% wi10% wi ththii
, ECOG PS, ECOG PS
er than 100than [ADDRESS_281580] ioionn
weats for mweats for m
apsed or refapsed or re
yy as defined as defineyy
k, 2008, 2008 ))]. ]. 
bendamustendamust i
!!Relapelap
coco$5<,1)250$7,21ntsnts
agnoagno sis anis an
cririteriteriiia:a:
velopment velopment
gressive or essive or 
or progressor progre
7$5(7$
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281581] an Eastern Cooperative Oncology Group (ECOG) performance status score of 
â‰¤2.
7. Females of childbearing potential (FCBP) must:
!Have a negative medically supervised pregnancy test prior to starting study drug.  She 
must agree to ongoing pregnancy testing during study drug therapy, and after discontinuation of study drug as specified in Appendix 21.[ADDRESS_281582] practices complete and continued sexual abstinence.
!Either commit to continued abstinence from heterosexual intercourse (which must be 
reviewed on a monthly basis) or agree to use, and be able to comply with, effective 
contraception without interruption, prior to starting study drug, during study drug 
therapy, and after discontinuation of study drug as specified in Appendix 21.[ADDRESS_281583]:
!Agree to use a condom during sexual contact [CONTACT_4490] a FCBP, even if they have had a 
vasectomy, during study drug therapy and af ter discontinuation of study drug as 
specified in Appendix 21.9 .
!Agree to not donate semen or sperm during study drug therapy and after 
discontinuation of study drug as specified in Appendix 21.[ADDRESS_281584]:
!Have an understanding that the study drug could have a potential teratogenic risk
!Agree to abstain from donating blood during study drug therapy and after 
discontinuation of study drug as specified in Appendix 21.9 .
!Agree not to share study drug with another person
!Be counseled about pregnancy precautions and risks of fetal exposure as specified in 
Appendix 21.[ADDRESS_281585] not meet any of the following exclusion criteria to be eligible for enrollment 
into the study:
1. Any serious medical condition, laboratory a bnormality, or psychiatric illness that would 
prevent the subject from signing the informed consent form
2. Active infections requiring systemic antibiotics
3. Systemic treatment for B-cell CLL within 28 days of initiation of len alidomide treatment
4. Alemtuzumab therapy within 60 days of initiating lenalidomide treatment5. (removed in protocol amendment #3)
6. Prior therapy with lenalidomide
7. History of grade 4 rash due to prior thalidomide treatment8. Planned autologous or allogeneic bone marrow transplantation&(/*(1([ZIP_CODE],(7$5<,1)250$7,21st be t be 
ectctive ive 
yy drug drug yy
x 21.9x 21.9 .
n if they han if they ha
on of studyn of stu
g therapyherapy ayy
ndix 21.9ndix 21.9
g coulg cou d havd hav
during studuring stu
ecified in ecified in AA
wiwiththii anotheanothhh
ancy precauancy pre
sion Critesion Crit
t any of thet any of t
us medical us medical
t the subjecthe subje
tive veinfectiinfecti
SySystemic mic 
4.4.AleAlemm
5.(r(
6
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 55 CC-5013-CLL-009 Amendment 6 Final 15Apr20159. Pregnant or lactating females
10. Central nervous system (CNS) involvement as documented by [CONTACT_15209][INVESTIGATOR_137732].  Subjects who have signs or symptoms suggestive of leukemic meningitis or a 
history of leukemic meningitis must have a lumbar puncture procedure performed within two weeks prior to initiating study drug
11. Prior history of malignancies, other than CLL, unless the subject has been free of the 
disease for â‰¥5 years.  Exceptions include the following:
#Basal cell carcinoma of the skin
#Squamous cell carcinoma of the skin
#Carcinoma in situ of the cervix
#Carcinoma in situ of the breast
#Carcinoma in situ of the bladder
#Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
12. History of renal failure requiring dialysis13. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and/or 
Hepatitis C Virus (HCV) infection
14. Evidence of TLS per the Cairo-Bishop defi nition of laboratory TLS (subjects may be 
enrolled upon correction of electrolyte abnormalities)
15. Any of the following laboratory abnormalities:
#Calculated (method of Cockroft-Gault) creatinine clearance of <60 mL/min 
(creatinine clearance may also be obtained by [CONTACT_941] 24-hour collection method at the investigatorâ€™s discretion)
#Absolute neutrophil count (ANC) < 1,000/ Î¼L (1.0 X 10
9/L)
#Platelet c ount < 50,000/ Î¼L (50 X 109/L)
#Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic 
transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 3.0 x upper limit of normal (ULN)
#Serum total bilirubin > 1.[ADDRESS_281586]
16. Uncontrolled hyperthyroidism or hypothyroidism17. Venous thromboembolism within 12 months18.â‰¥ Grade-2 neuropathy
19. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
20. Disease transformation [i.e. Richterâ€™s Syndrome (lymphomas) or prolymphocytic 
leukemia]
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21tage of T1aage of T1
ititis B Viruis B V
n of laboran of labora
malitmalit ies)ies)
aliititiiiies:es:
roftoft-Gault) Gault) 
also be obtalso be ob
etion)etion)
il count (Ail count (A
< 50,000/ Î¼ < 50,000/ Î¼
partate aminpartate a
minase (SGOinase (SG
saminase (Ssaminase (S
SerumSerum  tota tomm
controlled hontrolled 
Venous thVenous th
18.18.â‰¥ Graâ‰¥ Gra
19.9.UU
2
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 56 CC-5013-CLL-009 Amendment 6 Final 15Apr201521. Participation in any clinical study or having taken any investigational therapy within 28 
days prior to initiating lenalidomide therapy
22. Known presence of alcohol and/or drug abuse
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 57 CC-5013-CLL-009 Amendment 6 Final 15Apr201510. DESCRIPTION OF TREATMENT 
10.1. Description of Study Drug
Celgene Corporation will supply lenalidomide 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg 
capsules for oral administration.  Subjects will receive 28 days of lenalidomide per cycle.
Study drug will be packaged in bottles containing study capsules for 28 days.
10.2. Treatment Assignments
10.2.1. Randomization
Randomization will be accomplished by a validated interactive voice response system (IVRS) to 
ensure timely registration and randomization.  De signated site staff will be assigned password 
protected, coded identification numbers, which gives them authorization to call into the IVRS to 
enroll subjects.  The system will present a menu of questions by [CONTACT_233293]. When all questions have been answered, the IVRS will assign a subject number and study drug to the eligible subject. IVRS will fax a confirmation of 
registration and drug assignment for each subject to the site and Celgene.
Initially subjects will be randomized (1:1:1) in a double-blind fashion to the 5 mg, 10 mg, and 15 
mg starting dose arms (treatment arm 1, treatment arm 2, and treatment arm 3 respectively).  
Subjects will be stratified at randomization by:
#relapsed vs. refractory to their last purine-analog or bendamustine based treatment 
regimen (if subject has received both, the status post most r ecent purine-analog or 
bendamustine treatment regimen will be used for stratification) and
#age < 65 years of age vs. âˆ€65 years of age
After 18 subjects complete one 28 day cycle, an interim analysis will be conducted to review the 
safety of each starting dose arm(s).  Subsequent interim analyses to review the safety and 
progression rate of each starting dose arm(s) will o ccur at 13-week intervals.  After review of 
each interim analysis, a treatment arm may be dropped.  At any time accrual to a starting dose arm will also be stopped if unacceptable toxicities are observed in that arm.  If a treatment arm is 
dropped then all new subjects will be randomized equally into the remaining arm(s).
Site staff must contact [CONTACT_137822].
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21system (IVRystem (IVR
ssigned passsigned pas
o call into to call into t
thethesisite state sii
swered, thewered, the
l fax a confax a con
nd Celgene.d Celge
ind fashiod fashio
2, and treat2, and trea
st purinet purine --an
ed both, theed both, the
gimen will gimen will 
vs. vs. âˆ€âˆ€65 y65ea
8 day8 day  cycle cyclyy
m(s).  Subse(s).  Subse
rting dose ating dose
reatment arreatmen
ed if unacced if unacc
w subjects w subjects
concontact[CONTACT_233294]
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281587] tolerability, as 
follows:
Table 4: Dose Regimen by [CONTACT_233295] (oral administration)
ScheduleTreatment Arm 1
5 mg starting dose armTreatment Arm 2
10 mg starting dose armTreatment Arm 3
15 mg starting 
dose arm
Dose level +4 25 mg daily 25 mg daily 25 mg daily 28 days
Dose level +3 20 mg daily 25 mg daily 25 mg daily 28 days
Dose level +2 15 mg daily 20 mg daily 25 mg daily 28 days
Dose level +1 10 mg daily 15 mg daily 20 mg daily 28 days
Dose level 0 5 mg daily 10 mg daily 15 mg daily 28 days 
For toxicities requiring dose interrupt ion and/or modification (see Section 10.2.3 ), a more 
gradual stepwise dose escalation of lenalidomid e (more than one 28 day cycle for each dose 
level) might be needed at the discretion of the treating physician due to adverse events that do 
not require dose reduction or interruption.
Subjects unable to escalate to the [ADDRESS_281588] dose achieved in the previous cycle or as indicated in Section 10.2.3 Dose Modification 
or Interruption.
10.2.3. Dose Modification or Interruption
Subjects will be evaluated for AEs at each visit with the NCI CTCAE (Version 3.0) used as a 
guide for the grading of severity with the ex ceptions of hematological toxicities and TLS.  
Hematological toxicities will be graded accordi ng to iwCLL guidelines for the diagnosis and 
treatment of chronic lymphocytic leukemia ( Hallek, 2008 ) (Appendix 21.4 ).  TLS will be graded 
as specified by [CONTACT_137785]-Bishop grading system ( Appendix 21.3 ).
If a subject develops toxicity (see Table 5 Dose Reduction and Modification Guidelines), the 
dose may be reduced as outlined in Table 6 Dose Reduction Steps for Lenalidomide.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ScheduleSched27,27,2
07,2
28 day28 da000$50yy [PHONE_4876]
dailydaily25mg dailyg daily)2
15 m15 m g daig dai1)
<<<<, 1ee Sectionee Se
n one [ADDRESS_281589] each vis
yywiwiththii the ethe eh
be graded be graded 
hocyocytitiyyc lceu
roro--Bishop gBishop 
ps toxicitps toxicit y y (
duced as ouuced as ou
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 59 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 5: Dose Reduction and Modification Guidelines for Lenalidomide
Toxicity Severity Action
Neutropenia ANC < 500/ Î¼L#Dose should be held (once first result of ANC showing 
decrease below 500/ Î¼L is present)
#An additional CBC sample may be drawn at the 
investigatorâ€™s discretion within 24 hours of the ANC decrease, prior to interruption of lenalidomide therapy, 
to re-monitor the ANC and confirm ANC < 500/ Î¼L
#If the ANC is â‰¥ 500/Î¼L (Grade 4 neutropenia not 
confirmed), the same dose of lenalidomide may be 
continued without interruption or dose reduction
#If ANC is confirmed to be < 500/ Î¼L or confirmation is 
not required per the investigatorâ€™s discretion:
#Interrupt lenalidomide therapy
#Follow CBC every 7 days
#Resume lenalidomide (decrease one dose level) when ANC recovers to âˆ€500/Î¼L 
#Use of growth factors (i.e. G-CSF) is permitted at the 
investigatorâ€™s discretion
#Re-escalation to the next consecutive dose level is 
permitted as follows:
#If subject restarts dosing at one dose level 
lower on Day 1 to Day 14 of a cycle, and 
completes the remainder of that cycle at this lower dose without occurrence of toxicities 
requiring dose interruption/reduction, then 
the subject may be dose re-escalated by [CONTACT_31806]-dose level starting at Day 1 of the 
subsequent cycle.
#If subject restarts dosing at one dose level 
lower on Day 15 to Day 28 of a cycle, and completes the remainder of that cycle and 
the subsequent cycle at this lower dose 
without occurrence of toxicities requiring dose interruption/reduction, then the subject 
may be dose re-escalated by [CONTACT_31806]-dose level 
starting at Day 1 of the following cycle.&(/*(1([ZIP_CODE],(7$5<,1)250$7,
not ot 
may be may be 
eductionduction
L or confirmL or confir
â€™s discretions discre
domide theromide ther
C every 7 devery 7 
me lenalidomme lenalidom
el) when ANel) when AN
wth factors wth factors 
gatorâ€™s discrgatorâ€™s discr
esscalation calation 
perpermitted amitted 
&(152$7,21$7
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 60 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 5: Dose Reduction and Modification Guidelines for Lenalidomide (Continued)
Toxicity Severity Action
Febrile 
NeutropeniaANC < 1,000/ Î¼L 
with fever 
(temperature â‰¥ 
38.5Â°C)#Interrupt lenalidomide therapy
#Follow CBC every 7 days
#Use of growth factors (G-CSF, GM-CSF) is permitted at 
the investigatorâ€™s discretion
#Resume lenalidomide (decrease one dose level) when febrile neutropenia has resolved with ANC â‰¥ 500/Î¼L
#Re- escalation to the next consecutive dose level is 
permitted as follows:
#If subject restarts dosing at one dose level 
lower on Day 1 to Day 14 of a cycle, and 
completes the remainder of that cycle at this lower dose without occurrence of toxicities 
requiring dose interruption/reduction, then 
the subject may be dose re-escalated to next consecutive-dose level starting at Day 1 of 
the subsequent cycle.
#If subject restarts dosing at one dose level 
lower on Day 15 to Day 28 of a cycle, and completes the remainder of that cycle and 
the subsequent cycle at this lower dose 
without occurrence of toxicities requiring dose interruption/reduction, then the subject 
may be dose re-escalated to next 
consecutive-dose level starting at Day 1 of the following cycle.
Thrombocytopenia Platelets 
< 20,000/ Î¼L#Interrupt lenalidomide therapy
#Follow CBC every 7 days
#Resume lenalidomide (decrease one dose level) when 
platelet count recovers to â‰¥ 25,000/Î¼L
#Re-escalation to the next consecutive dose level is 
permitted if the subject completes one full cycle without occurrence of toxicities requiring dose 
interruption/reduction. &(/*(1&&(1([ZIP_CODE],(7$5<,1)250$7en 
0/Î¼LÎ¼L
level evel is is 
g at one dosg at one do
ay [ADDRESS_281590] may b
ecutivecutive --dosdo
he subsequehe subsequ$7,21
If subjecIf subje
lowerowe
coco
52$7
telets tele
< 20,000/ Î¼ < 20,000/ 3
(1
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 61 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 5: Dose Reduction and Modification Guidelines for Lenalidomide (Continued)
Toxicity Severity Action
Tumor Flare Grade 3 or 4#Interrupt lenalidomide therapy and initiate therapy with 
corticosteroids, NSAIDs and/or narcotics
#Resume lenalidomide (decrease one dose level) when 
symptoms resolve to &Grade 1
#Re-escalation to the next consecutive dose level is 
permitted at Day 1 of the subsequent cycle when Tumor 
Flare resolves to â‰¤ Grade 1.
Desquamating 
(blistering) rashAny#Permanently discontinue lenalidomide and follow for 
PD
Non-
desquamating rashGrade 3#Interrupt lenalidomide therapy.
#Resume lenalidomide when the rash resolves to â‰¤ Grade 
1 (decrease one dose level)
Non-
desquamating rashGrade 4#Permanently discontinue lenalidomide and follow for 
PD
Neuropathy Grade 3#Interrupt lenalidomide therapy. 
#Resume lenalidomide when the neuropathy resolves to â‰¤ 
Grade 1 (decrease one dose level)
Neuropathy Grade 4#Permanently discontinue lenalidomide and follow for 
PD
Venous 
thrombosis/emboli
smâ‰¥ Grade 3#Hold (interrupt) dose and start anticoagulation;
#Resume lenalidomide at investigatorâ€™s discretion 
(maintain dose level).
Hyperthyroidism 
or hypothyroidismAny#Interrupt lenalidomide and initiate appropriate medical 
therapy.
#Resume lenalidomide at investigatorâ€™s discretion 
(maintain dose level).
&(/*(1dismism
(/(1([ZIP_CODE]#PerP35,(7$5<,1)250$7,21Tumor Tumor $7
nd follow fond follow f50
n the rash rthe rash r
vel)l))2
continue lenontinue le5<
pt lenalidompt lenalidom
sume lenalidsume lenali
Grade 1 (deGrade 1 (de7$
m
PDP35
[PHONE_4877]
AnyAny1((1
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 62 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 5: Dose Reduction and Modification Guidelines for Lenalidomide (Continued)
Toxicity Severity Action
Serum Creatinine Grade 2 
(> 1.[ADDRESS_281591])
OR 
Grade 3 
(> 3.[ADDRESS_281592])#Interrupt lenalidomide
#Evaluate subject weekly (minimum) until the serum 
creatinine return to baseline 
#If serum creatinine resolves to < Grade 1 resume lenalidomide (decrease one dose level) 
#If serum creatinine has stabilized to grade 1 after a minimum of 3 weeks of dose interruption resume lenalidomide at the investigatorâ€™s discretion (decrease one dose level) 
#If serum creatinine has not stabilized to â‰¤ grade 1 after 5 
weeks of dose interruption:
#Permanently discontinue lenalidomide and 
follow for PD at the investigatorâ€™s discretion OR
#Contact [CONTACT_233296]
#If the serum creatinine worsens at any time to > Grade 3, or if dialysis is indicated, permanently discontinue lenalidomide and follow for PD 
#Upon resumption of lenalidomide, evaluate subject weekly x 2 weeks to ensure the serum creatinine does not worsen; if the serum creatinine again worsens during those 2 weeks, permanently discontinue and follow for 
PD
Serum Creatinine Grade 4 (> 6.[ADDRESS_281593])
OR
if dialysis is 
indicated#Permanently discontinue lenalidomide and follow for 
PD
&(/*(1([ZIP_CODE],(7$5<,1)250$7r a 
ume ume 
on (decn (dec rereasas
ed to ed to â‰¤ gradâ‰¤gra
discontinue lcontinue 
PD at the inD at the in
ntact the Centact the Ce
discuss subjdiscuss subj
erum creatinrum creatin
f dialysis is idialysis is
enalidomidenalidomide
UpUpon reon$7,21
weekw
no
52$7
Grade 4 (>Grade 4 (>
ULN)ULN)(
&((1
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 63 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 5: Dose Reduction and Modification Guidelines for Lenalidomide (Continued)
Toxicity Severity Action
TLS Laboratory TLS 
or Grade 1 TLS#Same dose of lenalidomide will be continued without 
interruption or dose reduction at the investigatorâ€™s 
discretion.
#Hospi[INVESTIGATOR_233239] 1 TLS, (hospi[INVESTIGATOR_233240]â€™s discretion)
#Provide with vigorous intravenous hydration and rasburicase therapy as needed to reduce hyperuricemia, until correction of electrolyte abnormalities.
#Dose escalation to the next consecutive dose level is permitted when laboratory TLS is resolved and Grade 1 TLS is resolved to Grade 0.
TLS â‰¥ Grade 2#Interrupt lenalidomide therapy.
#Resume lenalidomide (at the next lower dose level) 
when the TLS resolves to Grade 0.
#If lenalidomide is resumed prior to the start of the subsequent cycle, a chemistry test should be performed 
every other day for the first week following re-initiation 
of lenalidomide.
#Re-escalation to the next consecutive dose level is 
permitted after completion of one full cycle without 
laboratory TLS or â‰¥ Grade 1 TLS, or occurrence of 
toxicities requiring dose interruption/reduction. 
&(/*(1([ZIP_CODE],(7$5<,1)rapy.py.
e (at the next(at th
lves to Gralves to Gr
e is reis resumesum
t cycle, a cht cycle, a ch
ther day forther day for
nalidomidenalidomid
ReRe-1)250$7,21n)
uricemia, ricemia, 
e dose level dose lev
esolved andesolved an$7
esescalaticalat
perpermittemi
laborla
tot1)
52525252
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 64 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 5: Dose Reduction and Modification Guidelines for Lenalidomide (Continued)
Toxicity Severity Action
Liver Function 
Tests (LFTs)ALT > 3.0 and â‰¤ 
5.[ADDRESS_281594] and 
serum total 
bilirubin â‰¤ 1.[ADDRESS_281595] #Continue current dose level
#Test at next scheduled visit 
Liver Function 
Tests (LFTs)ALT > 3.0 and â‰¤ 
5.[ADDRESS_281596] anda 
serum total bilirubin > 1.[ADDRESS_281597]
OR
ALT > 5.[ADDRESS_281598]
OR 
Serum total 
bilirubin > 1.[ADDRESS_281599]#Interrupt lenalidomide therapy.
#Evaluate ALT and serum total bilirubin weekly until 
both return to baseline levels
#Resume lenalidomide when ALT and serum total bilirubin return to baseline.
#Maintain dose level if recovery from event occurs â‰¤ [ADDRESS_281600] result.
#Decrease by [CONTACT_233297] > 14 days but â‰¤ [ADDRESS_281601] be notified if values do not return to 
baseline within 28 days of the initial event.
Other 
lenalidomide-
related non-
hematologic AEsâˆ€Grade 3#Interrupt lenalidomide therapy.
#May resume lenalidomide when the adverse event 
resolves to â‰¤ Grade 2 (decrease one dose level or 
maintain dose level per the investigatorâ€™s discretion)
Lenalidomide dose may be interrupted/modified per the investigatorâ€™s discretion for any 
AE (any Grade) not outlined in Table 5 .
Dose escalation or re-escalation may begin on the scheduled Day 1 of a new cycle according to 
the protocol guidelines if toxicities requiring dose interruption and/or modification have resolved as specified in Table [ADDRESS_281602] assessments as per Table 2 every 28 days.  An unscheduled visit may be 
conducted to meet this requirement.
If a study drug interruption has lasted for 5 week s (35 days), the investigator should contact [CONTACT_233298].&(/*(1([ZIP_CODE],(7$5<,1)250$7,217
until til 
rum total um total 
from event orom event 
vel if recoveel if recov
but but â‰¤ 28 dayâ‰¤ [ADDRESS_281603] b
within 28 dwithin 28 77$7
InterrupI[INVESTIGATOR_233241]
##MaM5,
[ADDRESS_281604]
conducted tonducted t
f a stuf a stu
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 65 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Table 6: Dose Reduction Steps for Lenalidomide
Dose levelLenalidomide dose (oral administration)
ScheduleTreatment Arm 1
5 mg starting dose armTreatment Arm 2
10 mg starting dose armTreatment Arm 3
15 mg starting 
dose arm
Dose level +4a25 mg daily 25 mg dailyb25 mg dailyc28 days
Dose level +3a20 mg daily 25 mg daily 25 mg dailyc28 days
Dose level +2a15 mg daily 20 mg daily 25 mg daily 28 days
Dose level +1a10 mg daily [ADDRESS_281605] is at Dose Levels +1, +2, +3 or +4, a maximum of [ADDRESS_281606] will be discontinued from the study.
b.  For the 10 mg starting dose arm, if a dose reduction is required at Dose Level +4 (25 mg daily), the subject will 
be dose reduced directly to Dose level +2 (20 mg daily).  This will be counted as one dose reduction.
c.  For the 15 mg starting dose arm, if a dose reduction is required at Dose Level +3 (25 mg daily)or Dose Level +4 
(25 mg daily), the subject will be dose reduced directly to Dose level +1 (20 mg daily).  This will be counted as one dose reduction.
d.  If a dose reduction is required at Dose Level -4 (or at dos e level -3 in the 5 mg starting dose arm) subject will be 
discontinued from the study.
Site staff must contact [CONTACT_233299] a patient.  If the treatment has 
been withheld and the next cycle is delayed beyo nd [ADDRESS_281607] return to the study site and
return the empty bottle or any unused drug and a new bottle will be dispensed.  Subjects will be 
required to return the empty bottle or any unused drug prior to new drug being dispensed.   
Subjects should take study drug from the new bottle for the remainder of the cycle (i.e. if 
reduction occurs on Cycle Day 16, then the subject will take study drug for days 16 though 28).
10.3. Emergency Unblinding
This is now an open label protocol.  Therefore the dose of study drug will be identified on the 
package labeling.
10.4. Prior/Concomitant Medications
All medications (prescription and non-prescription), treatments and therapi[INVESTIGATOR_27585] [ADDRESS_281608] be r ecorded on the eCRF.&(/*(1([ZIP_CODE],(7$5<,1)250$7,217,2yss7,27,27,2 8 daysays$777
28 days8 days0$50505505028 da5050505025555
ailyily2mg dailyg daily)2
2.5 mg ever2.5 mg eve
day1)
<<<< ecutive doseecutive dose
ued fued f rorofffm them the
at Dose Levat Dose Lev
s will be counwill be co
quired at Dosquired at Dos
to Dose leveto Dose lev
or r at adose levdose le
ooobtain neobtain ne
ycle is delayycle is dela
ll be definebe define
e reductione reduction
ttleeor anyor any
rnrnthetheememppmm
uld take studd take stu
occurs on Cccurs on C
.. EmeEm
This is nowThis is now
package package 
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 66 CC-5013-CLL-009 Amendment 6 Final 15Apr201510.4.1. Prophylaxis and/or Treatment for TLS, TFR, Neutropenia, and 
Thromboembolic Events
[IP_ADDRESS]. Tumor Lysis Syndrome (TLS) Prophylaxis 
TLS prophylaxis, comprising of oral hydration a nd allopurinol 300 mg/day will be initiated at 
least [ADDRESS_281609] be instructed to drink 8 to 10 eight ounce (240 mL) glasses of water each 
day for the first [ADDRESS_281610]â€™s cardiovascular status 
indicates the possibility of volume overload.
Subjects will be monitored for TLS as follows:
!On Day 2 and 4 and then weekly (Days 8, 15, 22) for cycle [ADDRESS_281611] cycle of 
each dose escalation
!On Day 1, 8 and 15 of cycle 2 (if not dose escalated)
!At least every 28 days thereafter and as clinically indicated.
[IP_ADDRESS]. Tumor Flare Reaction (TFR) Treatment
Grade 1 TFR may be treated with NSAIDs and TFR â‰¥ Grade 2 may be treated with 
corticosteroids.  Narcotic analgesics may be added as needed for pain control in subjects 
experiencing â‰¥ Grade 2 TFR.
Subjects will be monitored for TFR as follows:
!On Day 2 and 4 and then weekly (Days 8, 15, 22) for cycle [ADDRESS_281612] cycle of 
each dose escalation
!On Day 1, 8 and 15 of Cycle 2
!At least every 28 days thereafter and as clinically indicated.
[IP_ADDRESS]. Neutropenia Supportive Treatment
The use of hematopoietic growth factors is permitted.  Treatment with myeloid growth factors is 
strongly encouraged following ASC O guidelines recommendation ( Smith, 2006 ) for dosing and 
administration when the absolute neutrophil count (ANC) is less than 1,000/ Î¼L [NOTE: per the 
inclusion criteria, subjects must have an ANC â‰¥1000/Î¼L to be eligible for study entry].
[IP_ADDRESS]. Infection Prophylaxis
Prophylactic antibiotics should be considered in s ubjects with neutropenia.  In addition, subjects 
who were on prophylactic treatment for infection while on alemtuzumab therapy should continue prophylactic treatment for at least [ADDRESS_281613] udy while continuing prophylactic therapy. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ch ch 
shoulshoul d d 
ular statusular statu
d the first cd the first 
dicated.dicate
â‰¥ Grade 2 mGrade 2 m
as needed fas needed 
ws:ws:
eklyekly (Days (Dayyy
ffCycle 2Cycle 2
days theredays the
ia Supportia Suppor
poietic growpoietic gro
aged foaged fo llollww
n when then when the
criiteriteriiiia, suba, sub
[IP_ADDRESS] InfeInf
ProphylactiProphylacti
who werwho w
ophh
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 67 CC-5013-CLL-009 Amendment 6 Final 15Apr201510.4.1.5. Thromboembolic Events Prophylaxis
Lenalidomide may increase the risk of thromboembolic events in subjects who are at high risk 
(high risk is defined for example as a history of a thromboembolic event and/or taking a 
concomitant medication associated with an increased risk for a thromboembolic event and/or a known hypercoagulable state regardless of thromboembo lic history). All subjects s hould receive 
anti-thrombotic prophylaxis duri ng study treatment.  For sub jects who enter the study with a 
platelet count close to the eligibility criteria of â‰¥ 50,000/ Î¼L, the medical monitor should be 
contact[CONTACT_233267]-thrombotic prophylaxis.  The recommended prophylaxis is low-dose 
aspi[INVESTIGATOR_248] [ASA] (70-100mg) daily; however, another prophylactic anti-thrombotic therapy may be 
used per investigatorâ€™s disc retion during study treatment. Choice of the most appropriate anti-
thrombotic therapy for each subject should be ba sed upon a careful evaluation of the different 
risk factors associated with each therapy, and a corresponding assessment of the individual 
subjectâ€™s underlying medical condition.  Selection should be based on the overall benefit-to-risk ratio. Use of low molecular weight heparin or warfarin (or equivalent Vitamin K antagonist) to 
keep the International Normalization Ratio (INR) in the range of 2-3 or other anti-thrombotic 
therapy according to hospi[INVESTIGATOR_233242].
If platelets drop below 50,000/ Î¼L, the investigator should consider interrupting or adjusting the 
dose of anti-thrombotic therapy.  In the event that platelets drop below 20,000/Î¼L and the anti-
thrombotic therapy has not already been in terrupted, the investigator should again strongly 
consider interrupting the anti-thrombotic therapy.  In addition, for platelets < 20,000/Î¼L, 
lenalidomide should be interrupted and CBC s hould be followed every 7 days.  Appropriate 
interventions (i.e., platelet infusion) should be considered where applicable. 
[IP_ADDRESS]. Other
Other therapi[INVESTIGATOR_164623]â€™s well being may be administered at the 
discretion of the Investigator.  These therapi[INVESTIGATOR_233243], analgesics, 
antihistamines, or other medications as well as growth factors and transfusions of red blood cells, 
platelets, or fresh frozen plasma given to assist in the management of complications associated 
with chronic lymphocytic leukemia or its therapy.
[IP_ADDRESS]. Prohibited Concomitant Therapy
Concomitant use of other CLL therapy or investigational therapi[INVESTIGATOR_233244].
10.5. Discontinuation from Treatment
The following events are considered sufficient reasons for discontinuing a subject from study drug:
!AEs that, in the judgment of the Investigator, may cause severe or permanent harm or 
which rule out continuation of study drug.
!Disease progression
!Subject withdraws consent
!Subject lost to follow-upse se 
yybby[CONTACT_233300] e
antint-
ifferent fferent 
dividuadividua l l 
l benefitl benefit -toto
n K antagonn K antago
her antier anti -ththrrhhh
ptableptable .
interruptininterrupt
belbelow 20,0ow 20,[ADDRESS_281614]â€™s  subjectâ€™
rapi[INVESTIGATOR_233245] m
as well as gas well a
ven to assiven to assi
mia or imia or i ts tts tiii
ncomitantcomitant
ther CLL thher CLL th
iscontinucontinu
wing eventng event
!!AA
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 68 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Death
!Protocol violation
!Other
The reason for discontinuation should be recorded in the eCRF and in the subjectâ€™s medical 
records. Celgene is to be notified of all discontinuations from study drug.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 69 CC-5013-CLL-009 Amendment 6 Final 15Apr201511. STUDY DRUG MATERIALS AND MANAGEMENT
11.1. Supplier(s)
Celgene Corporation will supply lenalidomide capsules.
11.2. Dosage Form
Lenalidomide will be supplied as 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for 
oral administration.
11.3. Dosage Regimen
Subjects will be randomized (1:1:1) via IVRS in a double blind fashion to receive three different 
starting dose of lenalidomide (5 mg daily versus 10 mg daily versus 15 mg daily) on days 1-[ADDRESS_281615] tolerability, as follow (see Table 4 ).
!Treatment Arm 1: 5 mg â†’10 mg â†’15 mg â†’20 mg â†’25 mg/daily
!Treatment Arm 2: 10 mg â†’15 mg â†’20 mg â†’25 mg/daily
!Treatment Arm 3: 15 mg â†’20 mg â†’25 mg/daily
11.4. Study Drug Packaging and Labeling
The lenalidomide study drug will be packaged in  bottles and each bottle w ill contain supplies for 
28 days.  The label for study drug supplied by C elgene will bear Celgeneâ€™s name [CONTACT_3816], 
the protocol number, EudraCT number (where required), product name, dosage form, and 
strength, medication identif ication/kit number, dosing instructions, storage c onditions, the 
quantity of study drug contained, and required cau tion statements and/or regulatory statements as 
applicable. Additional information may be included on the label as needed and/or applicable.
Daily dispensing of capsules will be clearly defined on the bottle. Subjects requiring dose 
reduction within a treatment cycle must return to the study site and return the empty bottle or any 
unused drug and a new bottle will be dispensed.  Subjects will be required to return the empty 
bottle or any unused drug prior to new drug being dispensed.   Subjects should take study drug 
from the new bottle for the remai nder of the cy cle (i.e. if reduction o ccurs on Cycle Day 16, then 
the subject will take study drug for days 16 though 28).
11.5. Study Drug Receipt and Storage
The Investigator(s) or designee(s) is responsible for taking an inventory of each shipment of 
study drug received, and comparing it with the accompanying study drug shippi[INVESTIGATOR_27582].  
The Investigator(s) or designee(s) will verify the accuracy of the information on the form and 
register receipt in the study drug supply sys tem.  The investigator must contact [CONTACT_233301].
At the study site, all investigational study drugs will be stored in a locked, safe area to prevent 
unauthorized access.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21or r 
ve three dive three 
daily) on dadaily) on d
individual individual
â†’25 mg/dail25 mg/dai
mg/dailymg/daily
ailyaily
lingling
n n bottlbottlessan
y Celgene y Celgene 
where requirwhere requi
number, doumber, do
d required d require
n n mamay y be be i
will be clewill be cle
ent cycycle mcle m
bottlbottlewillwil
d drug priodrug prio
tlleefofor the rr the r
ll take studtake stu
Study DStudy
InvestigatoInvestigato
tudytudy drug rdrug ryy
The InveThe Inve
gigisteste
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281616] of Administration
Accurate recording of all study drug administration (including dispensing and dosing) will be 
made in the appropriate section of the subjectâ€™s eCRF and source documents.
11.7. Study Drug Accountability
The Investigator(s) or designee(s) is responsible for accounting for all study drug that is issued to 
and returned by [CONTACT_137825].
11.8. Study Drug Handling and Disposal
FCBP should not handle or administer lenalidomide unless they are wearing gloves. All subjects should not extensively handle or open lenalido mide capsules and should maintain storage of 
capsules in the packaging until ingestion.
In investigational studies, st udy drug will be dispensed through a qualified healthcare 
professional (i ncluding but not limited to, nurses, pharmacists and physicians).
These healthcare professionals will be trained  by [CONTACT_233302].  Once trained, these healthcare staff will counsel subjects prior to lenalidomide being dispensed to ensure that the subject has complied with all requirements 
including use of birth control and pregnancy testing (FCBP) and that the subject understands the 
risks associated with lenalidomid e.  This step will be documented with a completed lenalidomide 
Education and Counseling Guidance Document ( Appendix 21.9 ), and no lenalidomide will be 
dispensed until this step occurs.  Counseling includes verification with the subject that required 
pregnancy testing was performed and results were negative. A Lenalidomide Information Sheet (Appendix 21.9 ) will be supplied each t ime lenalidomide is dispensed.  Celgene w ill instruct the 
Investigator(s) on the return or destruction of unused study drug.  If any study drug is lost or 
damaged, its disposition should be documented in the subjectâ€™s eCRF and source documents.  
Celgene will provide instructions for the return of study drug supplies at the end of the study.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d to to
ves. All subves. All sub
ntain storagtain storag
fied healthfied health
physicians).ysicians)
quirements uirem
will counsewill couns
as coas co mpmpliedlied
CBP) and tCBP) and t
e documene docume
(Appendix Appendix 
ncludes verncludes ver
ts were negs were ne
me me lelenalidnal
uction of unuction of
documocum entent
ns for the rens for the re
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 71 CC-5013-CLL-009 Amendment 6 Final 15Apr201512. ASSESSMENT OF EFFICACY
12.1. Assessments
!Physical Exam (lymph nodes, spleen and liver measurement)
!Complete blood count (CBC) and differential
!ECOG Performance Status
!Assessment of constitutional symptoms (weight loss, fever, night sweats, fatigue)
!Computed tomography (CT) scans
!Histopathology (bone marrow aspi[INVESTIGATOR_337]/biopsy)
!Assessment for MRD by [CONTACT_4133] (peripheral blood and bone marrow aspi[INVESTIGATOR_337])
!In addition, the following will be performed at screening:
#Clinical staging using Rai and/or Binet as defined by [CONTACT_233303] ( Hallek, 2008 )
#Immunophenotypi[INVESTIGATOR_233216]
12.2. Methods and Timing of Efficacy Assessments
Serial measurements of efficacy will be performed at scheduled intervals throughout the duration 
of the study as outlined in Table [ADDRESS_281617] a Â± [ADDRESS_281618]â€™s efficacy results.  Laboratory tests that may result in dose interruption and/or 
modification as specified in Table [ADDRESS_281619] visits.
At a minimum the following hematology/chemistr y assessments must be performed locally:  
hemoglobin, absolute lymphocyte count, absolu te neutrophil count and pl atelet c ount, potassium, 
calcium, phosphorus, creatinine, total bilirubin, AST/SGOT, ALT/SGPT, and uric acid.  
At screening, subjects must meet eligibility criteria based on central lab results.  At Study Day 1, 
subjects must meet eligibility criteria based on local or central lab results prior to initiating study 
therapy, however, a re-calculation of creatin ine clearance is not required at Study Day 1.
Clinical response evaluations
The following assessments for evaluation of clinical response will be performed as specified in 
Table 2
!Physical Exam (lymph nodes, spleen and liver measurement)
!Complete blood count (CBC) and differential
!ECOG Performance Status
!Assessment of constitutional symptoms (weight loss, fever, night sweats, fatigue)&(/*(1([ZIP_CODE],(7$5<,1)250$7,21gue)ue)
one mone m arrowarro
ythe ihe iwCLLwCLLii
)
phocyphocy tesy
ssessmentssessmen
d at schedulat schedul
ed visited visit s ws w
aboratoriaboratori ese
ally generatally genera
ests that msts that m
shoulshoul d alsd al
visivisits.ts.ii
hematolhemato og
mphocyhocy te cote coyyy
reatinine, treatinine, 
ects must mcts must m
meet eligibileet eligibil
ever, aever, a rere-
response esponse
fofollollowing awing 
able able 22
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281620], abdomen and pelvis 
to assess lymphadenopathies will be performed at the PR and CR/CRi confirmation visits ( â‰¥8 
weeks to â‰¤ [ADDRESS_281621] been met for PR or 
CR/CRi).  Those subjects whose response was down-graded based on the CT scan interpretation 
at the PR or CR/CRi confirmation visit will have the CT scan repeated [ADDRESS_281622] equipment used for the assessment.
Histopathology (bone marrow aspi[INVESTIGATOR_337]/biopsy)
For those subjects who reach CR or CRi, a bone marrow aspi[INVESTIGATOR_233209]/CRi confirmation visit ( â‰¥ 8t o  â‰¤ [ADDRESS_281623] been met).  If the bone marrow is hypocellular, a repeat specimen should 
be obtained after [ADDRESS_281624] recovered. If the bone marrow biopsy shows disease involvement (30% or greater lymphocytes, or nodules positive for B-CLL 
cells by [CONTACT_9064]), an additional bone marrow biopsy and aspi[INVESTIGATOR_233210] [ADDRESS_281625] analysis by [CONTACT_233266]/CRi confirmation visit.  The MRD samples will be analyzed by a local laboratory.
!If peripheral blood and bone marrow are both MRD-positive, peripheral bl ood 
samples will be repeated and assessed up to [ADDRESS_281626] negativity in subjects who reach confirmed CR or CRi (see 
Follow-up MRD assessments).
!If peripheral blood is MRD-negative and bone marrow is MRD-positive, both 
peripheral blood and bone marrow should be retested for MRD negativity after â‰¥ [ADDRESS_281627] will 
be performed.
!If both the peripheral blood and bone marrow are MRD-negative, peripheral blood 
will be tested every [ADDRESS_281628] discontinues study 
drug or the study ends.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21est, st, 
PDs, PDs, 
abdomen anbdomen an
of radiationf radiation
f the subjecthe subj
nd bone marbone ma
safafter allallf cll
cellular, a rcellular, a
ave ve recoverecov
phocytes, orphocytes, 
mmarrow biarrow b o
ponse remponse rem a
e subjects wsubjects w
e collected collecte
MRD sampMRD sam
d and boned and bone
e repeated aepeated 
ment MRD ment MRD
up MRD asMRD as
ripheral bloripheral bl
erieripheralpheralii blblll
weeks.weeks. IfIf
be perfep e r
!!If If
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281629] assessments:
!If any of the repeat peripheral blood asse ssments indicate MRD-negativity, a bone 
marrow aspi[INVESTIGATOR_233238] a nd retested as soon as possible to 
confirm MRD negativity. 
#If the bone marrow is MRD-positive, both peripheral blood and bone marrow 
should be retested for MRD negativity after â‰¥ [ADDRESS_281630] will be performed.
#If at any time, the bone marrow is MRD-negative, peripheral blood will be tested 
every [ADDRESS_281631] discontinues study drug or the study ends.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ested sted 
rugugor r 
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 74 CC-5013-CLL-009 Amendment 6 Final 15Apr201513. ASSESSMENT OF SAFETY
13.1. Assessments
!Vital signs: pulse, blood pressure, temperature, weight and height (height at screening 
only)
!The following clinical laboratory assessments will be analyzed locally:
#Hematology: hemoglobin (HGB), platelet c ount, absolute neutrophil count 
(ANC), absolute lymphocyte count (ALC)
#Blood chemistry: potassium, calcium, phosphorus, creatinine, total bilirubin, 
AST/SGOT, ALT/SGPT and uric acid
#Urinalysis:  ketones, sediments and specific gravity
#Calculated (method of Cockroft-Gault) creatinine clearance (creatinine clearance 
may also be obtained by [CONTACT_941] 24-hour collection method at the investigatorâ€™s discretion)
#At screening, subject must meet eligibility criteria based on central lab results.  At 
Study Day 1, subject must meet eligibility criteria based on local or central lab 
results prior to initiating study therapy.
!Pregnancy testing / counseling as per Appendix 21.9
!12-lead ECGs (performed and interpreted locally)
!Concomitant medications
!AEs by [CONTACT_4652] (Version 3.0) used as a guide for the grading of severity with 
the exceptions of hematological toxicities and TLS .  Hematological toxicities will be 
graded as specified in the iwCLL guidelines for the diagnosis and treatment of 
chronic lymphocytic leukemia ( Hallek, 2008 ) (Appendix 21.4 ).  TLS will be graded 
as specified by [CONTACT_137785]-Bishop grading system ( Appendix 21.3 ).Version 3.0 with 
modification recommended by [CONTACT_233304] ( Hallek, 2008 ) and Cairo-Bishop grading system (for TLS).
!Second primary malignancies will be monitored as events of interest and should be 
included as part of the assessment of adverse events throughout the course of the 
study.  Investigators are to report any second primary malignancies as serious adverse 
events regardless of causal relationship to study drug, occurring at any time for the duration of the study, from the time of signing the informed consent up to and 
including the survival follow up phase.  Subjects will be followed until 80% of the 
subjects have progressed or died or up to five years after the last subject was randomized, whichever occurs later.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21biilirubin, lirubin, 
nce (creatine (crea
d at the invd at the in
riria based oa base
riteriteriia basea bas
ppendix 21.ppendix 2
preted localreted loca
on 3.0) usen 3.0) us
ological toxogical to
 the the iwCLLiwCL
ic leukemic leukem
the Cairohe Cairo --B
recommenrecomme
Hallek, 200Hallek, 20
nd primary nd primary 
cluded as pauded as p
studystudy .  Inv.  Inv
events revents 
duratur
inin
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281632] a Â± 3 
day window unless otherwise stated.  Laboratory tests that may result in dose interruption and/or 
modification as specified in Table 5 should also be performed locally.
13.3. Recording and Reporting of Adverse Events
The recording and reporting of adverse events is described in Appendix 21.1 .
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 76 CC-5013-CLL-009 Amendment 6 Final 15Apr201514. OTHER ASSESSMENTS
14.1. Assessments Following Treatment Discontinuation
Subjects will continue in the study and receiv e study drug until discontinuation from the study 
for any of the following reasons: disease progression; AEs that, in the judgment of the 
Investigator, may cause severe or permanent harm  or which rule out continuation of study drug, 
subject withdraws consent, subject is lost to  follow-up, death, protocol violation that may rule 
out continuation of study drug, other reasons that  in the Investigators judgment that may rule out 
continuation of study drug.
For those subjects who discontinue study drug for reasons other than disease progression or 
withdrawal of consent, study visits should cont inue every [ADDRESS_281633].  During these visits only the following assessments will be required: hematology, ECOG performance status, evaluation of constitutional symp toms, physical exam 
for liver, spleen and lymph nodes, adverse events, second primary malignancies, concomitant 
medications/therapi[INVESTIGATOR_014], and assessment of response.
For subjects who develop PD characterized by [CONTACT_233264] a more aggressive histology 
[i.e. Richterâ€™s syndrome (lymphomas) or prolymphocytic leukemia], this diagnosis should be 
established by [CONTACT_233265].
Subjects who are discontinued from the study drug for any reason, except for withdrawal of 
consent, will be followed for survival, second primary malignancies and subsequent CLL 
therapi[INVESTIGATOR_233246] 80% of the subjects randomized to the study have 
progressed or died or up to five years after the last subject was randomized, whichever occurs 
later.
14.2. Assessment of Pharmacokinetics
Collection of pharmacokinetic samples is di scontinued as of this amendment, protocol 
amendment #6.  Pharmacokinetic assessments will be performed in up to [ADDRESS_281634]-dose (see 
Table 2 ).  On Cycle 1 Day 2, all PK subjects will return to the site to provide a PK blood 
sample at pre-dose (equivalent to [ADDRESS_281635] Day 1 dose).  The following information should be recorded on Cycle 1 Day 1:
!Actual date and time of dosing&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ule out ule out 
ession or ssion or 
ononse untse unt il il
n is started, n is started
will be reqwill be req
mptomtoms, phs, 
alignancieslignancie
to a more to a mor
eukemia], tukemia],
fofor anyr any  reasrey
imarymary myyaligali
of the subjef the subje
the last subhe last su
rmacokinmacokin
c samples samples is
kinetineic asseic ass
centers.  centers. F
mmandatoryandato
g will be peg will be pe
K sK samplinamplin
Cycle 1 DaCycle 1 D
n the mornn the morn
undergo undergo
Tableable
samsam
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 77 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Actual date and time for the last meal before dosing
Sparse PK sampling
Sparse PK sampling will be performed on Cycle [ADDRESS_281636] cycle at Dose 
Levels +1, +2, +[ADDRESS_281637] cycle at Dose Levels +1, +2, +3 overlap with the Cycle 2 sparse PK sampling t imepoints, 
only one sample is required.  At each of these sparse PK sampling visits, 1 blood sample will 
be collected between 1 and 10 hours (inclusive) after the morning dose. For each subject, effort should be made to collect the sample in approximately 1:1 ratio between the interval 1-
5 hours and the interval of 5-10 hours.  On the PK visit days, subjects should take the study 
drug in the morning (preferably prior to their arrival at the study site).  Subjects will not be required to fast for these PK visits.
Subjects will be asked to accurately provide the following information and report them to the 
study staff on the PK visit day for sparse PK sampling:
!Actual date and time of dosing on PK visit days and the day prior to PK visits
!Actual date and time for the last meal before dosing on PK visit days 
!Actual date and time for the food eaten within 4 hours after dosing on PK visit days
Actual date and time for blood draws should be recorded.  Lenalidomide concentration in plasma 
will be determined by a validated liquid chromatography-tendem mass spectrometry (LC-
MS/MS) method.
14.3. Assessment of Exploratory Biomarkers
The following exploratory assessment will be performed as specified in Table 2 .
!Blood samples for Î²2M will be collected at baseline.  
!Blood samples for ZAP-70, V Hmutational status /TP53 mutation analysis and FISH 
studies for cytogenetic assessment ( CCND1/IgH fusion, del 11q, del 17p, del 13q, 
and Trisomy 12),  and confirmation of disease diagnosis by [CONTACT_233305].  
 
 All samples will be  analyzed centrally.
 
 
14.4. Assessment of Other Outcomes
 &(4.4.44*(1([ZIP_CODE],(7$5<,1)250$7,21rval 1rval 1 --
he study he study 
will not be will not be 
d report thed report the
ypripriyor to Por to P
n PPK visit dvisit d
ours after dours after
 Lenalidom Lenalidom
hy-hytendemendem
BiomarkeBiomarke
ll be performl be perfor
ill be collecill be co
PP--70, V70, V HH
etic assessmetic asses
), 
llllbe collecbe coll35
1(3(1(*(1/*(/*(/*&(/
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281638]-Leu questionnaire ( Appendix 21.7 ) and EQ-5D ( Appendix 
21.8) will be assessed at Cycle 1 Day 1, every 8 weeks thereafter and at treatment 
discontinuation.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 79 CC-5013-CLL-009 Amendment 6 Final 15Apr201515. STATISTICAL ANALYSES
15.1. Overview
This study will be conducted using a randomized Bayesian schedule-administration design that 
jointly models toxicity/response outcomes using an extension methods developed in ( Bekele , 
2004 ) (Bekele, 2005 ) (Bekele, 2008a ) (Bekele, 2008b ).  Schedule-administration (or treatment 
strategy) designs differ from standard treatment de signs in that the object of interest is not to 
determine if one treatment is superior to an altern ative treatment, but to determine if a particular 
treatment administration schedule is superior to other competing schedules.  In the context of the 
current design Celgene is interested in evaluati ng whether various intra-patient dose-escalation 
schemes are safe and effective while monit oring safety and efficacy (futility).  Specifically, 
while treatment starts at various doses ranging from very low doses (such as 5 mg/daily) to 
moderately low (15 mg/daily), the goal is to perform intra-patient dose escalation (every 28 days as tolerated) until a maximum dose of 25 mg/daily is  achieved.  The decision to escalate is based 
on how well the subject tolerates the lower dose levels.  While these dose escalations are taking 
place, toxicity and the progression rate will be monitored.
 
 
 
 
Operationally, the study will proceed as follows:  Subjects will be randomized to one of the three 
treatment arms.  The first interim analysis (t oxicity only) will be performed once [ADDRESS_281639] completed one 28-day cycle.  Subsequent interim analyses will occur at 13-week intervals 
to monitor both combined toxicity and progression rate.   
&(/*(1llyly, the stud, the stud
t armrms.  Th.  T
oompmpleted ed 
mmonionitor botor boii5235,(7$5<,1)250$7,21icular icular 
ext of the t of the
escalatescalat ioion n
ecificallycifically ,
mmg/daily) tg/daily)mm
atatioion (evern (eve
ioion to escan to 
ose escalatose escala
235,(7$5<,
[ZIP_CODE](31(31((1
&(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 80 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!  
If a treatment arm is dropped then all new subjects will be randomized equally into the remaining 
arms.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15.2. Study Population Definitions
15.2.1. Intent-to-Treat Population
The efficacy analysis will be performed on the ITT population, which will include all subjects 
randomized.
15.2.2. Safety Population
All randomized subjects who receive at least one dose of study drug will be included in the 
safety analyses.
15.2.3. Subgroup Analyses
In addition to analyses that include all subjects, analyses will be performed to compare 
treatments within the following stratification subgroups:
!Relapsed vs. refractory to their last purine-analog or bendamustine based treatment 
regimen [relapsed/refractory as defined per the iwCLL guidelines for diagnosis and treatment of CLL ( Hallek, 2008 )].    If a subject has received both, the status post &(/*(1(35235DefinitionDefinition
PopulationPopulation
ll be perforll be perf
ty Populatity Populat
zed subjectzed subjec
alyses.ses.
.3..3. SubSub
In additn addit ioionn
reatmreatm ene(7$5<,1)250$7,21$7$0$75050250)25)21)2,1)<, 15<$5<7$5(75,(35,(235
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281640] recent purine-analog or bendamustine tr eatment regimen will be used for 
stratification.
!Age < 65 years of age vs. â‰¥ 65 years of age
Additional subgroups may be examined, as needed based on regulatory and clinical requests.
15.3. Efficacy Evaluation
Efficacy analysis will be performed on intent-to -treat population. Adjudicated response will be 
used for these analyses.
Response
Response, including evaluation of minimal residual disease (MRD), will be assessed by [CONTACT_233306] ( Hallek, 2008 ).  The response rate based on the 
best response during the treatment period and the relative proportions in each response category 
will be examined.  Exact test procedures for proportions will be used to compare response rate between the treatment arms.  Distributions of the responses into the response categories (CR, 
CRi, nPR, PR, SD, PD) will be provided for each treatment arm.  Response rates 
(CR+CRi+nPR+PR) together with confidence intervals will be provided for each regimen, both for the entire population and for the subgroups defined by [CONTACT_83353].
Responses from subjects after they received other anti-cancer treatments will not be counted, 
however, these subjects will be included in the denominator.
Duration of Response
Duration of response is defined as the time from the first visit where PR, CRi, or CR was 
documented to PD.  Duration of response will be censored at the last date that the subject was known to be progression-free for: 1) subjects who have not progressed at the time of analysis; 2) 
subjects who have withdrawn consent or are lost to follow-up prior to documentation of 
progression.
A two-sided log rank test stratified by [CONTACT_941] [ADDRESS_281641] documented date of 
PR, CRi or CR based on iwCLL guidelines.
Progression-free Survival (PFS)
Progression-free survival is calculated as the time from rando mization to the first documented 
progression or death due to any cause during or after the treatment period, whichever occurs 
first.  The progression date will be assigned to the earliest time when any progression is observed without prior missing assessments. If withdrawal of consent or loss to follow-up occurs before 
documented progression or death, then these observations will be censored at the date when the 
last complete tumor assessments determined a lack of progression.
For subjects who do not develop progressive disease at the time of analysis, if the response from 
the last visit was â€˜not evaluableâ€™, the most prior visit date with complete evaluation indicating no 
progressive disease will be used as the censor date.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d by [CONTACT_233307] t
response caesponse c
mpare resmpare res pp
onse categonse ca
sponse rateponse rate
ovided for vided for 
tratificationratific
er treatmenr treatm
ator.or.
m the first vithe first 
ll be censorl be censor
ctsctswho hawho ha
or are lost tr are lost 
ied by [CONTACT_941] 3ed by [CONTACT_941] 3
duration of duration of 
calculated aalculated
sed on iwCsed on iwC
free Survivee Survi
on--free survfree sur
ssion or dession or de
t.  The prog.  The prog
wiwiththii&out priout pri
documdocum en
st cot
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 82 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Event-free Survival (EFS)
Event free survival (EFS) is the interval between the start of treatment to the first sign of disease 
progression, or treatment for relapse, or death (whichever occurs first)
Time-to-Progression (TTP)
TTP is defined as the time from rando mization to the first documented progression.  For subjects 
who do not progress during the study, TTP will be censored at the last adequate response 
assessment showing evidence of no disease progression. TTP is the same as PFS when there is no death.
Overall Survival (OS)
OS is calculated as the time from rando mization to d eath from any cause.  OS will be censored at 
the last date that the subject was known to be alive for subjects who were alive at the time of 
analysis and for subjects who have withdrawn consent or were lost to follow-up before death was 
documented.
The analysis of OS will include survival information for all randomized subjects.  Subjects who 
discontinued from the study and who had possibly received other anti-cancer therapi[INVESTIGATOR_233247].  However, sensitivity analyses may
be performed in which these subjects will be censored at the date of the first dose date of the 
anti-cancer therapy.
15.4. Regression Analyses 
In addition we plan to perform both classical and Bayesian regression analyses in which 
predictors such as the stratification factors, treatment and possibly the treatment-by-stratification 
factor are included as covariates. Under the Bayesian framework these models will also be used 
to estimate posterior predictive probabilities for comparing the various treatments.
15.5. Background and Demographic Characteristics
Subjectsâ€™ age, weight, height and other continuous demographic and baseline variables will be 
summarized using descriptive statistics (mean, standard deviation, minimum and maximum), 
while performance status, gender, race and other categorical variables will be summarized with frequency tabulations for each treatment group separately and pooled over both treatment 
regimens. Medical history data will be summarized using frequency tabulations for each 
treatment arm separately and pooled over both arms. Individual patient listings will be provided.
Homogeneity of these variables will be assessed by [CONTACT_31806]-way analysis of variance for continuous 
measures and Fisherâ€™s exact test for categorical measures.
15.6. Study Drug
Dosage statistics (mean, median, mode, standard deviation and final dose, dose at each evaluation) will be provided for each treatment arm.  Time to the first dose reduction and reasons 
for dose reduction will be summarized for each treatment arm.  Reasons for discontinuation will be summarized.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21be censorede censore
t the time othe time o
up before d before d
d subjects. d subjects
ti-cancer thcancer th
ever, sensitver, sensit
ate of the fiate of th
Bayesian rBayesian 
atment andatment and
BayBayesian esian
tieies fs for comor comff
emograpmograp
and other cod other c
ve statistve statist ici
s, gender, ras, gender
for each trfor each
historyhistory  datdatyy
eparately aneparately a
tytyofofyy these these ff
s and Fishend Fish
6.6. StuSt
Dosage stDosage st
valuatvaluat
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 83 CC-5013-CLL-009 Amendment 6 Final 15Apr201515.7. Concomitant Therapy
All concomitant treatment usage documented during the study period will be su mmarized in 
frequency tabulations for each treatment group separately.  The Anatomical Therapeut ical 
Chemical (ATC) coding scheme of the World Health Organization (WHO) will be used to group 
medications into relevant categories for these tabulations.
15.8. Safety Evaluation
All subjects who receive at least one dose of study drug will be included in the safety analyses.
Adverse events (AE) will be classified using th e Medical Dictionary for Regulatory Activities 
(MedDRA) classification system. The severity of the toxicities will be graded according to the NCI CTCAE version 3.[ADDRESS_281642] may be used to analyze the 
difference between the treatment groups.
AEs leading to death or to discontinuation from treatment, events classified as NCI CTCAE 
version 3.0 Grade 3 or higher, study-drug-related events, and serious adverse events (SAEs), and events of interest (including second primary malignancies) will be summarized separately.
Laboratory data will be graded according to NCI CTCAE version 3.[ADDRESS_281643] finished one treatment cycle. Then toxicity and progression will be assessed subsequently at 
13-week intervals.  
 
 
 
If a treatment arm is dropped then all new subjects will be randomized equally into the remaining 
arms.es.
vititieies 
ng to the g to the 
ach treatmeach treatm
ennappropriappropr
be countedbe coun
the case ththe case th
t mt mayay bby[CONTACT_233308]) cies) will bwill b
CTCAE verCTCAE ver
uencies of encies of
, mmedians, edians,
where usefwhere us
eses
mmarized amarized a
ment cyment clecley
fa  t r efat r e1((1*(
(/(/*&(/(/(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281644] 3 months and a total of 41 to 55 subjects will accrue by 6 months with the 
remainder accruing by 60 weeks. Therefore, in addition to monitoring toxicity and progression, 
the accrual rate will be monitored.
 
15.11. Other Topi[INVESTIGATOR_1102]
15.11.1. Pharmacokinetics Analysis:If the data are sufficient, noncompartmental PK parameters, such as T
max, Cmax, AUC, CL/F, and 
t1/2, will be estimated.  Descriptive statistics will be provided for plasma concentrations and PK 
parameters.  Lenalidomide concentration data obtained from all visits may be used to develop the 
population PK mod el.  The relationship between pharmacokinetics and response (biomarkers or 
clinical outcomes as appropriate) will be explored.  Detailed methodology will be outlined in a separate PK data analysis plan and the results will be presented in a stand-alone PK report.
15.11.2. Exploratory Analysis 
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21n, 
Tmaxmax, C, Cma
plasma conasma con
ll visits mall visits 
kinetineticics ands and
ailed methoed meth
presented ipresented i50
5,(35
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 85 CC-5013-CLL-009 Amendment 6 Final 15Apr201516. QUALITY CONTROL AND QUALITY ASSURANCE
16.1. Monitoring 
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  Before the study is initiated at a s ite visit or at an investigator meeting, all aspects of 
the study are reviewed with the investigator(s) and the staff.  Prior to enrolling subjects into the 
study, a Celgene representative will review  the protocol, eCRFs, procedures for obtaining 
informed consent, record keepi[INVESTIGATOR_007], and reporting of AEs with the Investigator(s).  Monitoring 
will include on-site visits with the Investigator(s) and his/her staff as well as any appropriate 
communications by [CONTACT_2319], fax, or telephone.  At each monitoring visit, the facilities, study drug storage area, eCRFs, subjectâ€™s source documen ts, and all other study  documentation will be 
inspected/reviewed by [CONTACT_233309].
Accuracy will be checked by [CONTACT_12939] a direct comparison of 
the entries made onto the eCRF against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator(s) and/or his/her staff.  Any necessary corrections will be made directly to the eCRFs or via source data clarification forms by [CONTACT_3786](s) and/or his/her staff. Monitoring procedures require that informed consents, 
adherence to inclusion/exclusion criteria and documentation of SAEs and the proper recording be 
verified.  Additional monitoring activities may be outlined in a study-specific monitoring plan.
16.2. Audits and Inspections
In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  From time to time, re presentatives of this unit will conduct audits of 
clinical research activities in accordance with Celgene SOPs to evaluate compliance with Good 
Clinical Practice guidelines and regulations.
The Investigator(s) is required to permit direct access to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of subject participation for audits 
and inspections by [CONTACT_1744]/IECs, regulatory authori ties (e.g. FDA, EMA) and company authorized 
representatives.  The Investigator(s) should make every effort to be available for the audits 
and/or inspections.  If the Investigator(s) is contact[CONTACT_233310], he/she should contact [CONTACT_27740].
16.3. Investigator(s) Responsibilities
Investigator responsibilities are set out in the ICH guideline for Good Clinical Practice and in the 
US Code of Federal Regulations.  Celgene or a representative will contact [CONTACT_233311]-investigators who in turn will select their staff.  The investigator must give the monitor access to relevant records to confirm the above.  
The Investigator(s) is responsible for keepi[INVESTIGATOR_007] a record of all subjects who sign an Informed 
Consent Form and are screened for entry into the study.  For those subjects who fail screening, the reason(s) for exclusion must be recorded in the subjectâ€™s source documents and on the 
Screening Log provided by [CONTACT_27718].&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ng ng 
priate priate 
tudytudy drug drug yy
on will be n will be 
and good cand good
a didirect corectiii
mentation.  Aentation. 
her staff.  Aer staff.  
ta clarificata clar
equire that equire that
on ofon of  SAESAEff
ined in a stined in a st
ures, a Gooures, a Goo
time, repretime, repre
ce with Celce with Ce
ulatlatioions.ns.
to permit dio permit di
nd applicabnd applic
ECs, regulaECs, reg
nvestnvest igatorigator
If the Invef the Inve
e should coe should co
InvestigaInvestiga
gator respogator respo
Code of FeCode of Fe
nvestigatornvestigator
thhe meonioni
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 86 CC-5013-CLL-009 Amendment 6 Final 15Apr2015No procedure/assessment/measurement/test other than those outlined here, or in the schedule of 
study assessments, is to be performed without the prior written approval of Celgene, or unless 
deemed by [CONTACT_093](s) as necessary for th e subjectâ€™s medical care.  Investigator(s) and/or 
authorized designee(s) must enter study data onto eCRFs supplied by [CONTACT_27718].  The data on the eCRF will be recorded in an anonymous manner to protect the subjectâ€™s identity by [CONTACT_2329] a 
unique identifier that will prevent personal identifiable information.
The Investigator(s), or a designated member of the Investigatorsâ€™ staff, must be available at some 
time during monitoring visits to review data and resolve any queries and to allow direct access to 
the subjectâ€™s records (e.g., medical records, office charts, hospi[INVESTIGATOR_1332], and study related 
charts) for source data verification.  The eCRFs must be completed as soon as possible after the subjectâ€™s visit but no later than prior to each monitoring visit and be made available to the 
Celgene representative(s) so that the accuracy and completeness may be checked.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21to to 
fter the er the 
the the 
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281645]/Independent Ethics Committee Review 
and Approval
The protocol for this study has been designed in accordance with the general ethical principles 
outlined in the Declaration of Helsinki (see Appendix 21.2 ).  The review of this protocol by [CONTACT_5040]/IEC and the performance of all aspects of the study, including the methods used for obtaining informed consent, must also be in accordance with principles enunciated in the 
declaration, as well as ICH Gu idelines, Title 21 of the Code of Federal Regu lations (CFR ), Part 
50 Protection of Human Subjects and Part 56 Institutional Review Boards.  Before implementing this study, the protocol, the proposed informed consent form(s) and other information to subjects, 
must be reviewed by a properly constituted Institutional Review Board/Independent Ethics 
Committee (IRB/IEC).  A signed and dated statement that the protocol and informed consent have been approved by [CONTACT_1201]/IEC must be given to Celgene before the study initiation.  The 
names and occupations of the chairman and the members of the IRB/IEC must be supplied to 
Celgene.  
The Investigator(s) will be responsible for preparing documents for submission to the relevant 
IRB/IEC and obtaining written approval for this study .  The approval will be obtained prior to 
the initiation of the study.
A copy of the IRB/IEC approval for the protocol and the Informed Consent is to be provided to 
Celgene. The approval for both the protocol and informed consent must specify the date of 
approval, protocol number and version, or amendment number.
The Investigator(s) is responsible for notifying the IRB/IEC of any serious deviations from the 
protocol, or anything else that may i nvolve added risk to subjects.
Any advertisements used to recruit subjects for the study must be reviewed and approved by 
[CONTACT_137800]/IEC prior to use.
17.2. Protocol Amendments
Any amendment to this protocol that seems appropriate, as the study progresses (e.g. affects safety or efficacy) will be agreed upon between the coordinating and/or principal investigator(s) 
and the Celgene study physician.  Amendments will be submitted to the IRB/IEC for written 
approval before the implementation of the amended version.  The written signed approval from 
the IRB/IEC should refer specifically to the investigator(s) and to the protocol number and title and mention any amendment numbers that are applicable. Amendments that are administrative in 
nature do not require IRB/IEC approval but will be submitted to the IRB/IEC for information 
purposes.
17.3. Informed Consent
The Investigator(s) must obtain informed consent of a subject or his/her designee prior to any 
study related procedures as per Good Clinical Practices (GCP) as set forth in 21 CFR Parts 50 
and 56 and ICH guidelines.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21FR), Part FR), Part 
mplementmplement ini
ation to subjon to sub
ndent Ethicdent Eth
informed cinformed c
e studystudy iynitii
IEC must bEC must b
ts for subms for su
 approvalapprova wl
d the Informthe Info
nformed conformed c
ndment nudment nu
ying the IRing the IR
lve added rlve added
subjects foubjects f
o use.o use.
endmentndmen
s protocol ts protocol 
will be agrell be agre
studystudy  phys physyy
re the imple the imp
C should reC should re
tion any amn any a
e do not ree do not r
urposes.urposes
[IP_ADDRESS].
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281646]â€™s source documents.  The 
original consent form, signed and dated by [CONTACT_233312]â€™s entry into the study, must be maintained in the Investigatorâ€™s study files and a copy given to the subject.  In addition, if a protocol is amended and it impacts on the content of 
the informed consent, the informed consent must be  revised.  Subjects participating in the study 
when the amended protocol is implemented must be re-consented with the revised version of the informed consent.  The revised consent form, signed and dated by [CONTACT_233313], must be maintained in th e Investigatorâ€™s study files and a copy given to 
the subject.  
17.4. Subject Confidentiality
Celgene affirms the subjectâ€™s right to protection against invasion of privacy. In compliance with 
[LOCATION_002] federal regulations, Celgene requires the Investigator(s) to permit Celgeneâ€™s 
representatives and, when necessary, representatives of the FDA or other regulatory authorities to review and/or copy any medical records relevant to the study in accordance with local laws.
Should direct access to medical records require a waiver or authorization separate from the 
subjectâ€™s statement of informed consent, it is the responsibility of the Investigator(s) to obtain such permission in writing from the appropriate individual.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21to 
omompliancepliancemm
mit Celgenemit Celgene
egulatorygulatory aayy
rdance witance w h
zation sepazation sep
f the Invesf the Inves
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 89 CC-5013-CLL-009 Amendment 6 Final 15Apr201518. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645]
18.1. Data/Documents
The investigator(s) must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the study drug, th at is, copi[INVESTIGATOR_233248], 
original documents, data, and records (e.g., hospi[INVESTIGATOR_1097]; clinical and office charts; laboratory 
notes; memoranda; subjectâ€™s diaries or evaluat ion checklists; pharmacy dispensing records; 
recorded data from automated instruments; copi[INVESTIGATOR_27602]; microfiches; photographic negatives, microfilm, or magnetic media; x-
rays; subject files) and records kept at the pha rmacy, at the laboratories , and at medico-technical 
departments involved in the clinical study ar e complete, accurate, and filed and retained.
18.2. Data Management
Data will be entered into the clinical database per the guidelines established for the study.  These 
data will be electronically verified through use of on-line checks during data entry, and through 
programmed edit checks specified by [CONTACT_6098].  Discrepancies in the data will be brought 
to the attention of the clinical team, and investigati onal site staff.  Resolutions to these issues will 
be reflected in the database.  An audit trail within the system will track all changes made to the 
data.  A quality control audit will be performed per appropriate SOP(s) for the study.
18.3. Retention of Records
The investigator(s) must maintain records of all study documents and supporting information 
relating to the conduct of the study.  This documentation includes, but is not limited to, 
protocols, case report forms, advertising for subject participation, adverse event reports, subject 
source data, correspondence with health authorities and IRBs/IECs, informed consent forms, investigator(s) curricula vitae, monitor visit logs, laboratory reference ranges, laboratory 
certification or quality control proce dures and laboratory director curriculum vitae.  Subject files 
and other source data must be kept for the maximum period of time permitted by [CONTACT_5035][INVESTIGATOR_307], institution or private practice specified below.  The study monitor must be consulted if the 
investigator(s) wishes to assign the study files to  someone else, remove them to another location 
or is unable to retain them for a specified period.
For studies conducted in the [LOCATION_002] under a US IND, the investigator(s) must retain the 
study records for a minimum of 2 years after a marketing application for the indication is 
approved, or for 2 years after the IND is withdrawn.  If no application is filed, or if the application is not approved for the indication, the records are to be retained for two years after 
the investigation (i.e., the IND) is disconti nued, and FDA is notified of that fact.  For IND 
studies conducted outside the US, the investig ator(s), must retain study records for the time 
period described above or according to local laws or requirements, whichever is longer.  The 
monitor will inform the investigator(s) of the dates for retention.  All study documents should be 
made available if required by [CONTACT_233314].  For studies not conducted under the US 
IND, the investigator(s) records must be retained until at least [ADDRESS_281647] elapsed since the formal discontinuation of &(/*(1([ZIP_CODE],(7$5<,1)250$7,21yy
on as n as 
dia; x; x--
coo-technicatechnica
ained.ained.
shed for theed for t
ing data entng data en
ncies in the cies in the
ff.  Resol.  Reff utl
m will track will track
opriate SOPpriate SOP
l study docstudy do
cumcumentatientati oo
for subject for subject 
h authoritauthorit ii
itor visit logor visit lo
ocedures aocedures a
kept for thkept for th
ce specifiede specifie
o assign theo assign th
them for a them for 
ucted in theucted in the
for a minimor a mini
or for 2 year for 2 yea
on is not ais not a
vestvestigatigatioio
udiies condues condu
periperod desd des
oonitnitoo
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281648].  These documents should be retained for a 
longer period if required by [CONTACT_233315].
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281649] the right to discontinue a single site 
at any time during the study for reasonable medical or administrative reasons.  Possible reasons 
for termination of the study could be, but are not limited to:
!Unsatisfactory enrollment with respect to quantity or quality
!Inaccurate or incomplete data collection
!Falsification of records
!Failure to adhere to the study protocol
19.2. Study as a Whole
Celgene reserves the right to terminate this  clinical study at any time for reasonable medical or 
administrative reasons.
Any possible premature discontinuation would have to be documented adequately with reasons 
being stated, and information would be issued according to local requirements (e.g., IRB/EC, 
regulatory authorities, etc.).
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21for reasonafor reasona
umented adumented
local requiocal req
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 92 CC-5013-CLL-009 Amendment 6 Final 15Apr201520. REFERENCES
Badoux X, Wierda WG, O'Brien SM,, et al.  A phase II study of lenalidomide as initial treatment 
of elderly patients with chronic lymphocyt ic leukemia. Journal of Clinical Oncology , 2010 
ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 28, No 15_suppl (May 20 
Supplement), 2010: 6508
Bartlett JB, Dredge K, Dalgleish A.  The evolut ion of thalidomide and its IMiD derivatives as 
anticancer agents. Nature Reviews Cancer . 2004; 4:314-322.
Bekele BN, Ji Y., Shen Y, Thall P.F. Monitori ng late-onset toxicity in phase I trials using
predicted risks. Biostatistics. 2008a 9: 442-457.
Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression 
in a phase I/II dose-finding trial. Biometrics 2005;61:344-54.
Bekele BN, Thall PF. Dose-finding based on multiple  toxicities in a soft tissue sarcoma trial. 
Journal of the American Statist ical Association 2004;99:26-35.
Bekele N, Ji Y.  Adaptive randomization for multi-arm comparative clinical trials based on joint 
efficacy/toxicity outcomes.  Biometrics .  2008b Dec; 64 (4).
Binet JL, Auquier A, Dighiero G et al.  A new prognostic classification of chronic lmphocytic 
leukemia derived from a multivariate survival analysis.  Cancer.  1981; 48:198-204.
By[CONTACT_9063], Peterson BL, Morrison VA, et al, Randomized phase 2 study of fludarabine with 
concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-
cell chronic lymphocytic leukemia:  results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood .  2003;101(1): 6-14.
By[CONTACT_9063], Lin TS, Dalton JT, et al.  Flavopi[INVESTIGATOR_233249] a pharmacologically derived 
schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.  Blood .  2007 Jan 15; 109(2):399-404.
Cairo M, Bishop M.  Tumour lysi s syndrome:  new therapeutic strategies and classification.  
British Journal of Haematology.   2004; 127: 3-11.
Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for 
patients with chronic lymphoc ytic leukaemia (the LRF CLL4 Trial): a randomized controlled 
trial. Lancet . 2007; 370:230-239.
Chanan-Khan A, Miller KC, DiMiceli L, et al. Results of Phase II study of Lenalidomide (L) 
{Revlimid
Â®} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood . 
2005:106(11);Abstract 447.
Chanan-Khan A, Miller KC, Musail L, et al. Clin ical Efficacy of Lenalidomide in Patients With 
Relapsed or Refractory Chronic Lymphocytic Leukemia:  Results of a Phase II Study. J 
ClinOncol . 2006a;22(34):  5343-5349.
Chanan-Khan A, Musial L, Miller KC, et al.  Low-dose Prednisone Decreases the Severity but 
Not the Frequency of Lenalidomide Associated Tumor Flare Reaction (TFR) in Chronic 
Lymphocytic Leukemia (CLL) Patients. Blood .  2006b; Abstract 4987.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21g
arker exprearker expre
ssue sarcosue sarco
e clinical tre clinical
assificatassificat io
Cancer.  19Cancer.  
zed phase 2zed phas
mab in symmab in sy
m mCancer aCancer 
opi[INVESTIGATOR_233250] a
linical efficlinical ef
007 Jan 15;007 Jan 1
lysis syndrlysis synd
ology.ogy.  [ZIP_CODE]
S, Matutes S, Matutes
c lymphoclymphoc
7; 370:2307; 370:230
n A, Millern A, Miller
dÂ®} in pat} in pat ieie
06(11);Abs06(11);Ab
anannan-Khan-Khan
Relapsed oRelapsed o
ClinOncClinOn
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 93 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Chanan-Khan A, Miller KC, Whitworth A, et al.  Clinical activity of lenalidomide in relapsed or 
refractory chronic lymphocytic leukemia (CLL) patients:  updated results of a phase II clinical 
trial.  Leukemia and Lymphoma .  2007; 48(suppl 1):S166.
Chen C, Harminder P, Xu W, et al. A Phase II St udy of Lenalidomide in Previously Untreated, 
Symptomatic Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts),
2008; 112: 44
Cockcroft DW, Gault MH.  Prediction of creatinine clearance from serum creatinine.  Nephron 
1976; 16: 31-41.  
Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine m odulation and T- cell 
activation by [CONTACT_184698]- Î±. 
Journal of Immunology 1999; 163(1):380-6.
Corral LG, Muller GW, Moreira AL , Chen Y, Wu M, Stirling D, Kaplan G. Selection of novel 
analogs of thalidomide with enhanced tumor necrosis factor Î± inhibitory activity. Molecular 
Medicine 1996; 2(4): 506-15.
Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic 
leukemia. French Co-operative Group on Chronic Lymphocytic Leukemia. New England 
Journal of Medicine 1998; 338 (21):1506.
Eichhorst B, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine 
alone in first-line therapy of younger pa tients with chronic lymphocytic leukemia. Blood . 2006; 
107(3): 885-891.
Ferrajoli A, Lee BN, Schlette E, et al. Lenalidomide induces complete and partial responses in 
patients with relapsed and treatment-refractory chronic lymphocytic leukemia (CLL). Blood .  
2008; 111(11):5291-5297
Ferrajoli A, Keating M, Wierda W, et al.  Lenalidomide is active in patients with relapsed / 
refractory chronic lymphocytic leuk emia (CLL) carrying unfavorable chromosomal 
abnormalities.  Blood .  2007;110(11).
Fiegl M, Falkner A, Hopfinger G, et al. Routine Clinical Use of Alemtuzumab in Patients with 
Heavily Pretreated B-C ell Chronic Lymphocytic Leukemia. Cancer . 2006; 107(10):2408-2416.
Galustian C, Labarthe MC, Bartlett BJ, Thalidomide-derived immunomodulatory drugs as 
therapeutic agents. Expert Opin. Biol. Ther . 2004;4(12): 1963-1970.
Ghai P, Circosta P, Scielzo C, et al.  In:  Caligaris-Cappio F, Dalla-Favera R, eds.  Chronic 
Lymphocytic Leukemia. [LOCATION_013]:  Springer-Verlag Berlin Heidelberg; 2005:135-145.
Hallek M, Cheson B, Catovsky D et al.  Guidelines for the diagnosis and treatment of chronic 
lymphocytic leukemia:  a report from the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 
Guidelines; Blood ; January 23, 2008; 111:5446- 5456.
Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon 
SP, Richardson P, Anderson KC. Molecular mechanisms whereby [CONTACT_233316]: Clinical application. British Journal of Haematology 2005; 
128(2): 192-203.f TNFTNF--Î±.Î±.
lectectioion of nn o
vitvity.y.Molecol
chronichroni c lymc lym
ukemia. ukemia. NN
cyclophospcyclophosp
nic lymphocc lymph
de inducesde induce
ychronichroni c lyc ly
l.  .  LenalidoLenalid
emia (CLL)mia (CL
11).11).
er G, et al. er G, et al. 
Chronic Lyhronic L
MC, BartleMC, Bartl
Expert Opi[INVESTIGATOR_233251]
a P, Scielza P, Scie
c Leukemiac Leukemi
M, Cheson M, Cheson
hocyhocy titiyyyc lleue
eukemia (iwukemia (iw
GuiGudelinesdeline
ayaasas
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 94 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Hernandez-Ilizali turri FJ, Reddy N, Hol kova B, et al. Immunomodulatory drug CC-5013 or CC-
4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse 
lymphoma model. Clinical Cancer Research 2005; 11(16): 5984-92.
Hillmen P, Skotnicki A, Robak T, et al. Alemtuzu mab Compared with Chlorambucil as First-
Line Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology . 
2007;25(35):5616-5623.
Hoffbrand AV, Panayiotidis P, Reittie J, Ganeshaguru K Autocrine and paracrine growth loops
in chronic lymphocytic leukemia.  S emin Hematol. 1993;30(4):306-17.  PMID: 7505482 
[PubMed - indexed for MEDLINE].
Keating M, Flinn I, Jain V et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients 
who failed fludarabine:  results of a large international study.  Blood 2002;19 (10):3554-3561.
Lapalombella R, Yu B, Triantafillou G, Liu Q, et al. Lenalidomide down-regulates the CD20 
antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008; 112(13):5180-9.
The Leukemia and Lymphoma Society, FACTS 2008-2009 http://www.leukemia-
lymphoma.org/attachments/National/br_1215783647.pdf; The Leukemia and Lymphoma Society, 2009; accessed 24 October 2008.
Montserrat E, Rozman C. Chronic lymphocytic leukemia:  Present status. Annals of Oncology . 
1995; 6:219-235.
Oâ€™Brien SM, Kantarjian HM, Cortes J, et al.  Results of the Fludarabine and Cyclophosphamide 
combination Regimen in Chronic Lymphocytic Leukemia.  J ClinOncol.  2001;19(5): 1414-
1420.
Osterborg A, Dyer M, Bunjes D, et al. Phase II Multicenter Study of Human CD52 Antibody in 
Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology . 1997; 15(4): 
1567-1574.
Rai KR.  A critical analysis of staging in CLL.   In:  Gale RP, Rai KR, eds. Chronic Lymphocytic 
Leukemia:  Recent Progress and Future Directions.  [LOCATION_001]:  Alan R. Liss.; 1987:253-264.
Rai K, Peterson BL, Applebaum FR, et al. Fludarabine compared with chlorambucil as primary 
therapy for chronic lymphocytic leukemia. N Engl J Med . 2000; 343 (24):1750-1757.
Ramsay AG, Johnson AJ, Lee AM, GorgÃ¼n et a.  Chronic lymphocytic leukemia T cells show 
impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation 2008;118(7):2427-37.
Smith TJ, Khatcheressian J, Lyman GH, et al..  2006 update of recommendations for the use of 
white blood cell growth factors: an evidence-based clinical practice guideline. Journal Clinical 
Oncology 2006;24(19):3187-205.
Tam C, Oâ€™Brien S, Lerner S, et al., The natural history of fludarabine-refractory chronic 
lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.  Leukemia & Lymphoma. 2007; 48(10):  1931 â€“ 1939.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21atitients ents 
3554554-3561.-3561
ates the CDates the C
ofofririfftuximatuximii
9.9.
ww.leukemiw.leukemi
ukemia and kemia and
Present statresent sta
s of the Flus of the F
eukemia.  eukemia. J
se II Multe II Mult ii
ic Leukemc Leukem
taging in Caging in C
and Future and Future 
lebaum FRlebaum 
mphocymphocy tiyc
nson AJ, Leon AJ, Le
nonolologigicalcal
al of Clinial of Clini cc
J, KhatcherJ, Khatche
e blood celle blood ce
ncologyncology [ZIP_CODE]
TamTa C, OC, Om
mphmph
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 95 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Thomas D, Oâ€™Brien S, Kantarjian H et al.  Outcome in 203 patients (pts) with relapsed or 
refractory B-cell chronic lymphocytic leukemia (CLL) with salvage therapy (RX):  retreatment 
with fludarabine (FLU).  ASH 1998; Abstract 419.
Tohnya TM, Sylvia SW, Dahut WL, et al. A Phase I Study of Oral CC-5013 (Lenalidomide, 
Revlimidâ„¢), a Thalidomide Derivative, in P atients with Refractory Metastatic Cancer. Clinical 
Prostate Cancer . 2004; 2(4):  241-243.
TREANDAÂ®(bendamustine hydrochloride) [package insert]. Frazer, Pennsylvania: Cephalon 
Oncology; 2008.  TREANDAÂ®is a registered trademark of Cephalon Inc.
Wendtner C, Mahadevan D, Stilgenbauer S, et al.  Final Results of the Phase I Study of 
Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). Blood (ASH Annual Meeting Abstracts) , 2010; Abstract 1376.
Wierda W, Oâ€™Brien S, Wen S, et al. Chemoimmunotherapy With Fludarabine, 
Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia. J ClinOncol . 2005;23(18): 4070-4078.
Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-
mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clinical Cancer Research 2008;14(14):4650-7.
Yang H, Rosove MH, Figlin RA.  Tumor lysi s syndrome occurring after  the administration of 
rituximab in lymphoproliferative disorders:  high-grade non-Hodgkinâ€™s lymphoma and chronic lymphocytic leukemia.  American journal of hematology . 1999 Dec;62(4):247-50.CLLCLL -001 -001 
mphocymphocy titiyc
er cell and mr cell and m
ated CD20ated CD2
ccurring aftcurring aft
nonon--HodgkHodg
ogyogy. 1999 D1999 D
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 96 CC-5013-CLL-009 Amendment 6 Final 15Apr201521. APPENDICES
21.1. Adverse Event
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence occurring at 
any dose that may appear or worsen in a subject during the course of a study. It may be a new 
intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment 
of the subjectâ€™s health, including laboratory test values (as specified by [CONTACT_65801]), regardless of etiology. Any medical condition that was present prior to the signing of informed 
consent and that remains unchanged or improved should not be recorded as an AE. If there is a 
worsening of that medical condition, this should be considered an  AE. A diagnosis or syndrome 
should be recorded on the AE page of the Case Report Form rather than the individual signs or 
symptoms of the diagnosis or syndrome.
All AEs will be recorded by [CONTACT_737](s) from the signing of informed consent to the 
treatment discontinuation visit.  All AEs that lead  to study discontinuation should be followed 
until resolution or stabilization. For subjects who discontinue study tr eatment but continue to be 
followed every [ADDRESS_281650]â€™s source documents.
Abnormal laboratory values defined as adverse events
An abnormal laboratory value is considered to be an AE if
the laboratory abnormality is 
characterized by [CONTACT_39132]:
!Results in discontinuation from the study.
!Requires treatment, modifi cation/in terruption of study drug dose, or any other 
therapeutic intervention.
!Is judged by [CONTACT_737](s) to be of significant clinical importance.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page of the eCRF. If the abnormality was not a part 
of a diagnosis or syndrome, then the la boratory  abnorm ality s hould be recorded as the AE.
Serious adverse event
A serious adverse event (SAE) is any AE which:
!Results in death
!Is life-threatening (i.e., in the opi[INVESTIGATOR_689](s) the subject is at 
immediate risk of death from the AE)
!Requires inpatient hospi[INVESTIGATOR_27588]
!Results in persistent or significant disability/incapacity (a substantial disruption of the 
subjectâ€™s ability to conduct normal life functions)&(/*(1([ZIP_CODE],(7$5<,1)250$7,21med med 
ere is a e is a 
r syndromer syndrome
dual signs dual signs
ed consent d consent 
on should bn shou
reatmreatm ent bent
e reported ureported 
er occurs lar occu
ayys post ls post l asas
drug if it isdrug if it is
RF and in thRF and in th
e eventse events
be an AE be an AE 
room mththe stustu
difificatiion/ion/i
ioion.n
InvestigatoInvestiga
lilitytyiii iiys onene
be recordee recorde
syndrome, syndrome, 
rse eventrse event
s adverse evdverse 
!ResuRes
!!
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 97 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Is a congenital anomaly/birth defect
!Constitutes an important medical event
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospi[INVESTIGATOR_059], or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Second primary malignancies will be monitored as events of interest and must be reported as 
serious adverse events.  This includes any second primary malignancy, regardless of causal 
relationship to study medication, occurring at any time for the duration of the study, from the 
time of signing the ICF up to and including any follow-up, observation and/or survival follow-up period.  In this study, sub jects will be followed until 80% of the subjects ha ve progressed or died
or up to five years after the last subject wa s randomized, whichever occurs later.  Events of 
second primary malignancy are to be reported using the SAE report form and must be considered an â€œImportant Medical Eventâ€ even if no other serious criteria apply; these events must also be 
documented in the appropriate page(s) of the CRF and subject's source documents.  
Documentation of the diagnosis of the second primary malignancy must be provided at the time 
of reporting as a serious adverse event (e.g., any confirmatory histology or cytology results).   
Events not considered to be SAEs are hospi[INVESTIGATOR_65777]: were planned before entry into the 
clinical study; are for elective treatment of a condition unrelated to the studied indication or its treatment; occur on an emergency outpatient basis and do not result in admission (unless 
fulfilling other criteria above); are part of the normal treatment or monitoring of the studied 
indication and are not associated with any deterioration in condition.
If an AE is considered serious, both the AE pages of the eCRF and the SAE Report Form must 
be completed.
For each SAE, the Investigator(s) will provide in formation on severity, start and stop dates, 
relationship to study drug, action taken  regarding study drug, and outcome.
Classification of severity
For both AEs and SAEs, the investigator(s) must assess the severity of the event.
The severity of AEs will be graded based upon the subjectâ€™s symptoms according to National 
Cancer Institute (NCI) Common Terminology Criteria (CTCAE, Version 3.0) with the 
exceptions of hematological toxicities and TLS.  Hematological toxicities will be graded as specified in the iwCLL guidelines for the diagnosis and treatment of chronic lymphocytic 
leukemia ( Hallek, 2008 ) (Appendix 21.4 ).  TLS will be graded as specified by [CONTACT_137785]-Bishop 
grading system ( Appendix 21.3 ).  AEs will be evaluated for severity according to the following 
scale:
Grade 1 = Mild
Grade 2 = ModerateGrade 3 = Severe
Grade 4 = Life Threatening or disabling AE
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21s 
sal al 
omom the  the mm
val foval fo llowllow
ogressed oogressed o
tere.  . Eventsvents
and must bend must be
ese events ese even
ce documene docume
ymmyust be pt be pm
histolistologyogoy
ch: were plh: were p
nrelated torelated t
nd do not red do not
mal treatmemal treatm
rioration inoration in
E pages of tpages of 
will provide ll provid
taken regataken reg
the investithe inve
will be grawill be gr
NCI) CommNCI) Com
hematologiematolog
the the iwCLLiwCLL
(Hallek, 2Hallek, 
ng system (ng system (
le:e:
Graderade
G
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 98 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Grade 5 = Death
Classification of Relationship/Causality of adverse events (SAE/AE) to study drug
The Investigator(s) must determine the relationship between the administration of study drug and 
the occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: The temporal relationship of the adverse event to study drug 
administration makes a causal relationship unlikely or 
remote , or other medications, therapeutic interventions, or 
underlying conditions provide a sufficient explanation for the 
observed event
Suspected: The temporal relationship of the adverse event to study drug 
administration makes a causal relationship possible, and other 
medications, therapeutic interventions, or underlying conditions 
do not provide a sufficient explanation for the observed event.
Monitoring and reporting of adverse events
All subjects will be monitored for AEs during th e study.  Assessments may include monitoring 
of any or all of the following parameters: the subjectâ€™s clinical symptoms; laboratory, pathological, radiological, or surgical findi ngs; physical examination findings; or other 
appropriate tests and procedures.
Immediate reporting of serious adverse events
Any AE that meets the criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE pages of the eCRF.  The Investigator(s) is required to 
ensure that the data on these forms is accurate and consistent.  This applies to all SAEs, regardless of relationship to study drug, that occur during the study, those made known to the 
Investigator(s) within [ADDRESS_281651]â€™ s last dose of study drug, and those made known to 
the investigator(s) at anytime that are suspected of being related to study drug.
Second primary malignancies will be monitored as events of interest and must be reported as 
serious adverse events.  This includes any second primary malignancy, regardless of causal 
relationship to study medication, occurring at any time for the duration of the study, from the time of signing the ICF up to and including any follow-up, observation and/or survival follow-up 
period.  In this study, sub jects will be followed until 80% of the subjects have progressed or died
or up to five years after the last subject wa s randomized, whichever occurs later.  Events of 
second primary malignancy are to be reported using the SAE report form and must be considered 
an â€œImportant Medical Eventâ€ even if no other serious criteria apply; these events must also be 
documented in the appropriate page(s) of the CRF and subject's source documents.  Documentation of the diagnosis of the second primary malignancy must be provided at the time 
of reporting as a serious adverse event (e.g., any confirmatory histology or cytology results).   
The SAE must be reported immediately (i.e., within 24 hours of the Investigatorsâ€™ knowledge of 
the event) to the Celgene Safety Monitor by [CONTACT_233317].  A phone call is to be made 
to the Safety Monitor and an initial written report (prepared by [CONTACT_737](s) using the SAE &(/*(1([ZIP_CODE],(7$5<,1)250$7,21drug rug 
and other and other 
ng conditng condit io
bserved evserved ev
mentns mayay
al symptoml sympto
xaminatminat ioionn
quires the couires the c
of the eCRFof the eCR
urate and corate and c
g, that occuthat occu
a subjectâ€™ssubjectâ€™
at are suspet are suspe
s will be ms will be m
his includehis incl
edicatedica ion, n
ICF up to aCF up to a
udyudy, subjec, subjec
years after tars after 
marymary mmyyaligalig
ortant Medortant Med
mmented in tented in
ocumumentatientati
ofof reporti reportiff nii
he She S
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 99 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Report Form provided by [CONTACT_27718]) is to be faxed to the Safety Monitor (see below for contact 
[CONTACT_3031]).
The SAE report should provide a detailed description of the SAE and include copi[INVESTIGATOR_233252].  If a subject has died and an autopsy has been performed, copi[INVESTIGATOR_233253] e to be sent to Celgene as soon as these 
become available.  Any follow-up data will be detailed in a subsequent SAE Report Form, and 
sent to Celgene.
The Investigator(s) is responsible for informing the Institutional Review Board/Ethics 
Committee (IRB/IEC) of the SAE and providing them with all relevant initial and follow-up 
information about the event. The Investigator(s) must keep copi[INVESTIGATOR_137746], including correspondence with Celgene and the IRB/IEC on file.  All SAEs that have not 
resolved upon discontinuation of the subjectâ€™s participation in the study must be followed until 
either the event resolves completely, stabilizes/resol ves with sequelae, or returns to baseline (if a 
baseline value is available).
Pregnancies
Pregnancies and suspected pregnancies (includi ng a positive pregnancy test regardless of age or 
disease state) of a female subject or the female partner of a male subject occurring while the 
subject is on study drug, or within [ADDRESS_281652]â€™s last dose of study drug, are considered 
immediately reportable events.  Study drug is to be discontinued immediately and the subject 
instructed to return any unused portion of the study drug to the investigator(s).  The pregnancy, 
suspected pregnancy, or positive pregnancy test must be reported to the Celgene Safety Monitor 
immediately by [CONTACT_233318].
The female should be referre d to an obstetrician-gynecologist experienced in reproductive 
toxicity for further evaluation and counseling.
The Investigator(s) will follow the female subject until completion of the pregnancy, and must 
notify the Celgene Safety Monitor of the outcome of the pregnancy as a follow-up to the initial 
SAE report.
If the outcome of the pregnancy meets the criteria for immediate classification as an SAE (i.e., 
spontaneous or therapeutic abortion [any congenital anomaly detected in an aborted fetus is to be 
documented], stillbirth, neonatal death, or congenital anomaly [including that in an aborted 
fetus]), the Investigator(s) should follow the pro cedures for reporting SAEs (i.e., report the event 
to the Celgene Safety Monitor by [CONTACT_233319] 24 hours of the Investigatorâ€™s 
knowledge of the event).
In the case of a live â€œnormalâ€ birth, the Celgene Safety Monitor should be advised by [CONTACT_137809] 24 hours of the Inve stigatorâ€™s knowledge of the event.
All neonatal deaths that occur within [ADDRESS_281653] to 
causality, as SAEs.  In addition, any infant death  after 30 days that the Investigator(s) suspects is 
related to the in utero exposure to the study dr ug should also be reported to the Celgene Safety 
Monitor by [CONTACT_233319] 24 hours of the Investigatorsâ€™ knowledge of the event.
If the female is found not to be pregnant, any determination regarding the subjectâ€™s continued 
participation in the study will be determined by [CONTACT_737](s) and the Celgene Medical 
Monitor.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21up p
on, 
e not e not 
ollollowed unwed un
ns to baselins to base
ancy tecy te st regst reg
subjectbj occoc
t dose of stt dose of 
inued immnued imm
g to the inveg to the in
be reportebe reporte
E Report FE Report F
an-gynecogyneco ll
ng.g.
ale subject le subjec
f the outcothe outcff
ncy meets tncy meets t
 abortiaborti on [[
 neonatal dneonatal 
ator(s) shouor(s) shou
afetfety y MoniMoni ttii
the event).he event)
e of a live â€œof a live â€œ
simile withsimile with
neonatalneonatal ddll
causalitausalit y,y,aa
relelatedated t
oni
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 100 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to lenalidomide based on the Investigator Brochure.
For countries within the European Union, Celg ene will report in an expedited manner to 
Regulatory Authorities and Ethics Co mmit tees concerned, AEs in accordance with the Detailed 
Guidance on collection, verification and presentation of adverse reaction reports arising from 
clinical studies on medicinal products for human use (ENTR/CT3) and also in accordance with country-specific requirements.
Celgene shall notify the Investig ator of the following information:
Any AE associated with the use of study drug in this study or in other studies that is both serious 
and unexpected, i.e., suspected unexpected serious adverse reaction (S[LOCATION_003]R). Note that such 
cases from blinded studies will be unblinded for reporting purposes.
Any finding from tests in laboratory animals that suggests a significant risk for human study 
subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by [CONTACT_19666], the Investigator shall notify his/her IRB/IEC promptly of
these new serious and unexpected AE(s) or significant risks to study subjects.
Celgene safety contact [CONTACT_233320], please refer to the Serious Adverse 
Event Report Form / Completion Guidelines or to the Pregnancy Report Form / Completion 
Guidelines.
&(/*(1([ZIP_CODE],(7$5io$5<,1)250$7,21both seriousboth serious
te that suche that suc
k for humanfor human
citty.y.
/her IRB/IEer IRB/IE
tudy subjectudy subjec
n, pleasen, pleas
e Pregnance Pregna
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 101 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.2. Declaration of Helsinki
The Declaration of Helsinki can be found at: http://www.wma.net/e/policy/b3.htm
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 102 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.3. Cairo-Bishop Definition and Grading of Tumor Lysis Syndrome 
(Cairo, 2004 )
Cairo-Bishop Definition of Laboratory Tumor Lysis Syndrome (LTLS)
Uric Acid â‰¥ 476 Î¼mol/l (â‰¥ 8.0 mg/dl) or 25% increase from baseline
Potassium â‰¥ 6.0 mmol/l ( â‰¥ 6.0 mEq/l) or 25% increase from baseline
Phosphorous â‰¥1.45 mmol/l  ( â‰¥ 4.5 mg/dl) or 25 % increase from baseline
Calcium â‰¤ 1.75 mmol/l ( â‰¤ 7.0 mg/dl) or 25% decrease from baseline
Laboratory tumor lysis syndrome (LTLS) is defined as either a 25% change or level above or below normal, as 
defined above, for any two or more serum values of uric acid, potassium, phosphate, and calcium within 3 days 
before or 7 days after the initiation of chemotherapy.  This assessment assumes that a patient has or will receive 
adequate hydration (Â± alkalinization) and a hypouricaemic agent(s).
Cairo-Bishop Definition of Clinical TLS
The presence of laboratory TLS and one or more of the following criteria:
1. Creatinine:  â‰¥ 1.[ADDRESS_281654] (age > 12 years or age adjusted)
2. Cardiac arrhythmia / sudden death3. Seizure*
ULN, Upper limit of normal
*Not directly attributable to a therapeutic agent
Cairo-Bishop Grading System for TLS
Grade LTLS Creatinine Cardiac Arrythmia Seizure
0- â‰¤ 1.[ADDRESS_281655] None None
1 + 1.[ADDRESS_281656] Intervention not 
indicatedNone
2 + > 1.5 â€“ 3.[ADDRESS_281657] Non-urgent medical 
intervention indicatedOne brief generalized seizure; seizure(s) 
well controlled or infrequent; focal motor seizures not interfering with ADL
3 + > 3.0 â€“ 6.[ADDRESS_281658] Symptomatic and 
incompletely controlled medically or controlled with deviceSeizure in which consciousness is altered; 
poorly controlled seizure disorder; breakthrough generalized seizures despi[INVESTIGATOR_164380]
4 + > 6.[ADDRESS_281659] Life-Threatening Seizures of any kind that are prolonged, 
repetitive, or difficult to control
5 + Death* Death* Death*
LTLS, laboratory tumor lysis syndrome; ULN, upper limit of normal; ADL, activities of daily living
*Probably or definitely attributable to clinical TLS5&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7$7$7$70$
below norelow nor mamrrr
alcium withinalcium withi
atient has or tient ha50
,1
riteria:iteria:5<$5
(7
LSS
Cardiardia2352NonNo5252525235555
5 â€“â€“3.0 x UL3.0 x UL(
(> 3.0 > 3.0 (((1
(*(
44(((/&(&
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 103 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.4. Grading of Hematological Toxicity ( Hallek, 2008 )
GradeaDecrease in Plateletsb or Hbc(nadir) 
From Pretreatment value (%)Absolute neutrophil count/ Î¼Ld (nadir)
0 No change to 10% â‰¥ 2,000
1 11% - 24% â‰¥1,500 and < 2,000
2 25% - 49% â‰¥1,000 and < 1,500
3 50% - 74% â‰¥ 500 and < 1,000
4 â‰¥ 75% < 500
a.Grades: 1, mild; 2, moderate; 3, severe; 4, life-threatening; 5, fatal.  Death occurring as a result of toxicity at any 
level of decrease from pretreatment will be recorded as grade 5.
b. Platelet counts must be below normal levels for grades 1-4.  If, at any level of decrease the platelet count is 
<20,000/Î¼L, this will be considered grade 4 toxicity, unless a severe or life-threatening decrease in the initial 
platelet count (e.g., 20,000/ Î¼L) was present pretreatment, in which case the patient is not evaluable for toxicity 
referable to platelet counts.
c.Hb levels must be below normal levels for grades 1-4.  Baseline and subsequent Hb determinations must be 
performed before any given transfusions.  The use of erythropoietin is irrelevant for the grading of toxicity, but should be documented.
d. If the absolute neutrophil count (ANC) reaches less than 1,000/ Î¼L, it should be judged to be grade 3 toxicity. 
Other decreases in the white blood cell count, or in circulating granulocytes, are not to be considered, since a decrease in the white blood cell count is a desired therapeutic end point.  A gradual decrease in granulocytes is not a reliable index in CLL for stepwise grading of toxicity.  If the ANC was less than 1,000/ Î¼L prior to therapy, the 
patient is not evaluable for toxicity referable to the ANC.  The use of G-CSF is irrelevant for the grading toxicity, 
but should be documented.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2177$7$7$7$70$$
000000500025)2result of toxresult of tox
ecrease the plcrease the p
atening decreening decre
atient is not etient is not 
bsequent Hb bsequent Hb
is irrelevant firrelevant
00/Î¼L, it sho00/Î¼L, it sho
ng granulocyng granuloc
eutic end poinutic end poi
y.  If the AN If the AN
ANC.  The uANC.  The u
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 104 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.5. ECOG Performance Status Scale
Score Description
0 Fully active, able to carry on all pre-disease performance without 
restriction
1 Restricted in physically strenuous activity but ambulatory and able to 
carry our work of a light or sedentary nature, e.g., light housework, 
office work.
2 Ambulatory and capable of all self-care but unable to carry out any 
work activities.  Up and about more than 50% of waking hours.
3 Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours.
4 Completely disabled.  Cannot carry on any self-care.  Totally confined 
to bed or chair
5 Dead
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210nyny
s.000
r more thanr more tha25
care.  Totalcare.  Tot1)
5<$5
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 105 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.6. Clinical Staging of CLL Patients
21.6.1. Rai staging system (modified) ( Rai, 1987 )
Low-risk disease Lymphocytosis with leukemia cells in the blood and/or marrow 
(lymphoid cells > 30%)
Intermediate risk disease Lym phocytosis, enlarged nodes in any site, and splenomegaly 
and/or hepatomegaly (lymph nodes being palpable or not)
High risk disease Disease-related anemia (as defined by [CONTACT_233321] 11 g/dl or thrombocytopenia (as defined by [CONTACT_233322] 100 x 109/ L)
21.6.2. Binet staging system ( Binet, 1981 )
Staging is based on the number of involved areas, as defined by [CONTACT_233323] > 1 cm in diameter or organomegaly, and on whether there is anemia or 
thrombocytopenia.
Area of involvement considered for staging:
1. Head and neck, including the Waldeyer ring (this counts as one area, even if more than 
one group of nodes is enlarged)
2. Axillae (involvement of both axillae counts as one area)3. Groins, including superficial femorals (involvement of both groins counts as one area)
4. Palpable spleen 
5. Palpable liver (clinically enlarged)
Stage A Hemoglobin â‰¥ 10 g/dL and platelets â‰¥ 100 x 10
9/L and up to two of the 
above areas involved
Stage B Hemoglobin â‰¥ 10 g/dL and platelets â‰¥ 100 x 109/L and organomegaly 
greater than that defined for stage A (i.e. three or more areas of nodal or 
organ enlargement)
Stage C Hemoglobin < 10 g/dL and/or platelet count < 100 x 109/L, irrespective of 
organomegaly
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$count count $$
250$
presence opresence
here is anemhere is anem
this countsthis counts
ounts as onounts as on
rals (invorals (invo lvlv
nlarged)nlarged)
â‰¥ 10 g/dL â‰¥ 10 g/d
as invoas invo lvedl52
oglglobin obin â‰¥ â‰¥ 
reater than reater than 
organ enlorgan en(
*e C HemHe
o***(
(//*
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281660]-Leu Questionnaire
50$7,21

('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 107 CC-5013-CLL-009 Amendment 6 Final 15Apr2015
50$7,21

('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 108 CC-5013-CLL-009 Amendment 6 Final 15Apr2015
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21

('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 109 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.8. EQ-5D Health Questionnaire
Health Questionnaire
(English version for the [LOCATION_006])
(validated for use in Eire)
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e [LOCATION_006])[LOCATION_006])
in Eire)in Eire)
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 110 CC-5013-CLL-009 Amendment 6 Final 15Apr2015%\SODFLQJDWLFNLQRQHER[LQHDFKJURXSEHORZSOHDVHLQGLFD WHZKLFKVWDWHPHQWVEHVW
GHVFULEH\RXURZQKHDOWKVWDWHWRGD\
Mobility
,KDYHQRSUREOHPVLQZDONLQJDERXW 
,KDYHVRPHSUREOHPVLQZDONLQJDERXW 
,DPFRQILQHGWREHG 
Self-Care
,KDYHQRSUREOHPVZLWKVHOIFDUH 
,KDYHVRPHSUREOHPVZDVKLQJRUGUHVVLQJP\VHOI 
,DPXQDEOHWRZDVKRUGUHVVP\VHOI 
Usual Activities (e.g. work, study, housework, family or
leisure activities)
,KDYHQRSUREOHPVZLWKSHUIRUPLQJP\XVXDODFWLYLWLHV 
,KDYHVRPHSUREOHPVZLWKSHUIRUPLQJP\XVXDODFWLYLWLHV 
,DPXQDEOHWRSHUIRUPP\XVXDODFWLYLWLHV 
Pain/Discomfort,KDYHQRSDLQRUGLVFRPI[INVESTIGATOR_13318]

,KDYHPRGHUDWHSDLQRUGLVFRPI[INVESTIGATOR_13318] 
,KDYHH[WUHPHSDLQRUGLVFRPI[INVESTIGATOR_13318] 
Anxiety/Depression
,DPQRWDQ[LRXVRUGHSUHVVHG 
,DPPRGHUDWHO\DQ[LRXVRUGHSUHVVHG 
,DPH[WUHPHO\DQ[LRXVRUGHSUHVVHG &(/*(1([ZIP_CODE],(7$5<,1)250$7,21


mily ormily or
XDODFWLYLWLHDODFWLYLW
JP\XVXDOP\XVXD
DFWLYLWLHVDFWLYLWLH
RPI[INVESTIGATOR_233254]RUGLVSDLQRUGLV
PHSDLQRUHSDLQR
ety/Depreety/Depre
DPQRWDQDPQRWD
DPPDP P
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 111 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.9. Pregnancy Prevention Risk Minimization Plans
21.9.1. Lenalidomide Pregnancy Prevention Risk Management Plan
[IP_ADDRESS]. Lenalidomide Pregnancy Risk Minimisation Plan for Celgene Clinical Trials 
Section 21.9.1 applies to all patients receiving lenalidomide therapy. The following Pregnancy 
Risk Minimisation Plan documents are included in this appendix: 
1. Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth   
Control Methods (Section [IP_ADDRESS] ); 
2. Lenalidomide Education and Couns eling Guidance Document (Section [IP_ADDRESS] ); 
3. Lenalidomide Informat ion Sheet (Section [IP_ADDRESS] ).
1. The Lenalidomide Risks of F etal Exposure, Pregnancy Testi ng Guidelines and Acceptable 
Birth Control Methods document (Section [IP_ADDRESS] ) provides the following information:
!Potential risks to the Fetus associated with lenalidomide exposure
!Definition of Female of Childbearing Potential
!Pregnancy testing requirements for patients receiving Lenalidomide who are females 
of childbearing potential
!Acceptable birth control methods for both female of childbearing potential and male 
patients receiving Lenalidomide in the study
!Requirements for counseling o f all study patients receiving Lenalidomide about 
pregnancy precautions and the potential risks of fetal exposure to lenalidomide
2. The Lenalidomide Education and Counseling Guidance Document (Section [IP_ADDRESS] ) must be 
completed and signed by [CONTACT_5640] a trained counselor or the Investigator at the participating 
clinical center prior to each dispensing of lenalidomide study treatment.   A copy of this document must be maintained in the patient records.
3. The Lenalidomide Information Sheet (Section [IP_ADDRESS] ) will be given to each patient 
receiving lenalidomide study therapy. The patien t must read this document prior to starting 
lenalidomide study treatment and each time they receive a new supply of study drug.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21th   h   
ines and Acnes and Ac
lowing inwing i f
e exposureexposur
eiving Lenaving Len
th female oth female 
he studye study
all studyall study papayy
e potential re potential r
CounselinCounse
r a trained traine
dispensingdispensing
ained in theained in 
nformatformat ioion
omide studymide stu
tudytudy treatmtreatmy
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281661] be 
observed.
Criteria for females of childbearing potential (FCBP)
This protocol defines a female of childbearing potential as a sexually mature woman who: 1) has 
not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally 
postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) 
for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
Counseling
For a female of childbearing potential, lenalidomide is contraindicated unless all of the following 
are met (i.e., all females of childbearing potential must be counseled concerning the following 
risks and requirements prior to the start of lenalidomide study therapy): 
!She understands the potential teratogenic risk to the unborn child
!She understands the need for effective contraception, without interruption, 4 weeks 
before starting study treatment, throughout the entire duration of study treatment, dose interruption and 28 days after the end of study treatment
!She should be capable of complying with effective contraceptive measures
!She is informed and understands the potential consequences of pregnancy and the 
need to notify her study doctor immediately if there is a risk of pregnancy
!She understands the need to commence the study treatment as soon as study drug is 
dispensed following a negative pregnancy test
!She understands the need and accepts to undergo pregnancy testing based on the 
frequency outlined in this protocol (Section [IP_ADDRESS] ).
!She acknowledges that she understands the hazards and necessary precautions 
associated with the use of lenalidomide
The investigator must ensure that for females of childbearing potential:
!Complies with the conditions for pr egnancy risk minimization, including 
confirmation that she has an adequate level of understanding
!Acknowledge the aforementioned requirements&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e 
in n 
must be ust be m
womwom an whn wh
n naturallyn naturally
ut childbearut childbe
in the precethe prece
ntraindicatntraindicat
t be t becounsecouns
mide studymide study
genic risk tenic risk 
fectective conive con
ent, throughnt, throug
daydays after ths afte
e of comple of compl
and understand unde
hher studystu dy
rstands the stands th
sed fosed fo llollowiwi
e understanundersta
frequencyfrequency
!!She ache ac
assass
The investThe invest
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 113 CC-5013-CLL-009 Amendment 6 Final 15Apr2015For a female NOT of childbearing potential, lenalidomide is contraindicated unless all of the 
following are met (i.e., all females NOT of childbearing potential must be counseled concerning 
the following risks and requirements prior to  the start of lenalidomide study therapy): 
!She acknowledges that she understands th e hazards and necessary precautions 
associated with the use of lenalidomide
Traces of lenalidomide have been found in semen.  Male patients taking lenalidomide must meet 
the following conditions (i.e., all males must be counseled concerning the following risks and 
requirements prior to the start of lenalidomide study therapy):
!Understand the potential teratogenic risk if engaged in sexual activity with a pregnant 
female or female of childbearing potential
!Understand the need for the use of a condom even if he has had a vasectomy, if 
engaged in sexual activity with a pregnant female or female of childbearing potential.  
Contraception
Females of childbearing potential (FCBP) enrolled in this protocol must agree to use two reliable 
forms of contraception simultaneously or to pr actice complete abstinence from heterosexual 
contact [CONTACT_233324]: 1) for at least 28 days before 
starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 
[ADDRESS_281662] include one highly effective method and one 
additional effective (barrier) method. FCBP must be referred to a qualified provider of 
contraceptive methods if needed. The following ar e examples of highly effective and additional 
effective methods of contraception:  
!Highly effective methods:
#Intrauterine device (IUD)
#Hormonal (birth control pi[INVESTIGATOR_3353], injections, implants)
#Tubal ligation
#Partnerâ€™s vasectomy
!Additional effective methods:
#Male condom
#Diaphragm
#Cervical Cap
Implants and levonorgestrel-releasing intrauterine sy stems are associated with an increased risk 
of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics 
should be considered particularly in patients with neutropenia. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21pregnant egnant 
ctomy, if tomy, if 
dbearing pobearing p
st agree to ut agree to
nence fromnce from
) for at leasor at lea
e interruptioe interrup
e one highle one high
e referred toe referred 
are examplere exampl
UD)UD)
ontrolontrol  pi[INVESTIGATOR_233255]
#CerCe
plants and llants and 
offiiffnfectnfect ioio
shoulhould bd 
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 114 CC-5013-CLL-009 Amendment 6 Final 15Apr2015Pregnancy testing
Medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL must be 
performed for females of childbearing potential, including females of childbearing potential who 
commit to complete abstinence, as outlined below.
Before starting study drug
Female Patients:FCBP must have two negative pregnancy tests (s ensitivity of at least 25 mIU/mL) prior to 
starting study drug.  The first pre gnancy test must be performed within 10-[ADDRESS_281663] be performed within 24 hours prior to the 
start of study drug.  The patient may not receiv e study drug until the study doctor has verified 
that the results of these pregnancy tests are negative.
Male Patients :
Must practice complete abstinence or agree to use a condom during sexual contact [CONTACT_4490] a 
pregnant female or a female of childbearing potential while participating in the study, during 
dose interruptions and for at least 28 days following study drug discontinuation, even if he has 
undergone a successful vasectomy.  
During study participation and for 28 days following study drug discontinuation 
Female Patients:
!FCBP with regular or no menstrual cycles must agree to have pregnancy tests weekly 
for the first [ADDRESS_281664] 
28 days and then every 14 days while on study, at study discontinuation, and at days 14 and 28 following study drug discontinuation.  
!At each visit, the Investigator must confirm with the FCBP that she is continuing to 
use two reliable methods of birth control.  
!Counseling about pregnancy precautions and the potential risks of fetal exposure 
must be conducted at a minimum of every 28 days. 
!If pregnancy or a positive pregnancy test does occur in a study patient, study drug
must be immediately discontinued.
!Pregnancy testing and counseling must be performed if a patient misses her period or 
if her pregnancy test or her menstrual bleeding is abnormal.  Study drug treatment must be discontinued during this evaluation.
!Females must agree to abstain from breastfeeding during study participation and for 
at least 28 days after study drug discontinuation.
Male Patients:
!Counseling about the requirement for complete abstinence or condom use during 
sexual contact [CONTACT_4490] a pregnant female or a female of childbeari ng potential and the &(/*(1([ZIP_CODE],(7$5<,1)250$7,21the he 
or to the to the
verified erified 
l contact [CONTACT_233325] w
ng ng in the stuin the s
ontntinuatinuat ioin
dy drug disdy drug d
s must agres must ag
ioon and then and th
fofollollowingwing
he pregnance pregnanc
ys while onys while on
drug discondrug disco
stigator mustigator m
thods of bihods of bi
out pregnant pregnan
ducted at a ducted at 
ancy or a pancy or a p
be immedibe immed
Pregnancy tPregnancy t
if f her preher pre
must bust b
!!FF
alel
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281665] be conducted at a minimum of 
every 28 days.  
!If pregnancy or a positive pregnancy test does occur in the partner of a male study 
patient during study participation, the investigator must be notified immediately.
Additional precautions
!Patients should be instructed never to give this medicinal product to another person 
and to return any unused capsules to the study doctor at the end of treatment.
!Female patients should not donate blood during therapy and for at least 28 days 
following discontinuation of study drug.
!Male patients should not donate blood, semen or sperm during therapy or for at least 
28 days following discontinuation of study drug.
!Only enough study drug for one cycle of therap y may be dispensed with each cycle of 
therapy. 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21r fr for at lor at lfff eaea
ed wited wit h each ea
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 116 CC-5013-CLL-009 Amendment 6 Final 15Apr201521.9.1.3. Lenalidomide Education and Counseling Guidance Document
To be completed prior to each dispensing of study drug
Protocol Number: ____________________________________________
Patient Name (Print): __________________ DOB: _____/_____/_____ (mm/dd/yyyy)
(Check the appropriate box to indicate risk category)
Female: 
If female, check one:
FCBP (Female of childbearing potential): sexually mature female 
who: 1) has not undergone a hysterectomy  (the surgical removal of 
the uterus) or bilateral oophorectomy (the surgical removal of both 
ovaries) or 2) has not been naturally postmenopausal (amenorrhea 
following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time 
during the preceding 24 consecutive months)
NOT FCBP
Male:    â¯
Do Not Dispense study drug if:
!The patient is pregnant.
!No pregnancy tests were conducted for a FCBP.
!The patient states she did not use TWO reliable methods of birth control (unless 
practicing complete abstinence of heterosexual contact) [at least 28 days prior to 
therapy, during therapy and during dose interruption.
FCBP:
1. I verified that the required pregnancy tests performed are negative.2. I counseled FCBP regarding the following:
!Potential risk of fetal exposure to len alidomide:  If lenalidomide is taken during 
pregnancy, it may cause birth defects or death to any unborn baby.  Females are 
advised to avoid pregnancy while taking lenalidomide. The teratogenic potential of 
lenalidomide in humans cannot be ruled out.  FCBP must agree not to become pregnant while taking lenalidomide. 
!Using TWO reliable methods of birth control at the same time or complete abstinence 
from heterosexual contact [at least 28 days prior to therapy, during therapy, during 
dose interruption and 28 days after discontinuation of study drug].
!That even if she has amenorrhea she must comply with advice on contraception  &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ofof
ffbothboth
norrhea norrhea
 potential) potential)
ses at anyses at any ty
ucted for aucted for 
not use TWot use T
stinence oftinence o
apy and dapy and d
e required prequired 
FCBP regarFCBP rega
otentiotenti alalriri
pregnancpregnanc
advisedvise
lenlen
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 117 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Use of one highly effective method and one additional method of birth control AT 
THE SAME TIME. The following are examples of highly effective and additional effective methods of contraception:  
#Highly effective methods:
!Intrauterine device (IUD)
!Hormonal (birth control pi[INVESTIGATOR_3353], injections, implants)
!Tubal ligation
!Partnerâ€™s vasectomy
#Additional effective methods:
!Male condom
!Diaphragm
!Cervical Cap
!Pregnancy tests before and during treatment, even if the patient agrees not to have 
reproductive heterosexual contact.  Two pregnancy tests will be performed prior to receiving study drug, one within 10 to 14 days  and the second within 24 hours of the 
start of study drug.
!Frequency of pregnancy tests to be done:
#Every week
during the first [ADDRESS_281666] every 28 
days during the patientâ€™s participation in this study if menstrual cycles are regular 
or every 14 days if cycles are irregular.
#If the patient missed a period or has unusual menstrual bleeding.  
#When the patient is discontinued from the study and at day 28 after study drug 
discontinuation if menstrual cycles are regular.  If menstrual cycles are irregular, pregnancy tests will be done at discontinuation from the study and at days 14 and 28 after study drug discontinuation.
!Stop taking study drug immediately in the ev ent of becoming pregnant and to call 
their study doctor as soon as possible. 
!NEVER share study drug with anyone else.
!Do not donate blood while taking study drug and for 28 days after stoppi[INVESTIGATOR_126149].
!Do not breastfeed a baby [CONTACT_233326] 28 days after 
study drug discontinuation.
!Do not break, chew, or open study drug capsules.
!Return unused study drug to the study doctor.
3. Provide Lenalidomide Informat ion Sheet to the patient. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21patpatieientnt agr a
ests will be ests will be
d the secondd the seco
s of this stus of this stu
patatioion n in thin t
irregular.irregular.
riod or hasriod or ha
discontscont inueinu
menstrual menstrual
s will be dos will be d
dyydrug discdrug disyy
studystudy drugugy
dydoctor adoctor ay
VER share VER share 
DDo not dono not don
drugdrug..
!!Do Do 
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 118 CC-5013-CLL-009 Amendment 6 Final 15Apr2015FEMALE NOT OF CHILDBEARING POTENTIAL (NATURAL MENOPAUSE FOR AT 
LEAST 24 CONSECUTIVE MONTHS, A HYSTERECTOMY, OR BILATERAL 
OOPHORECTOMY):
1. I counseled the female NOT of child bearing potential regarding the following:
!Potential risk of fetal exposure to le nalidomide (Refer to item #2 in FCBP)
!NEVER share study drug with anyone else.
!Do not donate blood while taking study drug and for 28 days after stoppi[INVESTIGATOR_126149].
!Do not break, chew, or open study drug capsules
!Return unused study drug cap sules to the study doctor.
2. Provide Lenalidomide Informat ion Sheet to the patient.
MALE:
1 I counseled the Male patient regarding the following:
!Potential risk of f etal expos ure to len alidomide (Refer to item #2 in FCBP).
!To engage in complete abstinence or use a condom when engaging in sexual contact
(including those who have had a vasectomy) with a pregnant female or a female of childbearing potential,  while taking study drug, during dose interruptions and for 28 
days after stoppi[INVESTIGATOR_11743].
!Males should notify their study doctor when their female partner becomes pregnant 
and female partners of males taking lenalidomide should be advised to call their healthcare provider immediately if they get pregnant
!NEVER share study drug with anyone else.
!Do not donate blood, semen or sperm while taking study drug and for 28 days after 
stoppi[INVESTIGATOR_11743].
!Do not break, chew, or open study drug capsules.
!Return unused study drug capsules to the study doctor.
2. Provide Lenalidomide Informat ion Sheet to the patient.
Investigator/Counselor N ame (Print): ____________________
(circle applicable)
Investigator/Counselor Si gnature: _______________________ Date: ____/_____/_____
(circle applicable)
**Maintain a copy of the Education and Counseling Guidance Document in the patient records.**dydy
de(Refer t(Refer
e a condome a condom
ectomy) witctomy) wit
ggstudystudy  drudryy
tudytudy doctordoctoryy
males takingales takin
mmediatelymmediately
udyudy drugdrugy w
te blood, sete blood, 
studytudy drugdrugyy
ot break, chot break, c
Return unusReturn unu
ide LenalidLenali
vestestigator/igator/ C
(cicircle apprcle appii
vestest
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-[ADDRESS_281667] important information I should know about lenalidomide?
1. Lenalidomide may cause birth defects (deformed babies) or death of an 
unborn baby. Lenalidomide is similar to the medicine thalidomide. It is known 
that thalidomide causes life-threatening birt h defects. Lenalidomide has not been 
tested in pregnant women but may also cause birth defects. Findings from a 
monkey study indicate that lenalidomide caused birth defects in the offspring of 
female monkeys who received the drug during pregnancy .
If you are a female who is able to become pregnant:
!Do not take study drug if you are pregnant or plan to become pregnant
!You must practice complete abstinence or use two reliable, separate forms of 
effective birth contract at the same time:
!for 28 days before starting study drug
!while taking study drug
!during dose interruptions of study drug
!for 28 days after stoppi[INVESTIGATOR_11743]
!You must have pregnancy testing done at the following times:
!within [ADDRESS_281668] dose of study 
drug
!weekly for the first 28 days
!every [ADDRESS_281669] 
irregular menstrual periods
!if you miss your period or ha ve unusual menstrual bleeding
![ADDRESS_281670] dose of study drug ([ADDRESS_281671] 
dose if menstrual periods are irregular)
!Stop taking study drug if you become pregnant during treatment
!If you suspect you are pregnant at any time during the study, you must 
stop study drug immediately and immediately inform your study 
doctor.  Your study doctor will report all cases of pregnancy to Celgene 
Corporation&(/*(1([ZIP_CODE],(7$5<,1)250$7,21een een 
a 
spring of pring of 
an to becoman to bec
e two reliae two r
dyy drugdrugy
ons of ns of studstu
stoppi[INVESTIGATOR_233256]14 day14 day
eekly for thekly for 
every 28every 28
irreguirregu
!!ifi
!!
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 120 CC-5013-CLL-009 Amendment 6 Final 15Apr2015!Do not breastfeed while taking lenalidomide
!The study doctor will be able to advise  you where to get additional advice on 
contraception.
If you are a female not of childbearing potential:
In order to ensure that an unborn baby [CONTACT_117210], your study doctor 
will c onfirm that you are not able to become pregnant.
If you are a male:
Lenalidomide is detected in trace quantities in human semen. The risk to the foetus in 
females of child bearing potential whose male partner is receiving lenalidomide is 
unknown at this time.  
!Male patients (including those who have had a vasectomy) must practice complete 
abstinence or must use a condom during sexual contact [CONTACT_4490] a pregnant female or a female who that can become pregnant:
!While you are taking study drug
!During dose interruptions of study drug
!For [ADDRESS_281672] immediately infor m your study doctor. The study 
doctor will report all cases of pregnancy to Celgene Corporation.
Your partner should call their healthcare provider immediately if 
they get pregnant
2. Restrictions in sharing study drug and donating blood:
!Do not share study drug with other people. It must be kept out of the reach 
of children and should never be given to any other person.
!Do not donate blood while you take study drug and for 28 days after stoppi[INVESTIGATOR_117120]. 
!Do not break, chew, or open study drug capsules.
!You will get no more than a 28 -day supply of study drug at one time.
!Return unused study drug capsules to your study doctor.
Additional information is provided in the informed consent form and you can 
ask your study doctor for more information.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21is is
ctictice coce co mpl
egnant femagnant fema
orr s rremenemen
y drugdrugy .
is is prpregnagn
nform nform youyo
of fprpregnaegna
their their heahea
study drugstudy dru
study drustudy d
n and shoun and s
t t donatedonate b
dydy drug drugyy . 
Do not brDo not b
!!You wYou w
!R
AddAdd
a
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 121 CC-5013-CLL-009 Amendment 6 Final 15Apr2015235,(7$5<,1)250$7,[ZIP_CODE],(7$5<,1)250$7
&(/*(1(352&(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 122 CC-5013-CLL-009 Amendment 6 Final 15Apr2015 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7
35,(7$5<,1)2235523
&(/*(1(352
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 123 CC-5013-CLL-009 Amendment 6 Final 15Apr201535,(7$5<,1)250$7,215,(7$5<,1)250$7,2
&(/*(1([ZIP_CODE]
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 124 CC-5013-CLL-009 Amendment 6 Final 15Apr2015 
 
 
 
 
 
 
  
 
 
  
 
 
 ( [ZIP_CODE],(7$5<,1)250$7,21(7$5<,1)250$7,25,(352355235235(31((1(*(1*(/*(/*&(/&(&5,(7
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 125 CC-5013-CLL-009 Amendment 6 Final 15Apr2015 
 
 
  
 
(1([ZIP_CODE],(7$5<,1)250$7,21$7
(1([ZIP_CODE],(7$5<,1)250$
&(/*(1
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 126 CC-5013-CLL-009 Amendment 6 Final 15Apr2015&(/*(1([ZIP_CODE],(7$5<,1)250$7,21(1([ZIP_CODE],(7$5<,1)250$
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 127 CC-5013-CLL-009 Amendment 6 Final 15Apr2015(1([ZIP_CODE],(7$5<,1)250$7,21(1(1([ZIP_CODE],(7$5<,1)250$
&(/*(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 128 CC-5013-CLL-009 Amendment 6 Final 15Apr2015&(/*(1([ZIP_CODE],(7$5<,1)250$7,215,(7$5<,1)250$7
&(/*(1([ZIP_CODE],
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 129 CC-5013-CLL-009 Amendment 6 Final 15Apr2015(1([ZIP_CODE],(7$5<,1)250$7,21(1([ZIP_CODE],(7$5<,1)250$7,2
&(/*(
('06'RF1XPEHULenalidomide (CC-5013)
Protocol CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 130 CC-5013-CLL-009 Amendment 6 Final 15Apr2015&(/*(1([ZIP_CODE],(7$5<,1)250$7,21)250$7,
('06'RF1XPEHU
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature [CONTACT_13695].
8VHU1DPH 
7LWOH 'DWH7XHVGD\0D\$0(DVWHUQ'D\OLJKW7LPH0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21   
Lenalidomide (CC-5013)
Summary of Changes CC-5013-CLL-[ADDRESS_281673] for the patients that remain on study drug.
The key change in this protocol amendment is to change the study drug packaging from blister 
cards with matching placebo capsules to bottles.  This will reduce the number of capsulespatients are required to take each day.
The amendment further clarifies that patients cu rrently on study drug may remain on study drug, 
beyond the 80% event milestone, until final co mpletion of the study at which time they may 
transition to non-study lenalidomide.  The transition will be at the discretion of the site primary 
investigator and any local regulations.
Significant changes included in this prot ocol amendment #6 are summarized below:
!IVRS will be discontinued for this protocol.  Sites will or der study drug when needed 
through Celgene investigational drug dispensing program.  This will permit sites to order 
study drug only when needed rather than maintain a stock of study drug for the IVRS to 
allocate.  The change is possible at this time since few patients remain on study drug and the study drug is no longer blinded.  
!Removed the 1.25-mg dose level and app lied corresponding changes in the Dose 
Reduction Steps for Lenalidomide (Table 6) as no patients utilize this dose level.
!As all subjects are beyond the risk for TLS, Celgene will no l onger provide allopurinol 
supply for site outside of North America.
!Remove lymph node biopsy and fine needle aspi[INVESTIGATOR_233257].
!Remove additional PK sample collection.  PK samples were drawn at study day [ADDRESS_281674] patient randomized was 2012, further dose escalations are not anticipated and hence no further PK samples.  This will permit the final analysis and 
reporting of this exploratory endpoint at this time.
!Remove the requirement to submit blood sa mples (hematology, chemistry, thyroid 
hormone,  MRD ), urine (urinalysis) and bone marrow 
(biopsy and aspi[INVESTIGATOR_337]) samples to central lab for analysis.  Local labs w ill continue to be 
collected in this protocol.  The purpose of this change is to simplify the protocol procedures in effort to reduce the workload for the site personnel.
!   Tumor flare 
events are anticipated at the start of study drug administration.  Since the last patient randomized was 2012, additional events of tumor flare are not anticipated.  The purpose of this change is to simplify the protocol procedures in effort to reduce the workload for 
the site personnel.
!Remove the text for blinding and emergency unblinding activities as the protocol is 
unblinded.
&(/*events aevents 
randrand
ofof/*(1(nd aspid aspi [INVESTIGATOR_337])rate)ii
ed in this pd in this 
cedures in eedures in e( [ZIP_CODE],(7$5<,1)250$7,21drrugug, , 
may ay 
te primary te primary
elow:low:
y drug whendrug whenyy
s will permwill perm
f studytudy drugdrug
tients remants rema
esponding cesponding 
no patientsno patients
,Celgene wCelgene w
.
e needle ase needle as
le collecte collect io
last last patipatiene
nce no furthce no furt
ploratoryloratory eneyy
quiuirementrementiii tot
1(
(/*
Lenalidomide (CC-5013)
Summary of Changes CC-5013-CLL-009 Celgene Corporation
Confidential and Propri etary 4 CC-5013-CLL-009 Amendment 6 Final 15 Apr 2015!Change of Medical Monitor
!Changes for grammar and topographical errors
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
Lenalidomide (CC-5013)
Summary of Changes CC-5013-CLL-009           Celgene Corporation
Confidential and Proprietary                                            3       CC-5013-CLL-009 Amend ment 5.0 Final 9Nov20111. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!Increased the sample size and required that following the enrollment of [ADDRESS_281675] samples.  Enrollment will be extended to only those subjects who agree to 
participate in the PK sub-study. 
!Clarify that the second primary malignancy assessment should be completed during 
the progression free survival follow up phase and the survival phase
Clarified that the assessment for second primary malignancy should be completed during 
the 28-day follow up visits for all patients that discontinue the treatment phase for 
reasons other than progression of disease or withdraw of consent.  
Additionally, the assessment for second primary malignancy should be completed for all 
subjects in the survival phase regardless of the reason for study discontinuation.  These 
assessments were already included in Amendment 4 (but not specified in each sentence that mentioned the respective follow up).  
!Clarify the schedule for the baseline bone marrow biopsy and aspi[INVESTIGATOR_233258].  The bone marrow biopsy and aspi[INVESTIGATOR_233259].  The results are not specifically part of the inclusion exclusion criteria.  This change is being implemented to avoid unnecessary sampling for a subject who may 
eventually fail screening and not enter the study.  
!Expanded exclusion criteria surrounding history of prior malignancies from [ADDRESS_281676] a history of 
malignancies within the 5 years prior to starting the trial.  
!Update study contact [CONTACT_3031]&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_281677] phasehas
,1)hould be c
<, 1he treatm
5<,cons
$5<ignancy sh
$5son for 
ment 4 (but ment 4 (but
aseline bonaseline bon
aspi[INVESTIGATOR_233260] a
once the pance the p
marrow bimarrow b
s are not sps are not sp
plemented emented 
creening ancreening a
panded excanded ex
years to 5 years to 5 y
Recent mulent mu
a historya histor
durindurin
reqreq
Lenalidomide (CC-5013)
Summary of Changes CC-5013-CLL-[ADDRESS_281678] the new Clinical Research Physician and 
Study Manager.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
	





 
















































 



















		


  !  ;


#
 86
7

86
		

 67		<
;:=
'%
 !!
  
 (	


 ##
'8
89
;
 6

6
	
	 6


 676
:8
	

 6

6
7
:88
	
 66
8
6>

6
	
	 6%

 6
6>
8

67;?6


67
	
	 6
;
:

	


 66


6
	
	
 86
7

'8

7
:6
	

 9
7



 :
7

8
67;?
(


	

 878
97

6
	
	 6
8
7

67;?6
9

67
	 %
8

 6
;
	

 @7
8
6
	
	 6

6666

9
67
96


 6
676
96
96


	
 7
8
67%
7
	
 8
	

 6
8
(	
 6
	
 7


 7
8
6799
:
7
86
 & & &

)
 !
(


 67
66

8

 9
76
66

76%
8

 9

 :6
7


 ;
	
 :8
	
9

6>
766
6

 66

7

'8
$7
76
	
8
976
96

8

 89
;
	

 8
976
;%
AB
$7C
76
89
:
;



 76


#9
8
	
86
89
;
	 %
7

 8
	
A	 C
:8
67
7%
:8
 %

 8
	
(96
:8
A67
 C%
:8


	
 8
	






  #
'867

9

 :6
7

 9

 B;

	
	

 8
67

&(/*(1([ZIP_CODE],(7$5<,1)250$7,21

:
:


6
8
6
8



@7

@

6
 
6
		


6
6
:
7
86 :
7
86
&&
99
77

;
	
;
	
66

66


89
;
89
;

:
;
:
;
7
7


8
	

8

8
8





677
	





 






































 



















		


   ;


"
 75
6

75
		

 56		;
:9<
-5


	 $

	 58
5
95
	

 5
7
6	:


 56:=5
	
6

 
6


'7
>6

855
6  5
 $

?
9  5

'7
>6
855
6

 59 		

	

 '6	
55
"	
 '"

'6	

 *
'*:5


	
 7

 5

7






 56<
(
7


 5


 $
5
9
	 ;


	
	 @
 
	
	
 5

 
6

 A
5
56
BA

8

55

'"
9
:58

6
?6

7


 55

'"
6
6
7
5

5


	 $


 6


?

'7
95



 5

565
'*
6


 ?

(
7
	


 565
B $
5
5

  
	 	
@
97
	
 5
6


	C	6	

 
	 	 @
5



	
 7
	

 6$

5

:
'"


D

 5


 '"
.
 


A

+
7
D

55

565
'*$
E
6
6
7
5

5


	  
6
F

5


	

	
 7
	




 5	

7
>6
855

:
	

 5
7
:6

 >6
855

56:=5
'7

 

  
85

7
9G

A$$
  
855
6 



 ?9


 : >6

'7

 $
?$
A$
$
  
855
6




 7
5


 7
5
5


 A


855
6

  9
	
 8
7
		

 977
'"

565
'*
9


 7


 56
75

7
:
 <
'7


 7
6	:


	
	

 -

95	8

(855


 7


 5678
		
 7
5

78
F?
	 5

7
	
7

 5


 7

5@


 '75
5
:5

7
8:

65

6:$
	6;6	:$
6C	:$
:	65

 6	6	:
5
	7


	 :  9
	
 7
?

	
	 5

-
9
8
	
 78


 5
7


 :
5 


 7
56
865$
7
65
  >6
7
56:=57

	
 97

6

 :5
	
 '7

 956

 9
65

56:=597
	
 97
7

6


 :	65
:5
	
 	

'7 
8
:	65 
 A
7
5

	

 597


 %7
  7
		

 %
65

!6	
&5
!%

7
#6
%5

 #%
"






	
	
5
565
56B

55

55



 6 

 6
6





 
	

 
	
	

 
	
			
6$
6$
AA


+
77

 

		



>
A$A$$
$



 $
?$ $
?$
55
		
		
::


7
6	
7
6	
5
5


78
F?
 
78
F?


55
6:6:
		

	





 






































 







?











		


  556

58




 6
		
 7
	G
67;5
576
:


 :	65



 '7
	G
67;5
9
:
556



 :55
767
 ;
 6
-5

:8

7$
7
5

 9
:
6

 6
5
85
 
 6


 :	65:5
	
	

 56:=
75
8:7$
565
5
	5

6


:	65
	
	
 9
:
65
'7
 
5
9576


	 6;6	:
	
 9
:
5

E
5
'7


 >65
56:=5
97
9

 7
	


 97

	 6;6	:
7
576
6
7
	


 5
E
	75
9
7
56

	 6;6	:
76
56

'7
5

957
6

9
9
56:=5
97

	
		
	
 5
	6;6	:

:
5 


7
56
'7
65

 95
7

 9
5

 56:=597

75


	
 
7
:

 7
56:=
75
:
55


H
 
5


	

 7
56

'75C
95

5

	
 
7
8C

:5$

95
C

 6
7
:

 8
655
C65

56:=5



	 7
9

	
 7
5


 865
97
7
56
"
75
5
 75
 
56$

	 58
5
95
	

 7
9<
"6
9
:
5

AI

7
56:=5
	;

7
56
78
55




 56:=5


 56
6

7
	
7
56
5
5
9
:
5

		
 6



 :55

'75688
9
6
9
5
5

7
	

 56
56
'
"5

	7
5$
8

5
9

:
89


 



'7
5	

 5
5
-
 	:6$


,
D$
0!%6
565@'$
("!
55

 5

	

 55
55

 9
:
	

 :5
"6

 
 5
5

6
5

 '75
7
5
:
		

 8
655
5	
 56:=
97
	
86

5



 7
56&(/*('7'7(1([ZIP_CODE],(7$5<,1)250$7,21
	

6;6	:
6;6	:
56:=5
976:=5
9



56:=556:=59
:=

75
:75
:
55C
5$

9 5$


56:=5
 
56:=5

65
95
9
8
5 8


7
56:=
7
56:=
5
5


				


7
	
7
	
5$
8 5$
8
[ZIP_CODE](31((1**(*
(
	





 






































 



















		


   

'7
5	
	  5
 
55
7	G5
9
6
6

7 
85
576

 5 $


?
%

 5
5
6

75
		
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
	






 



   		
 


   :


"
 86
7

86
		

 67		<
 :

6
=
 6666	6
8
:
86
:
		
 


'7	

 '

	7
 66
:6


 8

  6


7 6

6

	 >

 8	
	 6


68:
8
	

 67
'
	7
676



8
A

 6

	
 6


 8
.


7;

'8
'
	7
 66
:
 
	

 6

 8
6	
6	
6
86


 8
1!
	7
676
66

:

B7

  
6	;


 8

 


1!
	7
676
@'
	7
 66

("!
676;

 
 

'8
	=	7	
7	 


	
	

 .

:6
6
	


C;

'86
:
:
	
89


 6

 
6



8
67;
(
8

8

 B7	

		

 8	 
8=6


67 >6
$

 7
:6


	 86<
8
	

	
 6D

 76
7
8
67;
'8
C
87
	


	
 86
 


 8

 6
86
6
:
		



 66
676

67

 6;

78
6

:8
67
7
687
 
	
 67

6


 67;

 6

#

		 6
B7

8
67;
'8
		
 6
76
69
8
	
 6

 6
-<
'$
%8
3$
#	
3$

;

'	
 66

 8
	 8
7?	
8


8

8:;

	

 
%8

 ;&(/*(1(3523





		
89
89
8
8

$
$




'8
C
87 '8
C
87
6
6
:
	:
	


5,(7$5
676
@'676
@'< ,1)250$7,21 6

 6

		
676

676





	

6

6
676
676
0$
5<$5<7$(7$5,(735,(3523
	


		






 



   
  
!	










				

			
  !
 "
#
	






$
%&'(%&') *+",'&
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
#





	


		






 



  ! 
 
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&
"#
$
%	

&	
!'
(
	


-.
+
/)
		 *
01
 

 20
/	
	



-.
+
/)
		 *
01
 

 2
0
/	
78


%
!'
(
/#8

0
/	

 !'

%
	
	
 6
&(/*(1([ZIP_CODE],(7$5
/	
/	
7878



((((/5,5<,1)250$7,21
21
4)./'45& 4)./'45&$7
//
/	/	
%%$7
50
,1<, 15<$5<
5,(5,5
	


		






 



   
  
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&

"#
!


/	


'6
/	
31
"	
,3

 #@
1










 11

 *

)
	

)
!-





	






 1


	

 *
1)
	
6

,

 )


#@
	

 )



 A

 #
	



 *
	 *
 *

> *
)
)
 *
	
	
 B
1)B

/%




 1


 #




	

 ,



1
	

 *
1)
	
 63

 #@
1










 11

 *

)
	

)
!-





	






 1


	

 *
1)
	
6

,

 )


1
	
 1
#
A$
	 *
%CD
	
*
)


		 *

 4	

 )*


	
 *
)
)*

	
	 > *

	

 6<


1
	
	
#
	

 #@
1

	


 #


#





 6


6666
"	#	#
%)
 470/%9/&%9/5.- 1&')2
0/:7;543.2
	
	


 8

	#	#
)

 #@
70/%9/&%9/5.- 1&')2
0/:7;543.2
	
	


 8

	#	#
)

 #@
<

 1

)


	
	#	#
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
21
/'45&6/0- /'45&6/0-,27,2
50
)
)


/%
/%






	

 ,	

 ,









1
111

	
	










1


1

	

	


6

,
6

,
1
1
		

25
5,
9/&%9/5.9/&%9/
:7;543.2:7;543.2
		
		##		1
&(&(&(&(2
	


		






 



  ' 
 
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&
1



 8

 8



 4	





	#	#
)
>
8

	
	

1


 8


	#	#
)
>

81
 #



	#	#
 6
/
#@
1
#
A

 )


 E//F
2
	


 6
&
//

 *


 1
	
1


 1

A)
G	
9


8

 &
 0	=
:
&0:




 !




	 #









 #61



 8

 8



 4	





	#	#
)
>
8

	
	

1


 8


	#	#
)
>

81
 #



	#	#
 6
/
#@

 )

	 #
 4


	 6

"
		
 4

1


 E//F
2
	 
B
1)*



	#

	
#


) H



	 6



	


	 #



 #@

 #
#



 )



 8


 1

 *



	


)
 #@H

	
 6



 #
#


 )
#

 8
6
<

 1
	
 1


 1

 A)
G	
9


 8

&
 0	=
:
&0:




 !




	#







 4
	
#

 )
#@
 6
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
21
/'45&6/0- /'45&6/0-,2

81

81




6
/
#@6
/

	#	#







E//F
2 
E//F

*

*


##


) H )
		6




 4 4
#



#@#@7,2
((((/5,50
	


		






 



   
  
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&


 #6
"#
!


/	
 (1&0;<(4;2
=>?2!9-1&0;<(4;2
=>?2!9-
2)(4;/6&4-7-;-5&!/


)
!-

)

#





 1
6
"#
!


/	
 (
;-5&4;4'(1&0;<=(4;2
@>?2!)7&0&46)&0
;-5&4;4'(1&0;<=(4;2
>?2!)7&0&46)&0



-'

A

 !
18

 .
186
"#
!


/	
0/-&(,0&2
A
.A
-/'6.0%4)./' 
1.2.)
7
	 1
 *
#*

 #




 :)1I0/-&(,0&2
A
.A
-/'6.0%4)./' 1.2.)
7
	 1
 *
#*

 #
I
:>:
/



 )
 *
J:>:
K
1



 #




	


A


 :>:
	
 )*

:
	
 )6

"
J


 :)1K
1

	


	

 )
 6
&


#	

	



)1*


)1


#
	1


#
	


&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
21
/'45&6/0- /'45&6/0-,27,2
/
/
))
$7
50
0;<=(4;2 ;<=(4;2
&46)&06)&0)2
3535350/-&(,0&20/-&(,0&25<
7
	 1 7
	
#*
#*

7$
5,<,
((((/5,
	


		






 



  . 
 
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&
A6
"#
!


/	0/-&(,0&2
A
.A
-/'6.0%4)./' 1.2.)
+:,
)A IA0/-&(,0&2
A
.A
-/'6.0%4)./' 1.2.)
+:,
)I
:>:
/



 )
 *
J:>:
K
1



 #




	


A


 :>:
	
 )*

:
	
 )6
"#
!


/	0/-&(,0&2
A
.A
-/'6.0%4)./' 1.2.)




I0/-&(,0&2
A
.A
-/'6.0%4)./' 1.2.)






I
:>:
/



 )
 *
J:>:
K
1



 #




	


A

 :>:
	
 )*

:
	
 )6
"#
!


/	

6





%D
1
#
	


6

/


 %D*

4
%D
1
#




 ,
*


 )
.
18
1


*


	
6





%D
1
#
	


6

/


 %D*

4
%D
1
#




 ,
*


 )
!
18
1


*


	

 )

1

%D
	





 -'

A

 !
18

.
186
"#
!


/	

86





(	

 ;7*
(D7*
("*
+G*
 *

 *
/0*
/*
	


686



(	 $

 #
	

 ;7*
:7*
(D7*
("*
+G*
 *

 *
/0*
/*
	


 6

/



A

 )


 #
&(/*(1([ZIP_CODE],(7[ZIP_CODE],5,




 %D 
 %D





.
18
1 .
18
	
	52

(	(	
+G*
+G*

/*
/
*(
((((/7$5<,1)250$7,21
21/'45&6/0- /'45&6/0-,2 AA667,2
.2.)2.)
50:
:
5050
)250//


JJ$7
50
0/-&(,0&20/-&(,0&25<
7$5<
(7$,(75,(5,
	


		






 



  2 
 
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&
8 
 #
	

 (D7*
/0*
/


 6

/
 *
#@
	
	
 #

 #


 #
6

/

,
*
#@
	
	
 #

 #




 #





	 6
"#
!


/	

6





	

	 *
	 *
 *
C!*
	 *
		 *
 *
7<0*
 *
 *
#	*

 *
8
 *

##*
/">DC"*
/">D"*
,(*


 66
 	 $

 #
	

	 *
	 *
 *
C!*
	 *
		 *
 *
7<0*
 *
 *
#	*

*
8
 *

##*
/">DC"*
/">D"*
,(*


 6


 #
	

	 *
	 *
 *
 *

##*
/">DC"*
/">D"*


 6

/
 *
#@
	
	
 #

#


 #
6

/

,
*
#@
	
	
 #

 #




 #





 6/



A

 )


 #
	 6
"#
!


/	0/ 3 
 $
	6< $




	
 1

 8*
	


 )6

/



A

 )


 #
	 6
"#
!


/	C

 $
	*
*

*
*
A*
*
*
*
*
)*
1*
4*
*
=*
*
##*
*
<
 )


*
*
*
A*
*
*
*
*
)*
1*
4*
*
=*
*
##*
*
*
:A





 J	K
"#
!


/	
 )
6




"(

	
	 *
"*

"'
)
1
#


 *


 ,


 )
.
6





"(

	
	 *

"*


 "'
)
1
#


 *


 ,


 )
!

 )

1

"(
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
21
/'45&6/0- /'45&6/0-,2
#
#
#
#
		7,2
50
	
	
	*
	*

	 *
	*

*
 *
 *
 *



/">DC"*
 /">DC

6


6



	
	
 *
 *

/">D" /">D
#@
	#@
	
##
,,)2
5,
23



*
A*
*
*
*
A*
*
*

*
*
(




"(
"(


"'"'
*(
((((/
	


		






 



  - 
 
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&

 *
)

18
1





	
 618
1





	
 6

/
	
1
#
=
 6	




 -'

A

 !
18

.
186
"#
!


/	
 )

 *
)

6




L




 #
	1


	
 1

#



 :3L6




L6/
#
	 1


	
1

 #
=




1
#



 :3L6<








 #
	1


#


 #
=
 *



 #
#	



 )16
"#
!


/	
 )

 )*
)

 1)6
 #
	
 1
#



 4



	 6


M/
2
4
 #
1
	 6

16




7
	

 N!+*
M/
2*
G(
	

 1
#


 6


M/
2
4
 #
1
	 6

 




<



	


4
	 6
/
	



	
 1
#
=
 6
"#
!


/	
 )

 1*
)

 416




3&(



	
0,>&(
*
A*
2
*

A*

"	
 !
1
#


46





7
	

 3&(



	
 0,>&(
*
A*
2
*

A*

"	
 !
1
#


 6

/
	
 1
#
=
 6<


	8


 1

4
	
 6
/
	



	
 1
#

21
/'45&6/0- /'45&6/0-,2		


A
7,2
50
	

	





:3L6:3L650505050




7
	



7

		
7$
5,



(
*
 (
*
!
1
#
 !
1
#

3
((((/(
	


		






 



   
  
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&
=
 6
"#
!


/	
 )
 *
*
A*
4*
*
=*
* ##**
:)

 A*
*
*
=*
*
##*
*
0/ &  

 


	 *

 1
	
1

 J/
	
 1
#
=
 K
 
+:,
)
 
 
 

 
 
9
/
	


	
 1
#
=
 6
"#
!


/	
 )

 *
)









 #


#@
	
 4
	


	
	

&(/*(((((1([ZIP_CODE],(7$5<

5,
(15<,1)))250$7,21
21/'45&6/0- /'45&6/0-,2 =
=
7,2


/
/

$7
50
)21)2
5<,$5<$5$
*(1*(
(/*(/*
	


		






 



   
  
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&


'66/	

%4
7	8
















 *

1




	4		
	 #

	

 #

	
 #
	



 #@



	

#
 #
6
!6!6 +

"	

 %
/	0/"
)



 4


 #@

 "


 8*
*
#	

 )

4	
 !
	)


2
8
6

(1)*


	


 4


 #@
1
)

 *
#

	
 *

=


 #@



 "
A	



	 6/

 )



 4

"



	
	
 #
A
#
%
		 >
&
 :)1
7
%>&:76
!6!6 +

"	

 %
/	145,4)./' /6 2)4),2
+:,

1
#
)


#@
1

 :

:6
/

 #

 #
145,4)./' /6 2)4),2
+:,

1
#
)


#@
1

 :

:6
/

 #

 #
/
	


	
 1
#
=
 6
&(/*(1([ZIP_CODE],(7,"
"

,,,(5,
)./'/6 )./'/6
:,

1 ,

1
#@
1 #@
1
1(
((((/,1)250$7,21
21/'45&6/0- /'45&6/0-,2

*
*




	4		4
		
7,2
5050252)21)2,<, 1<,5<$5<7$5(7$(7$
	


		






 



   
  
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&
	1 	
 1
#


 +:,

 #
1
	


 :>:
	
)6	1 	
 1
#


 +:,

 #
1
	


 :>:
	
)6

"
+:,
	
 1
#
=
#


 #6
6/%+%0"
C3
/3%"O
66/	
 #
 ) $
(	 $
1
#

;7*
	 #
(D7*
	
 ("*
	

 )	
 +G*
 *

 *
#


 /0*
#
	

 /*
	



7
	 $
	 *
	 *
 *
C 7!7*
	 *
		 *
 *
7<0*
 *
 *
#	*

*
8
 *

##*
/">DC"*
/">D"*
,(*



<

"
 $
"(*
"

"'
,
 #






	

 8
D


"
 1

 #
	
 1
#
=
 $
(	 $
1
#

;7*

#

 :7*
	 #
(D7*
	
("*
	

 )	
+G*
 *

*
#


 /0*
#
	

 /*
	



7
	 $
	 *
	 *
 *
C
7!7*
	 *
		 *
 *
7<0*
 *
 *
#	*

*
8
 *

##*
/">DC"*
/">D"*
,(*



< $

8*
	


 )
"
 $
"(*

"


 "'/



A

 )


 #
	 6
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
21
/'45&6/0- /'45&6/0-,27,2
50
	*
	*
7<0*
7<0*
	*

	*

 *
 *

DC"*
/"> DC"*
/">











DD##
=
=
11
#
#

#

#
#
(D7#
(D
"*
	
"*
	
+G*
+G*

##
##
25
&(&(&(&(5,
	


		






 



   ! 
 
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&


	

 #
#
#

!'


	


 ) H
,
 #






	

 8
D




	

 #
#
#

!'


	


 ) H

/
 *
#@
	
	
#

 #


#
6

/

 ,
*
#@
	
	
 #

 #




 #

 



 6
"
 1

 #
	
 1
#
=
$
(	 $
	 #
(D7*

*
#


/0*
#
	

/
7
	 $
	 *
	 *
 *
 *

##*
/">DC"*
/">D"



< $

8*
	


 )
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
21
/'45&6/0- /'45&6/0-,2

#

#

H
H
#@
	#@
	

#
6

/
6

/


	
	
	
	

#
#




""7,2
((((/5,50
	


		






 



   
  
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&

	

 8
D




	

 #
#
#

!'


	


 ) H

/
 *
#@
	
	
#

 #


#
6

/

 ,
*
#@
	
	
 #

 #




 #

 



 6
'6!6 /	

	 8	 8
	
 1
#
	



 '
#@
1
)




6

7
 )


 9
#
	
 1
#
	


 #@6	 8
	
 1
#
	



 '
#@
1
)




6

7
 )


 9
#
	
 1
#
	


 #@6

/
9
	
 1
#
=
 6/
	



	
 1
#
=
 6
'66/	

%4
7	8
 #
	

 7
!
+#
N!+*
3&(

 0,>&(
*

A*

2
*


 A*

"	
 !*
M/
2
4 *
G(
	

	 *


 #
	

 7
!
+#
N!+*
3&(

 0,>&(
*

A*

2
*


 A*

"	
 !*
M/
2
4 *
G(
	

	 *


/
	


	
 1
#
=
 6
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
21
/'45&6/0- /'45&6/0-,2



	
		
	
#




,
,

	
	











667,2
50

9

9
	

	

		
		
)
7$
5,

			
#
N!+#
N!+

0,>&0,>

2
*
2
*

	
 !*
	
!
GG((
				35
((((//*(/*
	


		






 



   ' 
 
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&

M/
2
4
 #
1
	
 1
#


 6




























M/
2
4
 #
1
	
 1
#


 6

"
	
 1
#
=
 6























&(/*((((/5235,(75,35232352335235(31(31((1(*(1/*((/*(/*< ,1)250$7,21
21/'45&6/0- /'45&6/0-,2
67,2
502)21)21),1)<, 15<$5<7$5(7$(7$(75,
	


		






 



   
  
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&





















































&(/*((((/52


235,(5,352235235235(31((1((1*(/*((/*1)250$7,21
21/'45&6/0- /'45&6/0-,27,2
502525
1),1)<, 15<$5<$57$5(7$(7(
	


		






 



   . 
 
!&-)./' 0&1./,2&3) &1.2&(&3) 4)./'45&6/0-74'8&




























1(5,,1)250$7,21
21/'45&6/0- /'45&6/0-,27,2
50525025)21)2,1)<, 15<$5<$57$5(7$(75,((